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Abstract 
Recent breakthroughs using novel chemistry and nanotechnology methodologies for 
cellular biology applications have spurred tremendous interest in the development of new 
technologies to manipulate cell-lines or cellular products for biotechnology applications, without 
complicated or permanent techniques used in academia and industry. Small molecule drugs, 
proteins, deoxyribonucleic acids (DNA) and ribonucleic acids (RNA) have been employed to 
manipulate and probe cellular behaviour with the intention of elucidating healthy and diseased 
molecular pathways for understanding human health. 
This research focused on the application of liposomal delivery of bioorthogonal 
chemoselective chemistry to cellular membranes to control biological functions.  These smart 
membranes were used to investigate cellular adhesion, cell spheroid aggregation kinetics and 
incorporation of ligands.  In Chapters 2 and 3, NMR spectroscopy, oxime reaction kinetics and 
oxime cell surface engineered cell adhesion was correlated and probed under microfluidic 
conditions, while the robustness of adhesion and flexibility of cluster and tissue formation was 
established using live cell technique microfluidics. Using this as a base strategy, we developed a 
general method for the microfluidic manipulation and CSE of cells for dual labelling and flexible 
delivery of nucleic acids and small molecule ligands (Paul O’Brien et al. 2017, in preparation).    
In Chapter 4, the bioorthogonal liposomal strategy originally utilized for cell adhesion 
and cell membrane ligand integration was modified and extended to transfect mammalian cell 
lines with nucleic acids, limiting the use of cationic charge as a mild and general method to tag 
and target cells in monocultures and co-cultures. The method was characterized using 
microscopy, protein production quantification and targeting in complex co-cultures for selective 
internalization. 
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Finally, in Chapter 5 a new chemical moiety termed “dialdehyde” was designed and 
synthesized for the easy and mild conjugation of primary amine containing molecules. This 
conjugation strategy was used to deliver small molecule ligands and macromolecules to bacterial 
and mammalian cell membranes using a generalized liposomal formation method. The 
dialdehyde was characterized and modified to contain two dialdehyde moieties with a 
Polyethylene Glycol (PEG) linker for crosslinking proteins, inorganic surface functionalization, 
organic bead assembly and cell aggregation for tissue formation. 
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Chapter 1 
Cell Membrane Engineering for Cellular Manipulation Molecular Study and Cellular 
Adhesion Studies 
1.1 Introduction 
The creation of new platform biotechnologies to drive innovation necessitate the 
development of techniques to directly manipulate cells using transient methods to advance novel 
therapeutics, theranostics and basic research techniques. The benefit of transient techniques 
stems from preventing the introduction of permanent unpredictable alterations to germ-line gene 
expression, which can be a mixture of genetic, epigenetic and phenotypic changes. Therefore, 
cell manipulation methodologies must be general, have controllable characteristics, high cell 
viability and reduced cell death, have bio-orthogonal compatibility with natural cellular 
processes, but most importantly possess transient properties while harmlessly degrading or 
diluting with predictability. 
Cell membranes are a dynamic and robust barrier containing both active and passive 
properties for the exchange of information and nutrients within the environment. Signal 
transduction of environmental cues through the membrane results in altered gene expression 
producing appropriate output responses. Cells typically respond to external stimuli stemming 
from extracellular surfaces, soluble molecules, exosomes and adjacent cells using membrane 
bound receptors, channels or transmembrane proteins to transduce signals through a combination 
of mechanical, chemical or protein cascades beginning at the membrane, through the cytosol to 
reach the nucleus and alter gene expression resulting in phenotypic changes and behavioral 
responses such as movement, growth, apoptosis and mitosis.1 2 3 Therefore, the cell membrane is 
a vital signaling gateway for behavioral responses. Thus techniques which can manipulate the 
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membrane directly  are essential in order to control cellular behavior without introducing 
permanent changes to the cell.   
Interest in directly manipulating cells spurred the development of numerous techniques to 
engineer the cellular membrane using genetic engineering,4 polymer matrices, 5 6 metabolic 
labelling7 and cell surface engineering with bio-orthogonal ligands.8 These techniques aim to 
impart functionality to the cell by introducing exogenous proteins, chemical functionality or 
biophysical properties through adsorption or incorporation into the membrane. Manipulation of 
the membrane is a major hurdle to the study of human health, since it is the gateway to the cell 
interior which inhibits research to the study of complex cell membranes cellular interactions, 
tumor growth, juxtacrine, paracrine and autocrine signaling and cell migration within tissues. 
Therefore new techniques that manipulate the membrane are beneficial for understanding human 
biology and developing next generation therapeutics. 
The plasma membrane is composed of a variety of amphiphilic lipid molecules which 
include a hydrophilic polar head and a hydrophobic lipid tail, with highly dynamic biophysical 
properties arising from polar and Van der Waals interactions to form a bilayer, which can be 
actively modulated by the cell. There are two main classes of proteins which are associated with 
membrane modulation by the cell, integral proteins and peripheral proteins.  Integral proteins 
permanently associate with the membrane and can extend through the entirety of the membrane.  
These transmembrane proteins, act as transporters, channels or receptors controlling membrane 
morphology, allowing communication or gating functions between the external environment and 
the cytoplasm. Peripheral proteins however, temporarily associate with either the membrane or 
other surface proteins through electrostatic or hydrophobic interactions. The integral and 
peripheral membrane proteins play an intimate role in cellular adhesion, autocrine and paracrine 
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signalling, apoptosis, migration and cellular division. The integral proteins also mediate 
important active processes such as endocytosis and vesicle fusion, both of which are important 
signalling events and routes of cellular cytoplasmic entry exploited by chemical transfection 
reagents and liposome based drug delivery systems. Therefore, the introduction of groups or 
proteins on the cell surface which can mimic these adhesion molecules have great potential in 
manipulating the membrane and ultimately cellular behaviour. 
1.2 Traditional Techniques to Manipulate Cells 
 
1.2.1 Genetic Engineering of Cellular Membranes 
 
The use of genetic engineering to insert, delete or change the functional expression of proteins 
has been widely used to discover and elucidate biological pathways of healthy organisms,9 
disease states, as well as develop drugs, cell therapies,10 biologics, mono-clonal antibodies 
(mABs) and proteins for structural study.  Genetic engineering has recently been used to 
redesign cell surfaces by altering surface marker expression in cell lines by changing surface 
protein expression or introducing exogenous ligands upon red blood cell (RBC) progenitor 
membranes.4  The modified expression of RBC surface markers, was achieved by developing 
blood cell progenitors that matured into RBCs expressing proteins containing C-terminus linked 
LPTETG peptide chains which can be easily modified using Sortase enzymatic action. The 
murine RBCs were engineered to express exogenous human glycophorin A-LPTETG and 
targeted using Sortase-A enzymes from Staphylococcus aureus, which recognise the short 
peptide sequences of LPTETG to couple molecular probes containing a glycine cap (Figure 
1.1).4 Importantly, these peptide chains were selectively targeted and enzymatically coupled with 
exogenous molecules without damaging the cell. This methodology was also used to selectively 
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introduce biotin and single domain antibodies onto the cell surface to demonstrate that these 
altered cells were viable and did not significantly affect circulation survival time in mice. 
Engineered RBCs are potentially advantageous as therapeutic carriers for drugs or molecules to 
inhibit autoimmune responses, the process of terminal differentiation from modified erythroid 
progenitors removes the nucleus and genetic content of the cell, leaving no trace of the genetic 
modification. Although the technique requires the use of RBCs, without removal of the genetic 
content within the cell, its therapeutic value becomes difficult to justify to healthcare regulatory 
agencies and does not lend to other general applications that do not require RBCs.  
 
Figure 1.1: RBCs cell surface engineered with embedded Kell proteins and C-terminal 
coupled with sortase-mediated probes. The labelling of probes with GGG epitiopes 
(biotin/HA) allows conjugation using Sortase-A to the LPXTG-HA epitope allowing ease of 
coupling in the presence of live cells. (Taken from Shi et al, 2014).4 
Another application of genetic engineering of cellular membranes involved the 
introduction of surface recombinant proteins tagged with peptide recognition sequences which 
can be subsequently targeted by small molecules bearing bio-orthogonal chemical groups as site 
specific reaction handles.11  
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Figure 1.2: Cells were site-specific labeled by genetic labelling and probed using ketone and 
biotin containing molecules. HeLa or HEK cells were transfected with either acceptor protein 
(AP-CFP-TM) or (AP-EGFR) to express on the cell surface, then treated with a biotin containing 
carboxylic acid and biotin ligase. Then the biotin was targeted with a bi-functional hydrazine 
molecule to allow conjugation to Streptavidin-Alexa 658 or hydrazine containing fluorescent 
probe. (Taken from Chen et al. 2005).11 
Human embryonic kidney (HEK) cells were transfected with a cyan fluorescent protein fused 
with an acceptor peptide, which was attached to the transmembrane domain of the platelet-
derived growth factor receptor. The acceptor peptide was then targeted with an exogenous biotin 
ligase (BirA) enzyme from Escherichia coli, which accepts biotin containing ligands (Figure 
1.2). Once expressed on the surface of HEK or HeLa cells, they can be treated with a biotin 
labelled small molecule with an attached probe or ketone functional group, followed by 
treatment in vitro with hydrazine or hydroxylamine containing biophysical probes for functional 
analysis. This method allowed the rapid incorporation of recombinant proteins into the cellular 
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membrane for study, while maintaining a flexible platform for the targeted use of different 
synthetic biophysical probes.  
There has also been interest in using genetic engineering of cell surfaces for antiviral 
therapies, to either remove or block bacterial or viral points of entry into the cell. A recent 
breakthrough in human inmunodeficiency virus (HIV) treatments have shown that genetic 
manipulation of T-cells, a class of white blood cells that protect the body, can be made resistant 
to infection by the HIV virus.12 By altering viral or bacterial antigen recognition sites on 
mammalian cells, the infection rates can be altered or halted, by blocking viral docking with the 
cell membrane. Recently, in a small clinical population of CD4 T cells, an important immune 
system component directly targeted by HIV using the chemokine (C-C) motif (CCR5) surface 
receptor, was rendered permanently dysfunctional through gene editing that produced CD4 T 
cells resistant to the virus. Selected HIV infected patients were treated with autologous CD4 T-
cells by deleting the human CCR5 gene.13 Since this surface receptor contains an HIV binding 
site, deletion of the gene removes or hinders the virus’s capability to penetrate the T-cell 
membrane. 
Although permanent gene editing technologies for cell surface engineering have shown 
potential for niche research and clinical applications, there are major bottlenecks to the use of the 
technology and scope of its application. Genomic manipulation for plasma membrane 
localization of exogenous proteins involves both the complicated production of the protein of 
interest, as well as altering pathways for protein localization that lead from the endoplasmic 
reticulum (ER) or Golgi apparatus to the membrane by hindering phosphorylation,14 S-
palmitoylation, N-terminal myristylation and C-terminal prenylation protein amendments or 
modifications.15 16 Many membrane associated proteins play multiple roles in the membrane 
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contributing to fluidity, lipid raft formation, membrane stability, endocytosis and exocytosis to 
name a few. Changes in these proteins or associated pathways can result in the disruption of the 
cellular membrane itself through over-expression, fluidity and poor lipid content regulation, 
impacting fluid dynamics resulting in poor proliferation, oxidative stress and increased in 
apoptotic signalling. These changes can result in false positive results for gene pathway 
elucidation, incorrect conclusions about gene regulation and false avenues of inquiry for 
academic and industrial research leading to wasted time, expense and effort.  
1.2.2 Cellular Membrane Manipulation using Polymers 
 
Synthetic and natural polymer research has generated a variety of methodologies to 
directly modify cell behaviour through layering or adhesion of polymers to the cellular 
membrane, imparting tunable functionality to the cell. Polymers are a broad class of high 
molecular weight molecules composed of repeating subunits called monomers, which are 
covalently linked together to form linear or branching chains.17 Polymers occupy a special class 
of chemistry and biology due to their emergent macroscopic characteristics which arise from 
their unique chemical and mechanical traits. These macroscopic properties can be modulated 
based upon a number of explored factors, such as subunit chemical structure and placement, the 
amount of branching, chain length, molecular weight and mechanical processing to produce a 
wide array of polymer structures with vastly different properties. Developments using polymers 
such as cellular or membrane coatings can be used for autoimmune resistance in vitro,18 tissue 
engineering,19 20 cancer models,21  hypoxia studies,22 as well as cellular migration and delivery.23  
This research allowed the scientific community to develop a variety of synthetic polymers and 
characterized many naturally occurring biological polymers, enabling the creation of a variety of 
plastics and reagents with a broad range of properties. 
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 Control of cellular behaviour using ionic polymers has developed over the past 10 years 
to include cellular coatings, delivery and electronic control of cellular signalling.24 25 26 Recent 
work has produced novel methodologies using ionic polymers and neuronal cells to create an 
organic electronic ion pump for the study of cellular signalling of calcium ions.27 The group 
synthesized poly(3,4-ethylenedioxythiophene) (PEDOT) doped with poly(styrene sulphonate) 
(PSS) as a proof of concept to control ion homeostasis in single neuronal cells through 
confinement in micron-sized devices (Figure 1.3). 
 
Figure 1.3: Schematic depicting a conducting polymer matrix imbedded with neuronal cells 
used to make sensitive measurements of cell conductivity in response to stimuli. (Taken from 
Isaksson et al. 2007).27 
These non-toxic polymers acted as an electronic connection to the neuron cells to control the 
electronic environment of the cells, stimulating the release or inhibition of calcium ions through 
translation of the electronic signal into an ion flux. The group determined that in Human Cortical 
Neuronal (HCN-2) cells, activation of the pump induced an increase in the intracellular calcium 
and potassium, mimicking manual loading of potassium sulfate into the medium. Molecular 
control of ionic flux through polymer engineering of the cell surface produced meaningful data 
essential for the development of new systems biology approaches to research and clinical 
understanding of disease. 
 Two dimensional adherent surfaces composed of inorganic, synthetic or natural 
polymeric materials can promote growth, cellular migration and prolonged health of cellular 
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colonies.28 29 Polymer surfaces have been used to promote the growth of difficult or sensitive 
cells lines such as embryonic stem cells (ESCs) without inducing differentiation or variability, 
while limiting the use of soluble media factors. Adhesive polymer based cellular growth surfaces 
have recently been developed using polymer surface coating technique using poly[2-
(methylacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide] (PMEDSAH) to 
sustain hEMCs, removing the requirement of animal derived matrix (Matrigel) for long term 
growth in vivo (Figure 1.4).30 
 
Figure 1.4: UV activated polymer surface coatings of PMEDSAH promoted the adhesion and 
growth of hESCs with reduced reliance upon soluble growth factors. (Taken from Villa-Diaz 
et al, 2010).30 
This demonstrated that chemically defined surface engineering can displace inconsistent animal 
derived sources to produce better growth methodologies.   
 Type I diabetes affects over 300 million people worldwide, in which the pancreas does 
not produce sufficient amounts of the hormone insulin, a hormone regulating the cellular uptake 
of glucose for energy production. To treat this disease, there have been a number of approaches 
used, such as gene therapy, injected beta cell autografts, xenografts and pancreatic transplants in 
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an attempt to restore insulin function.31 However, detrimental autoimmune responses can arise in 
the host body. To combat autoimmune responses, researchers have used polymers to mask the 
grafted cells from the host immune system using permeable membranes but few have moved 
toward cell surface engineering as a solution. To protect implanted cells such as stem cell 
derived pancreatic cells for transplantation, they are encapsulated with the porous biomaterial 
triazole-thiomorpholine dioxide (TMTD) modified alginate (Figure 1.5).  
 
Figure 1.5: Microscopic images of polymer encapsulated pancreatic cells derived from 
Human Mesenchymal Stem Cells (HMSCs) for implantation. Cells were encapsulated with 
porous polymer materials to limit or eliminate autoimmune rejection by the host body. (Taken 
from Vegas et al, 2016).32 
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With spheroids consisting of SC-β cells in TMTD alginate spheres, long-term control of the 
glycemic forming porous encapsulated response can be obtained without the use of an 
immunosuppressive drug regime. 
Although polymers for cell based applications have been useful in niche applications, 
they have a number of drawbacks which limit their use in therapeutics and research applications.  
Polymers can be difficult to synthesize and purify in the lab, where batch to batch variability can 
be high, but most importantly controlled degradation of the polymers in a cellular context can be 
very difficult to control or predict. Polymers in living systems are constantly being degraded 
through active or natural processes and replaced as needed, such as in wound healing. For the 
most part, synthetic polymers react poorly to degradation producing toxic by-products, changing 
local pH, or introducing pockets of hypoxia to name a few. Naturally obtained polymers 
however, are expensive and contain significant batch to batch variability in composition, 
producing wildly varying results. Therefore, systems which are cheap, readily quantified and 
without by-products would be an ideal system to perform cellular membrane engineering, where 
molecular solutions can be transiently incorporated into the cells existing structures. 
1.2.3 Metabolic Labelling of Cellular Membranes 
 
A recently developed method for cell surface engineering termed metabolic labelling introduces 
molecular handles onto the cell membrane through the metabolic incorporation of unnatural 
sugars into the primary structure of surface glycans, proteins and peptides. Once added, the 
chemical groups residing on or in the functionalized cells can be used to incorporate 
carbohydrates,33 7 34 containing bio-orthogonal click-functional groups to be selectively targeted 
for imaging proteins,35 assembling small spheroids,34 8 labelling DNA,36 DNA ligation,37 as well 
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as DNA and protein cross-linking.38 39 Metabolic labelling typically requires the chemical 
modification of naturally occurring biological monomers such as sugars, sialic acids, amino acids 
or nucleotides, as shown in Figure 1.6 to include bio-orthogonal groups such as alkynes, where 
following incorporation can be targeted with other molecules such as azide tagged fluorescent 
probes to monitor active cellular processes.40 To incorporate chemistry into live protein within 
cellular structures, reactive analogues of natural cellular metabolites where exposed to cells as 
media additives of azidohomoalanine (Aha), a bio-orthogonal analogue of methionine (Met), in 
Met depleted cellular media.41 Once incorporated, the Aha azido bio-orthogonal group is targeted 
using the Staudinger ligation reaction with a phosphine labeled fluorescence molecule (Figure 
1.6) for structural elucidation and protein localization studies in vivo and in vitro.42 These bio-
orthogonal groups can be targeted using soluble fluorescent molecules, magnetic beads, 
radioactive tracers or labelled biomolecules containing the complimentary bio-orthogonal 
reaction group to quickly and reliably incorporate it into the functionalized proteins. 
 
Figure 1.6: Schematic for reacting metabolically incorporated Aha with soluble phosphine 
tagged reagents to form stable conjugates. (Taken from Kiick et al, 2002).41 
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An important application of live cell metabolic labelling involved the assembly of 
microtissues with the introduction of N-azidoacetylmannosamine to cellular media. These azide 
bearing sialic acid residues were applied to two separate fluorescent immune cell populations of 
Jurkat cells and then reacted with complimentary single stranded DNA (ssDNA) partners 
respectively (Figure 1.7A).8 These ssDNA strands contained a difluorinated cyclooctyne (DIFO)-
conjugating group to react with azide containing surface sugars to complete a bio-orthogonal 
copper-free ligation reaction. Two separate cell populations with complimentary ssDNA strands 
were then combined, resulting in strong polyvalent hydrogen bonding through complimentary 
base pairing to produce cell spheroids of 4-5 cells (Figure 1.7DEG).  
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Figure 1.7: Fluorescently labeled Jurkat cells with metabolically incorporated N-
azidoacetylmannosamine were separately treated with DIFO terminated ssDNA for surface 
conjugation of complimentary binding of ssDNA populations. These oligonucleotides direct 
the formation of 3-dimensional multicellular spheroids entrapped within Matrigel®. (Taken from 
Gartner et al, 2009).8 
A recent extension of this methodology of spheroid production method by developing ssDNA 
programmed assembly of cells to generate larger tissues using epithelial and Human Umbilical 
Vein Cells (HUVEC) cell lines as micro-tissues imbedded within a Matrigel extracellular matrix 
(ECM).43  
1.3 Bio-orthogonal Liposomes as Self-Assembled Nanoparticles for Delivery of Bio-
orthogonal Ligands to Cells 
1.3.1 Liposomes as Vehicles for Drugs or Molecular Delivery  
 
Liposomes were first described by Alec Bangham and colleagues, whom outlined a 
swollen phospholipid system, forming the basis of a model membrane.44 45 Liposomes refer to a 
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simple closed spherical bilayer structure composed of associated amphiphilic lipids, that contain 
a hydrophilic polar headgroup and nonpolar hydrophobic tail, when in an aqueous medium 
resemble the fundamental structure of biological membranes. Lipid polar head groups orient 
towards the interior and exterior aqueous phase while the acyl groups associate to form a internal 
hydrophobic environment, which has enabled these structures to be used extensively in 
commercial applications. The presence of an internal aqueous compartment and hydrophobic 
bilayer phase of liposomes provides these particles with tremendous capabilities as both 
hydrophilic and hydrophobic carriers for drug delivery,46 and use in the cosmetic and food 
industry.47 48 49 50 These molecules self-assemble in aqueous media through hydration of the 
headgroup and strong association of the acyl tails through Van Der Waals forces and 
electrostatics to produce the bilayer structure (lamella). Lipid bilayers systems such as 
liposomes, micelles and lipid-rafts have been used as model systems for the fundamental study 
of lipid mixing,51 membrane fusion52 and biological exosome trafficking.53  Although synthetic 
liposomes are simplified models of cellular membranes, they also occur naturally as exosomes, 
cell-derived particles found in biological fluids implicated in inter-cellular signaling, mRNA 
trafficking, waste excretion and coagulation.54   
Over the past 50 years, major technical advances have been made in synthetic liposomes 
to serve as potent applications for research and therapeutics. The development of better 
techniques for promote drug loading, homogeneous size, ligand targeting, triggered release and 
multiple drug delivery have enabled clinical trials for various cancer, fungal and antibiotic drugs 
previously thought impossible with traditional administration.55 With liposomal particles, 
optimal methods of formation and molecular loading to achieve specific practical biological 
applications must be determined.  There are several biological factors which guide liposome 
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selection including the clearance of liposomes by antibody recognition (vesicle opsonisation) of 
foreign particles and phagocytic scavenging by the reticuloendothelial system (RES),56 57 
absorption and disruption of phospholipid membranes by serum proteins in plasma or cell culture 
media,58 size (increased size results in decreased half-life caused by higher clearance rates by the 
liver and spleen),59 and passive targeting of organs such as lungs using large multilamellar 
vesicles (MLVs) and solid tumors.60 The utility of liposomes as drug delivery agents for 
pharmaceuticals has been well established, where physical liposomal characteristics enable the 
generation of new drug formulations and the re-purposing of previously discarded agents for use 
as cancer drugs. Drug delivery using liposome encapsulation of active pharmaceutical agents has 
resulted in the development of 15 liposomal based drugs including Abelcet®, Deposcy® and 
Lipo-Dox®, to treat a wide variety of indications including fungal infections, malignant 
lymphomatous meningitis, Kaposi’s sarcoma, breast cancer and influenza. This is possible as a 
result of the dynamic nature of the lipid particle, which can be tailored using a variety of 
different lipid components to increase drug circulation times, hinder metabolic degradation and 
target tissues of interest. 
Liposomes can be made to vary in size from 20 nm-100 nm as small unilamellar vesicles 
(SUVs), 100 nm-400 nm large unilamellar vesicles (LUVs) and giant unilamellar vesicles (>1 
µm) through the use of different lipids and additives as well as different formation techniques.  
Liposomes can be synthesized with multiple discrete internal lamella using advanced fabrication 
techniques such as extrusion or microfluidics to produce MLVs containing concentric discrete 
vesicles or multivesicular vesicles (MVVs), which consist of multiple individual vesicles with a 
similar appearance to cellular organelles.61  To prepare lipid dispersion for liposome self-
assembly, there are two general methods: mechanical and solvent dispersion.  Mechanical 
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dispersion is the most common and robust method to obtain liposomes and includes sonication, 
extrusion and freeze-thaw techniques, while solvent dispersion includes solvent vaporization, 
ethanol injection and reverse phase evaporation. 
Sonication is the most common mechanical technique due to its speed and the production 
of a general uniform size distribution of the liposome particles. It involves the use of cavitation 
in aqueous media to break up or induce budding of liposome structures from lipid aggregates in 
aqueous suspension resulting in SUVs from hydrated lipid suspensions.  Sonication produces 
SUVs with a typical average size of 70 nm depending on the length of exposure, and can be 
performed using either tip or bath sonicators.  Although sonication allows for fast and efficient 
production of liposomes, the main disadvantages of this method include low encapsulation 
efficiency, protein degradation, metallic contamination and the production of a mixture of SUVs 
and MLVs within the liposome suspension.   
1.3.2 Cellular Mechanisms of Liposome Uptake and Lipid Incorporation 
Endocytosis plays a significant role as an active mechanism for critical cellular metabolic 
processes such as nutrient uptake, antigen presentation, pathogen entry, receptor regulation, 
synaptic transmission and autocrine signalling.  There are three major mechanisms which 
involve active cellular trafficking of material through the plasma membrane, including 
phagocytosis, pinocytosis and receptor-mediated endocytosis (Figure 1.8). The immune system 
of multicellular organisms typically use phagocytosis to remove cellular debris generated 
through apoptosis or engulfing foreign particles such as bacteria into internal compartments 
called phagosomes.62 These phagosomes fuse with lysosomes, containing acidic pH or hydrolytic 
enzymes, to destroy the phagosome contents for later absorption.  Pinocytosis closely resembles 
phagocytosis, but involves the internalization of small molecules for hydrolysis in lysosomes, 
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commonly seen as an “eating or drinking” mechanism for the cell to obtain nutrients.  A well-
studied form of receptor-mediated endocytosis termed Clathrin-mediated endocytosis has been 
shown to be a ubiquitous internalization mechanism for cells, that involves Clathrin, a large 
cytosolic protein located on the proximal surface of the cellular membrane, which interacts with 
distal receptors such as the low-density lipoprotein (LDL) receptor and transferrin to remove 
LDL from the blood and ferric ions respectively, through internalization.63 64 
 
Figure 1.8: Depiction of three general active mechanisms of endocytosis in cells.  (A) 
Phagocytosis allows for cells to deform their plasma membrane and engulf a solid particle, 
commonly used by immune cells to ingest pathogens, through recognition of pathogen associated 
molecular patterns (PAMPs). (B) Pinocytosis involves the formation of pits in the plasma 
membrane for non-selective uptake of nutrients and liquids. (C) Receptor-mediated endocytosis 
utilizes specific transmembrane receptors to bind ligands which trigger actin reorganization for 
invagination of the plasma membrane and internalization. 
Clathrin proteins aggregate in patches on the inner membrane causing the formation of 
membrane buds, which pinch off creating cytosolic Clathrin coated vesicles, which can be 
trafficked within the cell. The plasma membrane of many cells types also contain Caveolae, 
small flask shaped pits consisting of the Vip21 cholesterol binding protein, which commonly 
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occur in smooth muscle, fibroblasts and adipocytes.65 Liposome fusion also plays an important 
role in cellular entry for internal functions, such as lipid shuttling within the ER and signal 
transduction in neuronal cells. 
Model lipid bilayer systems such as liposomes have been crucial for elucidating and  
mimicking the biophysical structure and fundamental behavior of biological membranes and 
membrane fusion. Membrane fusion occurs where two discrete bilayers merge lipid bilayers 
resulting in the mixing of both the lipid and internal aqueous environments. Lipid bilayers 
undergo three general stages to achieve fusion: (1) Membrane Contact (stalk formation), (2) 
Merging (hemifusion), and (3) Pore Formation (Figure 1.9).  
 
Figure 1.9: General depiction of two membranes undergoing membrane fusion. Initiated 
through close proximity, stalk structures form to bridge the proximal lipid layers. The 
membrane structures then become unstable resulting in hemifusion, where the distal layers 
interact, followed by pore formation and complete lipid mixing of the membrane lipids. 
Initiation of membrane fusion occurs when two proximal membrane layers come into close 
contact, overcoming both head group electrostatic repulsion and the dehydration of the 
interstitial water boundary layer, for approach within a few angstroms. Once in contact the layers 
must undergo destabilization, either through active protein complexation, covalent adhesion or 
electrostatic charge driven mixing.  These destabilized transition or intermediate membrane 
states are not fully understood but literature best describes the formation of stalk like structures 
(Figure 1.9), which rearrange into the hemifused structure as the distal boundary layers approach, 
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resulting in a pseudo-merging of the lipid layers. This hemifused structural intermediate then 
proceeds to form the pore structure, resulting in the merging and mixing of the two membrane 
layers. These fluid bilayer fusion mechanisms are also reflected in biological systems which use 
protein structures to deform or aid the thermodynamic process of membrane fusion to enable 
faster biological processing.  
 
Figure 1.10: Current model of Soluble NSF Attachment Protein Receptor (SNARE)-
mediated fusion. The distal membrane leaflets come into close proximity but the SNARES are 
not yet interacting. SNARE complexes interact and begin zipping from the amino-terminal end, 
drawing the membranes closer together. The zippering continues, increasing the membrane 
curvature and lateral tension of the individual membranes, exposing the hydrophobic interior of 
the bilayer. Hemifusion spontaneously occurs as the membranes are close enough in proximity. 
The lateral tension causes membrane breakdown to form a fusion pore, where the pore expands 
causing a reduction in membrane curvature surface tension. (Taken from Hu et al, 2007).66 
The biological use of membrane fusion allows for the rapid movement of intracellular 
factors, which have been well studied in neuronal synaptic signalling of the presynaptic 
membrane.67 Figure 1.10 demonstrates how vesicular surface markers interact with target 
membrane receptors for selective fusion of liposome-like delivery vesicles using N-
ethylmaleimide sensitive fusion (NSF) receptors, to mediate vesicle fusion of neurotransmitter 
carriers to target neuronal membranes. Synthetic liposomal carriers for cellular delivery exploit 
natural mechanisms either using specific receptor recognition events for molecular localization, 
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or non-specific interactions such as electrostatics or nanometer sized liposomes (high membrane 
curvature) to deliver cargo for passage through the plasma membrane.68 69  
Cationic liposome based nucleic acid delivery has been commonly used to introduce both 
endogenous and exogenous genes into cells for discovery of protein and cellular behavior 
pathways. Initially biophysical and biological methods such as electroporation and viral 
transfection respectively, were used to deliver macromolecules into cells.70 71 Recently, chemical 
methods have been developed to deliver oligonucleotides or other electrostatically charged 
molecules into the cell with charged liposome particles. The introduction of chemical based 
transfection reagents such as Lipofectamine® and Viafect® for cationic lipid-based delivery of 
anionic nucleic acids, allowing for cheaper and easier methods for elucidation of new biological 
processes and pathways using knock-in, knock out and gene silencing strategies to the benefit of 
life sciences and the clinical understanding of disease mechanisms. These methods generally 
utilize cationic liposome or lipid formulations to encapsulate anionic nucleic acids resulting in 
beneficial properties such as protection from degradation and delivery of encapsulated material 
into the cytosol.   
1.3.3 Bio-orthogonal Lipid Incorporation into Cellular Membranes via Liposome Fusion 
 
 Developing novel liposome based cell surface engineering strategies over previous 
methodologies requires a general set of criteria for improvement and adoption into cellular based 
research: (1) The method must deliver and label the outer plasma leaflets of any cell-type, 
without permanently altering the genomic content of the cell, (2) embedded engineering must 
selectively react under physiological or cell culture conditions, (3) applied ligands must be easy 
to synthesize, while displaying fast kinetics and stability in the plasma membrane with a 
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conjugation partner, (4) the system must be robust and programmable to enable cell labelling and 
cell surface reactions to take place with high cell economy and stoichiometry, (5) the method 
must be modular and compatible with existing techniques such as microfluidics, inorganic and 
organic surfaces as a complimentary technology. 
The Yousaf group has focused on developing methodology using bio-orthogonal 
chemistries upon inorganic and organic surfaces to probe, influence and model cellular behavior 
in vitro (Figure 1.11).  Bio-orthogonal chemistry functional groups have recently been 
 
Figure 1.11: Depiction of bio-orthogonal chemistry pairs used for chemical biology 
applications. These pairs can be incorporated into biomolecules and cellular structures without 
interfering with native biochemistry and can undergo reactions in complex cellular environments. 
popularized for use in chemical biology applications, such as genetic engineering techniques,72 73 
74 polymers,75 76 77 metabolic products,78 79 conjugating proteins,80 antibodies,81 and small 
molecules on bioactive surfaces to name a few. Most notably, the recent development of Cu2+ 
free reaction of strained cyclooctynes with azides (Huisgen Reaction) revived interest in using 
chemistry to probe and affect biology.82 The use of strained cyclic alkynes enabled the removal 
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of cytotoxic copper from these reactions to produce a true ‘click’ two body reaction with utility 
in cellular media and in the presence of live cells.   
 Oxime chemistry is a bio-orthogonal reaction where N-hydroxylamine functional groups 
quickly and selectively react with ketone moieties under aqueous physiological conditions.83   
Oxime reaction partners are beneficial to chemical biology applications, as oppposed to other 
bio-orthogonal methodologies, due to ease of synthesis and fewer synthetic steps. Initial work of 
oxime chemistry focused on using modified inorganic surfaces and liposomal cell surface 
engineering to create dynamic surfaces and inorganic surface functionalization for biological 
studies, rather than using genetic, polymer or metabolic based techniques.   
The Yousaf group pioneered the development of model gold surfaces patterned with 
molecular gradients of hydroxylamine terminated self-assembled monolayers (SAMs) (Figure 
1.12). These hydroxylamine gradients were then modified with Arginylglycylaspartic acid 
(RGD)-ketone molecules to create gradients of RGD peptides to study cell adhesion, polarity and 
migration.84 Diffusion and bio-orthogonal chemistry can be used to introduce a new functionality 
to inorganic surfaces for biological studies without interfering with biological processes, while 
modifying a surface simply and effectively. The method can be used widely for research in stem 
cell differentiation,85 high-throughput adhesive studies,86 switchable electroactive surfaces for 
protein structure,87 as well as cellular division on these bio-orthogonal gradient surfaces.88 
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Figure 1.12: Microfluidic gradient of O-hydroxylamine patterning on gold substrates for 
ketone terminated addition of RGD-ketones for cellular migration studies. (Taken from 
Yousaf et al.)84 
To enhance and provide greater control of the membrane, rather than modify adhesive substrates, 
the cell membrane can be directly modified to obtain a higher degree of cellular manipulation.  
Since previous work studied hydroxylamine SAMs on gold surfaces, indium tin oxide (ITO) 
surfaces and liposomes deposited onto glass surfaces which modelled the cellular surfaces and 
membranes for cell adhesion assays. Applying lipid bio-orthogonal chemistry directly into the 
cellular membrane became the next step in the evolution of this innovative surface modifying 
technology. Initial experiments applying bio-orthogonal lipids into the cellular membrane 
focused on the delivery of lipids for Fluorescence Resonance Energy Transfer (FRET) and 
fluorescent molecule targeting for imaging.89 The liposomal strategy has been successful in 
delivering liposome oxime conjugated fluorophores, as well as ketone lipids to cell membranes 
and conjugated in live cell culture with hydroxylamine fluorophores.   
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  The overarching objective of this thesis work is to develop a robust and enabling 
methodology based upon our CSE technology to perform microfluidic cellular manipulation, cell 
membrane labelling and cargo delivery applications. Over the course of this thesis I developed a 
CSE technology that enables new biological experiments through the ability to reliably and 
rapidly manipulate the plasma membrane, which led to separate downstream applications. To 
develop our CSE strategy as an enabling platform for biological research, we demonstrated the 
liposome technique as a microfluidic reagent to label cells rapidly and robustly, which is 
important for flow cytometry, mass spectrometry, cell sorting and sensing applications. To 
enable new experiments, we developed methods to label and build tissue structures with multiple 
different cell types with spatial orientation that have applications in tissue engineering, 
transplantation, drug assays and therapeutics. We demonstrated CSE strategy for cargo delivery 
using transfection as a model system which has applications in gene therapy, small molecule, cell 
surface protein delivery and mixed multi-modal delivery techniques. Finally, we developed a 
novel amine conjugation reaction with applications in protein labelling, antibody drug conjugates 
(ADCs) and future CSE abilities through conjugation with liposomes. The elucidation and 
development of our CSE technique over these fields of application will validate the unique and 
enabling properties across multiple research areas and applications. 
  
  
26 
 
1.4 References  
 
(1)  Li, S. Int. J. Biol. Sci. 2005, 1 (4), 152. 
(2)  Cappuccio, A.; Zollinger, R.; Schenk, M.; Walczak, A.; Servant, N.; Barillot, E.; Hupé, P.; 
Modlin, R. L.; Soumelis, V. 2015, 6, 6847. 
(3)  Fulda, S.; Gorman, A. M.; Hori, O.; Samali, A. Int. J. Cell Biol. 2010, 2010. 
(4)  Shi, J.; Kundrat, L.; Pishesha, N.; Bilate, A.; Theile, C.; Maruyama, T.; Dougan, S. K.; Ploegh, H. 
L.; Lodish, H. F. Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (28), 10131–10136. 
(5)  Liechty, W. B.; Kryscio, D. R.; Slaughter, B. V; Peppas, N. A. Annu. Rev. Chem. Biomol. Eng. 
2010, 1 (1), 149–173. 
(6)  Park, K. M.; Gerecht, S. 2014, 5, 4075. 
(7)  Laughlin, S. T.; Bertozzi, C. R. Nat. Protoc. 2007, 2 (11), 2930–2944. 
(8)  Gartner, Z. J.; Bertozzi, C. R. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (12), 4606–4610. 
(9)  Fernandez-Suarez, M.; Baruah, H.; Martinez-Hernandez, L.; Xie, K. T.; Baskin, J. M.; Bertozzi, C. 
R.; Ting, A. Y. Nat Biotech 2007, 25 (12), 1483–1487. 
(10)  Smith, D. J.; Liu, S.; Ji, S.; Li, B.; McLaughlin, J.; Cheng, D.; Witte, O. N.; Yang, L. Proc. Natl. 
Acad. Sci.  2015, 112 (5), 1523–1528. 
(11)  Chen, I.; Howarth, M.; Lin, W.; Ting, A. Y. Nat. Methods 2005, 2 (2), 99–104. 
(12)  Leslie, G. J.; Wang, J.; Richardson, M. W.; Haggarty, B. S.; Hua, K. L.; Duong, J.; Secreto, A. J.; 
Jordon, A. P. O.; Romano, J.; Kumar, K. E.; DeClercq, J. J.; Gregory, P. D.; June, C. H.; Root, M. 
J.; Riley, J. L.; Holmes, M. C.; Hoxie, J. A. PLOS Pathog. 2016, 12 (11), e1005983. 
(13)  Tebas, P.; Stein, D.; Tang, W. W.; Frank, I.; Wang, S. Q.; Lee, G.; Spratt, S. K.; Surosky, R. T.; 
Giedlin, M. A.; Nichol, G.; Holmes, M. C.; Gregory, P. D.; Ando, D. G.; Kalos, M.; Collman, R. 
G.; Binder-Scholl, G.; Plesa, G.; Hwang, W.-T.; Levine, B. L.; June, C. H. N. Engl. J. Med. 2014, 
370 (10), 901–910. 
(14)  Silhavy, T. J.; Benson, S. A.; Emr, S. D. Microbiol. Rev. 1983, 47 (3), 313–344. 
(15)  Li, L.; Haynes, M. P.; Bender, J. R. Proc. Natl. Acad. Sci.  2003, 100 (8), 4807–4812. 
(16)  Linder, M. E.; Deschenes, R. J. Nat Rev Mol Cell Biol 2007, 8 (1), 74–84. 
(17)  Crosby, A. J.; Lee, J. Polym. Rev. 2007, 47 (2), 217–229. 
(18)  Tzianabos, A. O. 2000, 13 (4), 523–533. 
(19)  Dhandayuthapani, B.; Yoshida, Y.; Maekawa, T.; Kumar, D. S. 2011, 20 (ii). 
(20)  Place, E. S.; George, J. H.; Williams, C. K.; Stevens, M. M. Chem. Soc. Rev. 2009, 38 (4), 1139–
1151. 
(21)  Petersen, R. C. 2013, 2013. 
(22)  Fonseca, A. C.; Serra, A. C.; Coelho, J. F. J. EPMA J. 2015, 6, 22. 
(23)  De Vos, P.; Lazarjani, H. A.; Poncelet, D.; Faas, M. M. Adv. Drug Deliv. Rev. 2014, 67–68, 15–
27 
 
34. 
(24)  Bushuyev, O. S.; Brown, P.; Maiti, A.; Gee, R. H.; Peterson, G. R.; Weeks, B. L.; Hope-Weeks, L. 
J. J. Am. Chem. Soc. 2012, 134 (3), 1422–1425. 
(25)  Zhang, Y.; Chen, X.; Lan, J.; You, J.; Chen, L. Chem. Biol. Drug Des. 2009, 74 (3), 282–288. 
(26)  Balint, R.; Cassidy, N. J.; Cartmell, S. H. Acta Biomater. 2014, 10 (6), 2341–2353. 
(27)  Isaksson, J.; Kjäll, P.; Nilsson, D.; Robinson, N. D.; Berggren, M.; Richter-Dahlfors, A. Nat. 
Mater. 2007, 6 (9), 673–679. 
(28)  Kato, D.; Takeuchi, M.; Sakurai, T.; Furukawa, S.; Mizokami, H.; Sakata, M.; Hirayama, C.; 
Kunitake, M. Biomaterials 2003, 24 (23), 4253–4264. 
(29)  Niu, J.; Lunn, D. J.; Pusuluri, A.; Yoo, J. I.; O’Malley, M. A.; Mitragotri, S.; Soh, H. T.; Hawker, 
C. J. Nat Chem 2017, 9 (6), 537–545. 
(30)  Villa-Diaz, L. G.; Nandivada, H.; Ding, J.; Nogueira-de-Souza, N. C.; Krebsbach, P. H.; O’Shea, 
K. S.; Lahann, J.; Smith, G. D. Nat Biotech 2010, 28 (6), 581–583. 
(31)  Bruni, A.; Gala-Lopez, B.; Pepper, A. R.; Abualhassan, N. S.; Shapiro, A. M. J. Diabetes, Metab. 
Syndr. Obes. Targets Ther. 2014, 7, 211–223. 
(32)  Vegas, A. J.; Veiseh, O.; Gürtler, M.; Millman, J. R.; Pagliuca, F. W.; Bader, A. R.; Doloff, J. C.; 
Li, J.; Chen, M.; Olejnik, K.; Tam, H. H.; Jhunjhunwala, S.; Langan, E.; Aresta-Dasilva, S.; 
Gandham, S.; McGarrigle, J. J.; Bochenek, M. A.; Hollister-Lock, J.; Oberholzer, J.; Greiner, D. 
L.; Weir, G. C.; Melton, D. A.; Langer, R.; Anderson, D. G. Nat. Med. 2016, 22 (3), 306–311. 
(33)  Ngo, J. T.; Adams, S. R.; Deerinck, T. J.; Boassa, D.; Rodriguez-Rivera, F.; Palida, S. F.; Bertozzi, 
C. R.; Ellisman, M. H.; Tsien, R. Y. Nat Chem Biol 2016, 12 (6), 459–465. 
(34)  Chang, P. V.; Chen, X.; Smyrniotis, C.; Xenakis, A.; Hu, T.; Bertozzi, C. R.; Wu, P. Angew. 
Chemie 2009, 121 (22), 4090–4093. 
(35)  Saxon, E.; Bertozzi, C. R. Science (80-. ). 2000, 287 (5460), 2007 LP-2010. 
(36)  Merkel, M.; Arndt, S.; Ploschik, D.; Cserép, G. B.; Wenge, U.; Kele, P.; Wagenknecht, H.-A. J. 
Org. Chem. 2016, 81 (17), 7527–7538. 
(37)  Roloff, A.; Seitz, O. Chem. Sci. 2013, 4 (1), 432–436. 
(38)  Dadová, J.; Vrábel, M.; Adámik, M.; Brázdová, M.; Pohl, R.; Fojta, M.; Hocek, M. Chem. - A Eur. 
J. 2015, 21 (45), 16091–16102. 
(39)  Hu, F.; Lamprecht, M. R.; Wei, L.; Morrison, B.; Min, W. 2016, 6, 39660. 
(40)  Laughlin, S. T.; Baskin, J. M.; Amacher, S. L.; Bertozzi, C. R. Science (80-. ). 2008, 320 (5876), 
664–667. 
(41)  Kiick, K. L.; Saxon, E.; Tirrell, D. A.; Bertozzi, C. R. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (1), 
19–24. 
(42)  Beatty, K. E.; Szychowski, J.; Fisk, J. D.; Tirrell, D. A. Chembiochem 2011, 12 (14), 2137–2139. 
(43)  Todhunter, M. E.; Jee, N. Y.; Hughes, A. J.; Coyle, M. C.; Cerchiari, A.; Farlow, J.; Garbe, J. C.; 
LaBarge, M. A.; Desai, T. A.; Gartner, Z. J. Nat Meth 2015, 12 (10), 975–981. 
28 
 
(44)  Bangham, A. D.; Standish, M. M.; Watkins, J. C. J. Mol. Biol. 1965, 13 (1), 238–IN27. 
(45)  Bangham, A. D.; Standish, M. M.; Watkins, J. C.; Weissmann, G. Bolis, L., Capraro, V., Porter, 
K. R., Robertson, J. D., Eds.; Springer Vienna: Vienna, 1967; pp 183–187. 
(46)  Pattni, B. S.; Chupin, V. V; Torchilin, V. P. Chem. Rev. 2015, 115 (19), 10938–10966. 
(47)  Perrie, Y.; Kastner, E.; Khadke, S.; Roces, C. B.; Stone, P. Fox, C. B., Ed.; Springer New York: 
New York, NY, 2017; pp 127–144. 
(48)  Raj, S.; Jose, S.; Sumod, U. S.; Sabitha, M. J. Pharm. Bioallied Sci. 2012, 4 (3), 186–193. 
(49)  Mohammadi, R.; Mahmoudzade, M.; Atefi, M.; Khosravi-Darani, K.; Mozafari, M. R. Int. J. 
Dairy Technol. 2015, 68 (1), 11–23. 
(50)  Taylor, T. M.; Weiss, J.; Davidson, P. M.; Bruce, B. D. Crit. Rev. Food Sci. Nutr. 2005, 45 (7–8), 
587–605. 
(51)  Duzgunes, N.; Allen, T. M.; Fedor, J.; Papahadjopoulos, D. Biochemistry 1987, 26 (25), 8435–
8442. 
(52)  Liu, J.; Jiang, X.; Ashley, C.; Brinker, C. J. J. Am. Chem. Soc. 2009, 131 (22), 7567–7569. 
(53)  Tian, T.; Zhu, Y.-L.; Hu, F.-H.; Wang, Y.-Y.; Huang, N.-P.; Xiao, Z.-D. J. Cell. Physiol. 2013, 
228 (7), 1487–1495. 
(54)  Thery, C.; Zitvogel, L.; Amigorena, S. Nat Rev Immunol 2002, 2 (8), 569–579. 
(55)  Allen, T. M.; Cullis, P. R. Adv. Drug Deliv. Rev. 2013, 65 (1), 36–48. 
(56)  Gregoriadis, G.; Gregoriadis, G.; Piper, J. R.; Papahadjopoulos, D.; Ghyczy, M.; Etschenberg, J.; 
Holstein, A. F. Trends Biotechnol. 1985, 3 (9), 235–241. 
(57)  Moghimi, S. M.; Hunter, A. C. Pharm. Res. 2001, 18 (1), 1–8. 
(58)  Jones, M. N.; Nicholas, A. R. Biochim. Biophys. Acta - Biomembr. 1991, 1065 (2), 145–152. 
(59)  Ishida, T.; Harashima, H.; Kiwada, H. Biosci. Rep. 2002, 22 (2), 197–224. 
(60)  Gabizon, A.; Papahadjopoulos, D. Proc. Natl. Acad. Sci. U. S. A. 1988, 85 (18), 6949–6953. 
(61)  Torchilin, V. P. Adv. Drug Deliv. Rev. 2012, 64, 302–315. 
(62)  Bilyy, R. O.; Shkandina, T.; Tomin, A.; Muñoz, L. E.; Franz, S.; Antonyuk, V.; Kit, Y. Y.; 
Zirngibl, M.; Fürnrohr, B. G.; Janko, C.; Lauber, K.; Schiller, M.; Schett, G.; Stoika, R. S.; 
Herrmann, M. J. Biol. Chem. 2012, 287 (1), 496–503. 
(63)  Marsh, M.; McMahon, H. T. Science (80-. ). 1999, 285 (5425), 215 LP-220. 
(64)  Anderson, R. G. W.; Brown, M. S.; Goldstein, J. L. Cell 2017, 10 (3), 351–364. 
(65)  Parton, R. G.; Simons, K. Nat Rev Mol Cell Biol 2007, 8 (3), 185–194. 
(66)  Hu, C.; Hardee, D.; Minnear, F. Exp. Cell Res. 2007, 313 (15), 3198–3209. 
(67)  Chen, Y. A.; Scheller, R. H. Nat Rev Mol Cell Biol 2001, 2 (2), 98–106. 
(68)  Robinson, M. S. Trends Cell Biol. 2017, 7 (3), 99–102. 
(69)  Helwa, Y.; Dave, N.; Liu, J. Soft Matter 2013, 9 (26), 6151–6158. 
29 
 
(70)  Neumann, E.; Schaefer-Ridder, M.; Wang, Y.; Hofschneider, P. H. EMBO J. 1982, 1 (7), 841–
845. 
(71)  Gardlík, R.; Pálffy, R.; Hodosy, J.; Lukács, J.; Turna, J.; Celec, P. Med. Sci. Monit. 2005, 11 (4), 
RA110-A121. 
(72)  Lang, K.; Davis, L.; Torres-Kolbus, J.; Chou, C.; Deiters, A.; Chin, J. W. Nat Chem 2012, 4 (4), 
298–304. 
(73)  Elliott, T. S.; Bianco, A.; Chin, J. W. Curr. Opin. Chem. Biol. 2014, 21, 154–160. 
(74)  Nguyen, D. P.; Elliott, T.; Holt, M.; Muir, T. W.; Chin, J. W. J. Am. Chem. Soc. 2011, 133 (30), 
11418–11421. 
(75)  Wu, C.; Jin, Y.; Schneider, T.; Burnham, D. R.; Smith, P. B.; Chiu, D. T. Angew. Chemie Int. Ed. 
2010, 49 (49), 9436–9440. 
(76)  Devaraj, N. K.; Thurber, G. M.; Keliher, E. J.; Marinelli, B.; Weissleder, R. Proc. Natl. Acad. Sci.  
2012, 109 (13), 4762–4767. 
(77)  Gattás-Asfura, K. M.; Stabler, C. L. ACS Appl. Mater. Interfaces 2013, 5 (20), 9964–9974. 
(78)  Homann, A.; Qamar, R.; Serim, S.; Dersch, P.; Seibel, J. Beilstein J. Org. Chem. 2010, 6, 24. 
(79)  Chang, P. V.; Chen, X.; Smyrniotis, C.; Xenakis, A.; Hu, T.; Bertozzi, C. R.; Wu, P. Angew. 
Chemie Int. Ed. 2009, 48 (22), 4030–4033. 
(80)  Kim, C. H.; Axup, J. Y.; Schultz, P. G. Curr. Opin. Chem. Biol. 2013, 17 (3), 412–419. 
(81)  Colombo, M.; Sommaruga, S.; Mazzucchelli, S.; Polito, L.; Verderio, P.; Galeffi, P.; Corsi, F.; 
Tortora, P.; Prosperi, D. Angew. Chemie Int. Ed. 2012, 51 (2), 496–499. 
(82)  Agard, N. J.; Prescher, J. A.; Bertozzi, C. R. J. Am. Chem. Soc. 2004, 126 (46), 15046–15047. 
(83)  Agten, S. M.; Dawson, P. E.; Hackeng, T. M. J. Pept. Sci. 2016, 22 (5), 271–279. 
(84)  Lamb, B. M.; Park, S.; Yousaf, M. N. Langmuir 2010, 26 (15), 12817–12823. 
(85)  Luo, W.; Yousaf, M. N. J. Colloid Interface Sci. 2011, 360 (2), 325–330. 
(86)  Pulsipher, A.; Yousaf, M. N. Chem. Commun. 2011, 47 (1), 523–525. 
(87)  Lamb, B. M.; Yousaf, M. N. J. Am. Chem. Soc. 2011, 133 (23), 8870–8873. 
(88)  Lamb, B. M.; Luo, W.; Nagdas, S.; Yousaf, M. N. ACS Appl. Mater. Interfaces 2014, 6 (14), 
11523–11528. 
(89)  Dutta, D.; Pulsipher, A.; Luo, W.; Mak, H.; Yousaf, M. N. Bioconjug. Chem. 2011, 22 (12), 2423–
2433. 
 
  
30 
 
Chapter 2 
Cell Surface Engineering in Flow Using Bio-orthogonal Liposomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contributions 
M.N.Y designed the study. P.J.O., D.R., and S.E. performed the experiments. M.N.Y., P.J.O., and S.E. analyzed the 
data. P.J.O. and M.N.Y. wrote the manuscript. 
  
31 
 
2.1 Introduction 
 Lack of efficient, cost-effective and general techniques to manipulate cells and the 
plasma membrane is a major challenge to the complex study of human health, where 3D cellular 
interactions in tissues, cell membranes, tumour growth, paracrine and autocrine signalling and 
cell migration within tissues are critical but difficult to explore. As a result, tremendous progress 
has been directed towards manipulating cellular membranes using molecular biology,1 synthetic 
metabolic incorporation via biosynthesis,2 3 4 natural or synthetic polymer coatings,5 6 and 
polymeric constructs.7 8 The Yousaf group has developed a complimentary general CSE 
methodology to introduce bio-orthogonal ‘click’ lipids to eukaryotic,9 and bacterial10 
phospholipid bilayers via liposome fusion for membrane probes, cell migration studies11 and 
tissue engineering applications through cell-cell ligation and rapid complex spheroid assembly 
through microfluidic control.12  
The combination of bio-orthogonal chemistry and liposome fusion for CSE provides 
numerous benefits over other methodologies for the manipulation of cellular membranes and 
cellular behavior: (1) bio-orthogonal CSE provides a general methodology to transiently alter the 
plasma membrane of different cell types, without manipulating genomic content, (2) bio-
orthogonal ligands, particularly ketone and hydroxylamine functional groups, can be relatively 
easy to synthesize as amphiphilic lipids or molecular probes, (3) bio-orthogonal chemical groups 
can react selectively in the presence of live cell culture conditions, without interfering with 
native biochemistry, (4) bio-orthogonal reactions undergo fast and stable conjugation under cell 
culture conditions, (5) liposome fusion and mixing of liposomes with cellular membranes is fast 
and well-understood through previously published literature, and lastly (6) the method can be 
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modular and compatible with other existing techniques such as microfluidics as a complimentary 
or enabling technology.  
To rewire and explore the capabilities of this integrated bio-orthogonal liposome 
approach to cellular manipulation using cell surface engineering, we focused on using 
microfluidics to study the efficiency, utility and speed of our method to undergo membrane 
fusion, cell functionalization and subsequent applications.  Figure 2.1 describes the CSE 
microfluidic methodology for the rapid delivery of complimentary bio-orthogonal ligands and 
moieties directly to the cell surface using membrane fusion to form engineered cell lines.  By 
integrating microfluidics with our CSE delivery technique we can probe the utility of membrane 
functionalization as well as quantify the amount of CSE necessary for various applications.  
Incorporating internal aqueous cargo in addition to membrane incorporated bio-orthogonal 
functionality, we demonstrate this dual delivery methodology as an example of the multiplexing 
ability via liposome technology.  Using a tandem payload delivery, multiplexed experiments 
enable the incorporation of nucleic acids, bio-orthogonal CSE and membrane probes for tissue 
assembly, transfection of complex tissues and molecular probe delivery.    
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Figure 2.1: Schematic depicting the utility of bio-orthogonal CSE strategies for general 
microfluidic manipulation of cellular suspensions. (A)  The combination of liposomes and 
cellular suspensions in microfluidics can be produced simply and rapidly to engineer cell 
membranes (R). (B) Combining lipid delivery of any small molecule (R) with liposome delivery 
strategies enables membrane fusion and mixing of the liposome leaflets into the plasma membrane 
for probe incorporation. (C) Bio-orthogonal chemistry embedded in the liposome membrane (X) 
does not interfere with hydrophilic cargo encapsulation (Y), allowing increased scope by enabling 
multiplexed reagents for cellular manipulation.  (D) Highly multiplexed microfluidic devices in 
combination with bio-orthogonal CSE (X) and (Z) can be used to form complex spheroid 
assemblies and tissues.  (E) Bio-orthogonal CSE can also be used for dual purpose biological 
applications such as simultaneous transfection (Y) and tissue assembly applications (X) and (Z) 
using microfluidics.  
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The combination of microfluidics, liposomes and bio-orthogonal chemistry can be a 
powerful enabler of new methodologies, while also incorporating a simple microfluidic delivery 
system of synthetic bio-orthogonal pairs to cellular membranes via liposome fusion to impart 
rapid and useful functionalities. Figure 2.2 depicts the composition of CSE liposomes and the 
base microfluidic system for treating cells for the formation of multiple cell-type tissues, dual 
assembly-nucleic acid transfected tissues and molecular probe delivery all within a single device.  
Liposomes engineered with bio-orthogonal lipids can be easily combined with other technologies 
such as nucleic acid transfection and small ligand delivery acting as probes for tissue formation 
and complex transfection of tissue constructs. The use of liposomes to deliver bio-orthogonal 
ligands was demonstrated to be mild, fast and efficient producing tissues and spheroids rapidly 
without purification in microfluidic flow. Using this methodology, we demonstrate the 
production of complex three cell-type spheroids and tissues, hybrid transfected tissue constructs 
in microfluidics and the delivery of oxime coupled biotin to mammalian cell lines. 
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Figure 2.2: Depiction of the formulation and delivery of bio-orthogonal lipid engineered 
liposomes to achieve engineered cells and tissues in microfluidic flow. (A) Bio-orthogonal 
liposomes used for CSE delivery and spheroid or tissue formation are composed of POPC (4), 
DOTAP (5) and synthetic ketone lipids (6) to form a ketone CSE liposome (7) in varying ratios of 
lipids (8) and total liposome concentration (9) to determine cellular adhesion efficiency.  (B) 
Complimentary hydroxylamine CSE liposomes are composed of POPC (4), DOTAP (5) and 
synthetic hydroxylamine lipid (10) to form hydroxylamine liposomes (11) in varying ratios of 
lipids (12) and total liposome concentration (13) for cellular fusion to suspension cells in 
microfluidic devices. (C) General microfluidic scheme depicting setup of a Y-channel microfluidic 
device used to engineer suspended native cells (14) through simultaneous injection with CSE 
liposomes (15), in combination with other aqueous soluble molecular agents (RED).  Under flow 
conditions, the liposome and cell suspension mix rapidly and undergo rapid membrane fusion (16) 
to achieve CSE cells (17), which can be probed using complimentary hydroxylamine CSE HNDF 
RFP cells or fluorescent imaging with hydroxylamine-Biotin/Streptavidin(FITC) binding.  (D) 
Small molecule membrane embedded ligands (GREEN) and cargo (RED) used to potentially 
enhance liposomal delivery systems. 
Cell populations were engineered using bio-orthogonal liposomal formulations 
containing readily available lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
(4) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) (5) and then combined with 
synthetic bio-orthogonal ketone (6) and hydroxylamine (10) lipids to form separate populations 
of ketone (7) and hydroxylamine (11) forming the liposomes shown in Figure 2.2A, B. Figure 
2.2C describes the microfluidic treatment of cells with bio-orthogonal liposomes (15), which can 
be easily varied to determine optimal CSE application to cell populations (14) for both tissue 
formation and ligand delivery. Ratios of ketone and hydroxylamine (8) and (12) lipids were 
varied, along with overall liposome concentration (9) and (13) to determine the minimum CSE 
necessary for polyvalent adhesion to occur. These liposome populations can be used together or 
individually as CSE carriers (16) with one or more payloads in microfluidic flow to engineer 
native cells (14) to achieve CSE cell lines (17). Microfluidics impart precision control of injected 
reagents, mixing, liposome fusion and elution of CSE cells (17) that can be further modified by 
adding additional channels and inlets. The small channel cross-sectional volume and large 
surface contact within microfluidic channels promote rapid mixing along the axis of flow, where 
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cells and liposomes associate through electrostatics resulting in increased uniform delivery of 
liposomes to the cellular surface. Microfluidic devices have led to innovations in genetic 
sequencing,13 cell sorting applications,14 enzyme kinetics,15 cell biology16 and biomedical 
research17 through the use of micron-sized reaction chambers which impart unique physical 
properties to the flow stream. Cell populations consisting of ketone and hydroxylamine CSE 
cells become rapidly labelled and in flow associate within 70 seconds, while controls missing 
either one or both bio-orthogonal chemical groups did not assemble. However, bio-orthogonal 
CSE cells which are cultured after application proliferate over time resulting in dilution of our 
labelling chemistry and retain viability. 
Liposomal drug delivery methodologies are well established and understood as delivery 
vesicles for a variety of therapeutics such as the cancer agents Myocet® and DaunoXome®, 
imaging technology,18 nucleic acid transfection19 20 and drug delivery.21 Liposome strategies 
have also been essential for the fundamental study of cell membrane dynamics and membrane 
biology through their utility as model membranes.22 23 24 Extending the capabilities of liposome 
technologies through bio-orthogonal CSE allows for additional functionality by adding 
complimentary complexity without inhibiting the ease of use or overall utility. Bio-orthogonal 
functional groups are a collection of chemoselective ‘click’ reactions which couple two 
molecules under physiological conditions rapidly and without side reactions,25 26 which has 
enabled greater understanding of molecular biology in areas such as proteomics27 and genetic 
regulation.28 29 Microfluidic technology was applied to control our CSE liposome fusion to create 
CSE cells and incorporate methods for subsequent applications.30   
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2.2 Materials and Methods 
2.2.1 Materials  
Fluorescent dyes were obtained from Fisher Scientific (Mississauga, Ont), fluorescence 
mounting media was obtained from Invitrogen (Carlsbad, CA), monster green fluorescing 
protein (MGFP) vector was obtained from Promega (Fitchburg, WI), cell samples C3H/10T1/2, 
NIH3T3/RFP and Neonatal Dermal Fibroblasts/GFP were obtained from ATCC (Manasssas, 
VA). All other materials were obtained from Sigma Aldrich (St. Louis, MO). O-
dodecyloxyamine-tetra(ethylene)glycol was synthesized as previously described.31 1-Palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1, 2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) were purchased from Avanti Polar Lipids (Alabaster, AL). 
2.2.2 Cell Culture  
C3H/10T1/2 mouse embryonic fibroblast cells were cultured and incubated for 3 days at 37°C 
and 5 % CO2 in 10 cm culture plates with media changed every other day using DMEM with 1 
% v/v PS and 10 % FBS as additives. NIH3T3/GFP expressing cells were obtained fresh from 
ATCC and cultured from liquid nitrogen storage and maintained using DMEM with 1 % v/v PS 
and 10 % FBS as additives. Human Neonatal Dermal Fibroblasts (HDNF)/RFP cells were 
obtained and cultured from liquid nitrogen storage and maintained using DMEM with 1 % v/v 
PS, 10 % FBS, 0.5 % w/w blasticidine hydrochloride, 5 mL L-glutamine and 5 mL non-essential 
Amino Acid Solution as additives. Cell cultures used for experiments were between 2 and 12 
passages. 
2.2.3 Surface Engineering Liposome Formulation  
To form separate liposome solutions bearing ketone and hydroxylamine functionalities, sterile 5 
mL vials were used and 60 µL, 30 µL, 10 µL and 1.0 µL of 2-dodecanone (10 mg/mL in CHCl3) 
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or undecyloxyamine (10 mg/mL in CHCl3) was added, followed by 454 µL POPC (10 mg/mL in 
CHCl3) followed by 10 µL of DOTAP (Avanti Polar Lipids) (10 mg/mL in CHCl3), which were 
then allowed to dry for 24 hours. Once the CHCl3 was evaporated, 3 mL of fresh PBS was 
added, followed by tip sonication. Sonication of the lipid suspensions was carried out over 10 
minutes using a 23°C water bath under 30 W. Subsequent suspensions were stored at 4°C.  No 
liposome suspension was used past one week. For bilayer formation experiments, 2-dodecanone 
or undecyloxyamine bearing liposomes were diluted using PBS after sonication to 5 %, 2.5 %, 1 
% and 0.5 % of the initial liposome concentration for subsequent microfluidic cell surface 
engineering experiments using tissue formation as our assay. 
2.2.4 Assembly of Microfluidic Devices 
The dual Y-reactor device used four luer-lock connectors (UpChurch Scientific) with four 
sections of PEEK tubing (McMaster Carr).  Each PEEK tube had an inner diameter of 254 µm 
and a length of 8.0 cm.  The four 8.0 cm lengths of tubing were connected to syringes and low 
flow volume T-mixer (UpChurch Scientific) passes into the subsequent reactor tube with a 
diameter of 254 µm, length of 68.5 mm and a total swept volume of 3.47 mm3. The flow was 
driven by two Hamilton Dual low flow rate dual syringe pumps. 
2.2.5 Surface Engineering and Adhesion Studies in Flow   
HDNF/RFP cells were grown in a 10 cm tissue culture dish using high glucose DMEM media 
containing 10 % FBS and 1 % Penicillin/Streptomycin (P/S) over 3 days, incubated at 37°C and 
5 % CO2. Cells used for experiments were approximately 90 % confluent. HNDF/RFP cell 
suspensions were prepared by washing the culture plates with 3 mL PBS, followed by aspiration, 
treated with 3 mL trypsin 0.25 % EDTA for 3 minutes and then quenched with 6 mL of serum 
media. The suspension was then transferred to a 15 mL tube and centrifuged at 800 RPM for 5 
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minutes. The media was decanted and the pellet re-suspended in fresh growth serum containing 
media to 4 million cells/mL scored using a hemocytometer. Then 250 µL of this suspension was 
loaded into a sterile 1 mL Hamilton gas-tight syringe, which was then attached using a luer lock 
connecter to the assembled microfluidic device. To surface engineer the cellular suspension, 250 
µL of separately prepared undecyloxyamine (hydroxylamine) bearing liposomes was injected 
into a separate 1 mL Hamilton gas-tight syringe and connected to the microfluidic device 
alongside the HNDF/RFP cell suspension injector, using a luer lock connector. NIH3T3/GFP 
expressing cells were grown in 10 cm culture plates to approximately 90% confluency alongside 
HDNF/RFP cells.   
The cell suspension was prepared for use by being washed with 3 mL of PBS, aspiration and 
subsequent treatment with 3 mL trypsin 0.25 % EDTA for 3 minutes and quenched with 6 mL of 
growth media.  The suspension was transferred to a 15 mL tube and centrifuged at 800 RPM for 
5 minutes, followed by decanting and re-suspending the pellet in fresh growth media to obtain a 
suspension concentration of 4 million cells/mL using a hemocytometer. Then 250 µL of the 4 
million cells/mL RFP suspension was loaded into a sterile 1 mL Hamilton gas-tight syringe 
which was then attached using a luer lock connecter to the assembled microfluidic device.  A 
separately prepared 250 µL suspension of 2-dodecanone (ketone) bearing liposomes were loaded 
into a separate 1 mL Hamilton gas-tight syringe and connected alongside the NIH3T3/GFP cell 
suspension syringe to the microfluidic device using a luer lock connector. The microfluidic 
device and syringes were sterilized by flowing 75 % ethanol through the assembled device, 
followed by sterile PBS for 5 minutes at 41.0 µL/min to remove any remaining ethanol and gas 
bubbles. Once the cell suspension and liposome syringes were connected to the microfluidic 
device, the syringes were attached to the Hamilton syringe pumps with a vertical configuration 
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and the flow was started from a high flow rate (41.0 µL/min) to low flow rate (0.69 µL/min) with 
mixing times ranging from 300 seconds to 5.0 seconds respectively, with the removal and 
discarding of the eluted head volume after 5 minutes so that flow equilibrium was established 
before cell deposition begins. Once flow equilibrium was established, the eluted flow volume 
was directly eluted onto prepared 1 cm2 glass slides placed in 35 mm culture plates containing 2 
mL of NIH3T3/GFP growth media, enough to immerse the glass slide. Once 20 µL of 
equilibrated flow volume was eluted onto the glass slide it was placed carefully in a cell culture 
incubator at 37°C and 5 % CO2 for 16 hours. For analysis, the samples were fixed for 20 minutes 
using 4 % formalin solution, drained and washed with PBS and then mounted on glass slides to 
perform confocal microscopy using a Zeiss LSM 700 to determine tissue assembly, growth and 
formation of multilayers. 
2.2.6 General Transfection and Assembly of Tissues in Flow using HDNF/RFP Cells and 
phMGFP   
HDNF/RFP cells were cultured using standard protocols using 10% FBS and 1% P/S High 
Glucose DMEM in 10 cm culture plates over 2 days to 75 % confluency. To prepare the cellular 
suspension for microfluidic injection, HNDF/RFP cells were trypsinized using 3 mL of 0.25 % 
trypsin for 3 minutes, followed by quenching with 6 mL of growth media. The suspension was 
then transferred to a 15 mL tube and centrifuged at 800 RPM for 5 minutes. The supernatant was 
decanted and the pellet was re-suspended in growth media to 4 million cells/mL using a 
hemocytometer and 250 µL of the suspension was loaded into two sterile 1 mL Hamilton gas-
tight syringes. To a sterile 1.5 mL Eppendorf tube, 60 µL of prepared ketone liposome 
suspension containing 410 µL POPC (10 mg/mL), 80 µL DOTAP (10 mg/mL) and 120 µL 2-
dodecanone (10 mg/mL) was added followed by the addition of 10 µL of (1.4 µg/µL) phMGFP.  
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This mixture was then incubated at 23°C for 30 minutes and then diluted with 200 µL of serum 
free DMEM media and loaded into a 1 mL Hamilton syringe. To a second sterile 1.5 mL 
Eppendorf tube, 60 µL of a prepared hydroxylamine liposome suspension containing 410 µL 
POPC (10 mg/mL), 80 µL DOTAP (10 mg/mL) and 120 µL undecyloxyamine (10 mg/mL) was 
added, followed by the addition of 10 µL of phMGFP (1.4 µg/µL). This mixture was incubated 
at 23°C for 30 minutes and diluted with 200 µL of serum free DMEM media and loaded into a 1 
mL Hamilton gas-tight syringe. Both of these syringes were then connected to our microfluidic 
device and flowed at 3.4 µL/min and eluted over 1 cm2 glass slides immersed in 2 mL of serum 
free media for 20 minutes, followed by incubation for 1 hour at 37°C and 5 % CO2. The media 
was aspirated and replaced with FBS containing growth media and incubated for 48 hours. The 
slides were fixed by washing 3 times with 3 mL PBS, followed by the addition of 5 % formalin 
solution for 15 minutes. The formalin solution was aspirated and the cells washed once with 
PBS, followed by mounting on glass cover slips for fluorescent microscopy using an Zeiss LSM 
700 Ziess microscope. 
2.2.7 Selective Transfection and Assembly of Tissues in Microfluidic Flow  
C3H/10T1/2 cells were cultured using standard protocols using 10 % FBS and 1 % P/S High 
Glucose DMEM in 10 cm culture plates over 2 days to 75 % confluency. HDNF/RFP cells were 
also cultured using standard protocols using 10% FBS and 1% P/S High Glucose DMEM in 10 
cm culture plates over 2 days to 75 % confluency. Once cells reached 75 % confluency, 5 % 
(v/v) ketone liposomes were added to the media, and incubated with cells at 37°C and 5 % CO2 
for 1 hour to create ketone-tailored cells. To prepare the C3H/10T1/2 and ketone-tailored 
HDNF/RFP cellular suspensions for microfluidic injection, the cell cultures were trypsinized 
using 3 mL of 0.25 % trypsin for 3 minutes, followed by quenching with 6 mL of growth media.  
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The suspensions were then transferred to 15 mL tubes and centrifuged at 800 RPM for 5 
minutes. The supernatant was decanted and the pellet was re-suspended in growth media to 4 
million cells/mL using a hemocytometer and 250 µL of the suspension was loaded into two 
sterile 1 mL Hamilton gas-tight syringes. To a sterile 1.5 mL Eppendorf tube, 60 µL of a 
prepared ketone liposome suspension containing 410 µL POPC (10 mg/mL), 80 µL DOTAP (10 
mg/mL) and 120 µL undecyloxyamine (10 mg/mL) was added, followed by the addition of 10 
µL of (1.4 µg/µL) phMGFP. This mixture was then incubated at 23°C for 30 minutes and then 
diluted with 200 µL of serum free DMEM media and loaded into a 1mL Hamilton syringe. The 
C3H/10T1/2 and phMGFP oxyamine liposome syringes were then connected to our microfluidic 
device, followed by the addition of the ketone-tailored HDNF/RFP suspension to the 
downstream luer lock connection and connected to a Hamilton 11 Plus syringe pump with a flow 
rate of 3.4 µL/min and eluted over 1 cm2 glass slides immersed in 2 mL of serum free media for 
20 minutes, followed by incubation for 1 hour at 37°C and 5 % CO2. The media was then 
aspirated and replaced with FBS containing growth media and incubated for 48 hours. The slides 
were fixed by washing 3 times with 3 mL PBS followed by the addition of 5 % formalin solution 
for 15 minutes. The formalin solution was aspirated and the cells washed once with PBS 
followed by mounting on glass cover slips for time-course fluorescent microscopy using an Zeiss 
LSM 700 3D confocal microscope. 
2.2.8 Microfluidic CSE of Liposome Coupled Biotin and Streptavidin (FITC) to Cellular 
Membranes   
To synthesize Biotin containing liposomes, to a sterile 5 mL glass vial 460 µL of POPC (10 
mg/mL), 10 µL DOTAP (10 mg/mL) and 120 µL, 240 µL and 360 µL of oxime-tethered 
biotinylated lipid 24 (10 mg/mL) were added and the solvent was allowed to evaporate over 10 
44 
 
hours. To the dried lipids, 3 mL of PBS was added and then tip sonicated for 10 minutes at 30 W 
using a 23°C water bath. The liposomes were then stored at 4°C for no longer than 7 days. For 
CSE experiments, C3H/10T1/2 cells were cultured using standard protocols to 75% confluency, 
followed by washing with 3 mL PBS and subsequent treatment with 3 mL trypsin 0.25% EDTA 
for 3 minutes and then quenched with 6 mL of serum containing media.  The cell suspension was 
then centrifuged in a 15 mL tube at 800 RPM for 5 minutes, followed by decanting and re-
suspension of the pellet in fresh media to 4 million cells/mL using a hemocytometer. Then 250 
µL of the untailored cell suspension was loaded into a 1 mL Hamilton gas-tight syringe and 
attached to the device using a luer lock connection. To a separate 1 mL syringe 250 µL of the 
prepared Biotin 24 containing liposomes were loaded and connected in tandem with the native 
C3H/10T1/2 syringe to our simple Y-channel device. The syringes were then attached to a 
Hamilton 11 Plus syringe pump and simultaneously injected at 6.8 µL/min for a residence time 
of 30 seconds before being eluted into serum containing media for dilution. After 20 minutes the 
flow was stopped and the diluted solution was centrifuged at 800 RPM for 5 minutes followed by 
decanting and re-suspension of the pellet in 500 mL PBS and 60 µL of 1 mg/mL Streptavidin-
FITC conjugate was added and incubated for 1 hour followed by dilution with 9 mL PBS, 
centrifuged, decanted and re-suspended in 500 µL PBS for flow cytometry. 
2.2.9 Synthesis of (24) (E)-2-(dodecan-2-ylideneaminooxy) acetic acid 
To a 10 mL dry argon filled vial containing  a magnetic stir bar 120 µL of 2-dodecanone (100.0 
mg, 184.32 g/mol, 0.542 mmol) (Sigma Aldrich) was added and dissolved in 2.5 mL of freshly 
distilled tetrahydrofuran (THF). To a separate vial 65.1 mg of o-(Carboxymethyl)hydroxylamine 
hemihydrochloride (109.30 g/mol, 0.596 mmol) (Sigma Aldrich) was added and dissolved in 2.5 
mL of freshly distilled THF. The solution of hydroxylamine was then cannulated into the 
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solution of 2-dodecanone and stirred overnight at 23°C. The next day the solvent was evaporated 
and the remaining solid was weighed (152.0 mg) and dissolved in ethyl acetate and passed 
through a small pad of celite. The solvent was evaporated to yield the isolated product 24 (126.0 
mg, 90 %). H1 NMR and C13 NMR were used to deem the product sufficiently pure to use for 
subsequent liposome experiments. H1 NMR (CDCl3, 300 MHz) δ 4.63-4.59 (m, 2H), 2.41-2.36 
(m, 1H), 2.22-2.15 (t, 2H), 1.90 (s, 3H), 1.45 (s, 2H), 1.27 (s, 14H), 0.917-0.875 (t, 3H) 
ppm.  C13 NMR (CDCl3, 300 MHz) δ 174.1, 161.5, 69.6, 35.6, 31.8, 29.5, 29.4, 29.3, 29.2, 29.1, 
26.2, 22.6, 14.3, 14.1 ppm. 
2.3 Results and Discussion 
The combined generation and application of CSE cells in microfluidic flow has potential 
applications in many areas of the life sciences. But to be an effective technology platform CSE 
delivery and manipulation must be robust and rapid. The efficient delivery of CSE liposomes has 
real world applications including imaging, cell purification, transfection and three-dimensional 
(3D) printing of tissues. Microfluidic devices have useful physical properties as analytical tools 
to integrate unit operations efficiently into single small devices, while accurately and rapidly 
(within seconds) mixing reagents within micron-sized channels. Microfluidic devices have been 
incorporated into many existing commercial technologies such as flow cytometry, mass 
spectrometry and 3D printing because of the unique physical and analytical properties these 
devices impart, such as particle sorting, short mixing regimes and liquid partitioning.  
Figure 2.3 describes our integrated microfluidic approach to apply CSE for cell-cell 
assembly, with potential applications for printing 3D tissues. Bio-orthogonal CSE delivery and 
assembly was probed through varying microfluidic flow rate, bio-orthogonal lipid ratios and 
overall liposome concentration to determine total efficiency of the CSE application and tissue 
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assembly. A three Y-joint microfluidic device was constructed and used to probe our integrated 
approach for applying ketone CSE (7) to NIH3T3/GFP (14) and hydroxylamine CSE (11) to 
tailor HNDF/RFP (17), followed by mixing for cell-cell assembly to produce two cell type 
spheroids (21) without purification (Figure 2.3). By varying residence time, composition and 
concentration of CSE liposomes, it was determined that cell labelling occurred at low total 
liposome concentrations (0.62 mM) for tissue engineering within 30 seconds and at low (1 %) 
ratios of both bio-orthogonal lipids (Supplementary Info.). The successful assembly of tissues 
using both low concentration and low percent ratios of bio-orthogonal lipids demonstrates the 
robust and efficient delivery and utility of CSE using microfluidics, where the number of 
polyvalent surface molecules (approx. ~1000) was sufficient to induce assembly. 
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Figure 2.3: Microfluidic scheme depicting our integrated tissue formation assay using 
microfluidic flow networks to perform CSE on cells in suspension, by simultaneously 
engineering NIH3T3-GFP (14) and HNDF-RFP (19) cell lines with ketone (7) and 
hydroxylamine (11) liposomes to produce tissues (21) in a continuous methodology. To 
determine CSE efficacy, the ratio of both liposomes (9) and (13) and bio-orthogonal components 
ketone (6) and hydroxylamine (10) were varied respectively. (Top) GFP expressing cells (14) were 
combined in flow with ketone presenting liposomes (7) to produce ketone presenting GFP cells 
(18). (Bottom) RFP expressing cells (19) were combined in flow with hydroxylamine presenting 
liposomes (11) to produce hydroxylamine presenting RFP cells (20). (Middle) CSE cells are 
directly mixed in a third microfluidic channel without further manipulation, which combine and 
assemble through polyvalent “velcro-like” oxime reactions to produce spheroids and tissues in 
culture (21). Probing assembling efficacy was accomplished by varying the ratio of the bio-
orthogonal pair, the liposome concentration and the ratio of individual lipids were varied to 
determine the minimum conditions necessary to produce tissue assemblies (21), which were 
probed using fluorescence microscopy. 
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Spheroid and tissue assembly of complex multicellular model structures for systems 
biology and other research applications using polymer scaffolds or metabolic labelling have 
several drawbacks which limit their general utility and adoption. More advanced systems are 
needed to enable three or more cell type assemblies to introduce better approximations of native 
tissue function using simple and robust methodologies. Figure 2.4 demonstrates our integrated 
microfluidic approach to rapidly label and generate bio-orthogonal CSE assemblies of three cell 
type spheroids and tissues using microfluidics. With the advancement of 3D printing engineering 
technology, the need for viable tissue constructs containing multiple cell lines with very high cell 
density is a major hurdle for many rapid therapeutic and tissue applications. To demonstrate 
rapid development of complex tissues and spheroids in flow, we developed a three-inlet 
microfluidic PMMA device shown in Figure 2.4A, with a standard Y-joint followed by a 
downstream inlet to allow for the injection of additional cell lines. We combined hydroxylamine 
tailored HDNF/RFP cells (28) and ketone tailored NIH3T3/GFP (29) in suspension, where they 
were mixed and combined with another suspension of live stained ketone tailored C3H/10T1/2 
(30) cells for assembly (31). The eluted spheroids were deposited for live cell fluorescence 
microscopy resulting in a range of spheroids sizes shown in Figure 2.4B-C. The three cell 
aggregation process was observed to be rapid, (within 30 seconds) fully forming three cell type 
spheroids. Tissues were generated through the deposition of higher quantities of spheroids shown 
in Figure 2.4D, with thicknesses ranging from 30 µm-300 µm which adhere upon contact and 
induces natural cell contact adhesion over 16 hours.  
49 
 
 
Figure 2.4: Complex spheroid and tissue formation using a simple microfluidic device to 
form three cell-line tissues and spheroids using three different CSE cell lines in flow. (A) 
Using a three inlet microfluidic device, a combination of ketone engineered HNDF/RFP cells (28) 
and hydroxylamine engineered NIH3T3/GFP (29) were injected, followed by the addition of 
CMSO (blue) stained ketone engineered C3H/10T1/2 cells (30) resulted in cell-cell assembly of 
multiple cell line spheroids through oxime adhesion (31) within 70 seconds, with an average size 
range of 50 µm - 70 µm. (B) Direct elution and dilution of the spheroid suspension resulted in 
three color spheroids (20X) under fluorescence microscopy without the use of trapping agents or 
fixation to produce stable live spheroids. (C) Three color spheroids (40X) demonstrates that 
HDNF/RFP cells are primary adhesive cells driving aggregation with a consistency of roughly 
2:1:1 (HDNF/RFP: NIH3T3/GFP: CMSO C3H/10T1/2). (D) Images of concentrated deposition 
of incubated three cell type tissues (40X) over 24 hours using Ziess LSM 700 confocal microscope. 
Cell based combinatory methodologies have been crucial components in the advancement 
of medical technologies, such as printing 3D tissues, closed medical diagnostic devices and 
cellular transfection. Microfluidic devices have largely been developed for analytical purposes to 
dissemble cells for DNA sequences, separation, purification of small particles and recently tissue 
engineering and cellular assays. Figure 2.5 demonstrates the flexibility of our modular 
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microfluidic combinatorial approach. CSE liposome pairs containing bio-orthogonal 
hydroxylamine and ketone groups were combined with nucleic acids to perform dual purpose 
assembly and transfection using microfluidics. To form multiplexed liposomes, ketone (7) and 
hydroxylamine (11) liposomes were combined with phMGFP to produce tailored CSE lipoplexes 
(33). Stably transfected RFP expressing HDNF cells (32) where treated with ketone-tailored 
phMGFP lipoplexes (33) to produce GFP-RFP (orange) monolayers (Figure 2.5). Figure 2.5E 
shows the production of transfected spheroids using our microfluidic device, where populations 
of HDNF/RFP (32) cells were treated with ketone and hydroxylamine tailored lipoplexes 
respectively to produce GFP transfected HDNF/RFP (orange) spheroids.   This demonstrates that 
CSE availability can be used for delivery of complex cargo, such as nucleic acids while the bio-
orthogonal ligands remain active in the plasma membrane for cellular assembly of contact 
inhibited cell lines. 
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Figure 2.5: Multiplexed delivery of CSE engineering and nucleic acids through CSE-
lipoplexes to HDNF/RFP cells in flow. (A) Control monolayer of non-CSE HDNF/RFP cultured 
cells (20X) adhered to 1 cm2 glass plates. (B) Scheme depicting microfluidic injection of 
HDNF/RFP cells (32) in suspension along with ketone engineered pGFP-lipoplex suspension (33), 
which undergo mixing, adhesion and transfection (34) in flow.  (C)  Deposited monolayer of flow 
delivered ketone CSE pGFP transfected HDNF/RFP cells (20X) which transform from red to 
orange upon GFP expression after 24 hours.  (D) Fluorescent microscopy image (20X) of 
microfluidic generated oxime assembled RFP HDNF cell spheroid using of CSE ketone and 
hydroxylamine liposomes.  (E) Ketone and hydroxylamine CSE pGFP transfected HNDF/RFP 
cells (20X) assembled using separate ketone CSE and hydroxylamine pGFP-lipoplexes over 24 
hours. 
 
The flexibility of CSE liposomal technology in combination with microfluidic devices 
can also rapidly synthesize novel mixed transfected tissue constructs using flow processes that 
do not require further manipulation. In Figure 2.6, we designed a single step process to tailor and 
selectively transfect cell lines for advanced tissue engineering applications. Using tailored ketone 
nucleic acid lipoplexes (33) and co-injected native cells (14) to deliver both CSE and nucleic 
acids (35) producing duel engineered cell lines (36), while a downstream inlet was used to 
introduce hydroxylamine tailored cells (28) to form mixed transfected spheroids without 
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purification. Initial spheroids did not express phMGFP (Figure 2.6B) but after 6-12 hours of 
incubation, spheroids become positive for GFP expression (Figure 2.6C). Using increasing cell 
density, we rapidly accessed tissues where (dark) cells (14) do not express GFP (Figure 2.6E), 
while after 24 hours GFP expression was localized in C3H/10T1/2 cells. This unique strategy 
produced tissues rapidly, while leveraging the properties of microfluidics to selectively express 
GFP, while HDNF/RFP (28) showed no GFP transfection. This strategy has many applications 
for systems biology, where knock-in and knock out methodologies can be used to determine cell-
cell interactions in a variety of organ-like contexts such as the kidney, blood brain barrier, 
cardiac and neuronal growth. This is a beneficial strategy over current methods where native 
cell-cell interactions can be studied over time in the context of decreases or increases a gene of 
interest protein pathway. 
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Figure 2.6: Single step selective nucleic acid transfection and microfluidic CSE assembly of 
tissues to produce complex transfected co-cultures containing two cell lines.  (A)  Schematic 
of microfluidic device for injection of suspended C3H/10T1/2 cells (14) with ketone engineered 
phMGFP-lipoplex solution (33), where both suspensions undergo mixing in the microchannel for 
30 seconds. During mixing the lipoplex and cells undergo mixing and adhesion (35) resulting in 
fusion (36) to produce CSE ketone displaying cells containing added phMGFP plasmids. An 
additional downstream inlet adds pre-engineered hydroxylamine HNDF/RFP cells (28) into the 
flow channel resulting in cell-cell assembly with CSE ketone phMGFP transfected cells through 
oxime ligation. (B) Mixed ketone engineered HNDF/RFP cells and hydroxylamine phMGFP 
transfected C3H/10T1/2 cells after microfluidic elution (40X). (C) Mixed ketone engineered RFP 
HNDF cells and hydroxylamine phMGFP C3H/10T1/2 cells after 12 hours of incubation (40X). 
(D) Control mixed HDNF/RFP cells and C3H/10T1/2 cells. (E) Top and side 40X confocal images 
of tissues composed of phMGFP transfected keto-C3H/10T1/2 cells and oxy-HDNF/RFP cells 
incubated for 2 hours, resulting in a thickness of approximately 30 µm. (F) Top and side images 
of mixed tissue composed of transfected keto-C3H/10T1/2 cells and oxy-HDNF/RFP cells 
incubated for 24 hours, where GFP is expressed (40X). 
To quantify the rapid and efficient incorporation of bio-orthogonal liposome CSE using 
microfluidics devices we utilized oxime coupled Biotin and Streptavidin-FITC (Strept-FITC) as 
CSE reporters to determine membrane incorporation of delivered lipids using varying 
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concentrations (Figure 2.7). Cells in suspension (14) were combined with biotin containing 
liposome (37) which were generated using ketone tailored liposomes (38) treated with 
hydroxylamine-biotin (39). Rates of bio-orthogonal liposome incorporation were measured using 
flow cytometry after treatment with Strept-FITC (41). Incorporation experiments show increased 
cell membrane incorporation of biotin using our liposomal format compared to treatment with 
free biotin conjugate (39) (Figure 2.7B-E). We quantified the transfer of our biotin liposome (37) 
to the cellular membrane using Molecules of Equivalent Soluble Fluorescence (MESF) based on 
Strept-FITC, to quantify delivery of lipids with 30 seconds of microfluidic treatment. Using 30 
seconds as our benchmark treatment time, we altered the ratio of biotin lipid (38), resulting in a 
near linear increase in MESF response. Interestingly, we observed fast turnover of biotin on the 
cellular membrane using live cell flow cytometry through rapid depletion of Streptavidin-FITC 
signal over time (to background levels) after 30 minutes. 
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Figure 2.7: Efficient microfluidic membrane incorporation of oxime coupled biotin and 
subsequent labelling with Strept-FITC conjugate for flow cytometry. (A) C3H/10T1/2 cell 
suspensions (14) were injected into a Y-joint microfluidic device with liposomes (37) containing 
oxime biotin conjugate (38) to produce biotin surface engineered cells (39) within 30 seconds.  
The biotin engineered cells were separately labelled with Strept-FITC marker (40) for flow 
cytometry (41). (B) Flow data of native C3H/10T1/2 cells using the microfluidic device for 30 
seconds. (C) Flow data of native cells flowed through our microfluidic device for 30 seconds, then 
incubated with Strept-FITC. (D) C3H/10T1/2 cells treated with non-liposomal oxime biotin 
molecule through microfluidic mixing for 30 seconds and incubated with Strept-FITC. (E) C3H 
10T1\2 cells treated with liposomal biotin through microfluidic mixing for 30 seconds, produces 
a strong fluorescent signal with subsequent Strept-FITC incubation.  (F) Graph depicting number 
of fluorescent Strept-FITC molecules on C3H/10T1/2 cell surfaces using flow cytometry (MESF).  
As the amount of biotin conjugate is increased (1X, 2X and 3X) the amount biotin available on the 
cell surface increases linearly. 
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2.4 Conclusion 
In summary, CSE liposomes and microfluidics can be used as a modular strategy to 
control CSE of cells and their use in co-culture tissue formation, gene and drug delivery as well 
as exogenous membrane ligand incorporation. The combination of CSE using liposome fusion 
delivery has also been demonstrated to be quick and efficient using microfluidics and flow 
cytometry. The oxime liposome fusion strategy rapidly imparts useful molecular agents to 
engineer cells in situ for real world applications and research for next generation therapeutic 
studies. Flexibility of the CSE strategy for incorporation into existing delivery methodologies 
has been shown to be useful for the critical adaptability in a range of applications. By varying 
flow rate and the length of microfluidic reactor channel, as well as the liposome composition, the 
optimal reaction time and liposome content can be rapidly determined and used for downstream 
applications quickly and efficiently, since cell types can have a range of division times and 
metabolic activity which may effect the amount of CSE available on the cell surface over time. 
Without altering the molecular biology or metabolic biosynthetic pathways of cells, this 
methodology serves as a platform for the development of new cellular capabilities using 
microfluidics to create medical devices capable of rapidly engineering cells for therapeutics and 
theranostics. Using our platform, we developed methods for modular microfluidic devices for 
use in flow cytometry, 3D printing and rapid automated drug testing. This methodology can 
potentially be used to tailor inorganic, polymeric or nanoparticles surfaces for the development 
of sensors, analytical devices and biological applications. 
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Chapter 3 
Cell-Cell Tissue Assembly and Particle Kinetics in Microfluidic Flow 
 
 
 
 
This work has been published in Bioconjugate Chemistry, Volume 9, pages 1939-1949 in 2015 under the title 
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3.1 Introduction 
 In vitro generated spheroids and tissues are crucial for next generation therapeutics, 
serving as human model systems to investigate paracrine and autocrine signalling, tumour 
growth, invasion models and commercial applications such as tissue chips for drug screening, 
organ grafting and organ replacement therapies.1 2 3 4 5 6 7 Due to the need for these types of 
organ-like constructs, tremendous progress towards spheroid and tissue formation has been made 
through manipulating cell adhesion properties via molecular biology, non-natural metabolite 
incorporation, polymer and de-cellularized tissue scaffolds.8 9 10 11 Current tissue engineering 
technologies lack control over the formation of cell-cell interactions and subsequent 3D 
architecture of tissue assemblies.  
 The Yousaf group recently developed the use of liposomes bearing bio-orthogonal oxime 
chemistry as a method to engineer contact inhibited cell lines using liposome fusion to deliver 
molecules to the plasma membrane. This is an important methodology that circumvents 
difficulties encountered with polymer scaffolds and metabolic and genetic engineering to adhere 
cells as a method to directly adhere cells together to create better tissue mimics of in vivo tissues. 
Mammalian cells largely exist within natural 3D environments, consisting of other cell types and 
secreted ECM where cell types and spatial orientation directly influence function and viability of 
tissues and organs. Tissue engineering has seen an explosion in the use of natural and synthetic 
biomaterials to reconstruct these tissues in vitro using materials such as collagen, hydrogels, 
Matrigel©, peptide coupled  polymers, polymers containing signalling agents and biodegradable 
polymers. Although these materials have shown some promise as in vitro models for basic 
research, these technologies have not seen wide spread adoption or development into products 
for regenerative medicine. Current challenges include the formation of continuous cell-cell 
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contacts across the millimeter scale, multiple cell type adhesion and controlling 3D spatial 
orientation.   
 In higher-order organisms, cell-cell and cell-ECM interactions coupled with control over 
spatial and temporal architecture are vital for function and survival. Tissue engineering seeks to 
recapitulate these functions in damaged or diseased human organs and tissues for both life-
saving and quality of life applications. Current advanced methods in tissue engineering use a 
number of different techniques to assemble cells into tissue-like structures in attempts to recreate 
natural 3D environments such as natural ECMs, de-cellularization of natural organs, followed by 
re-cellularization using autologous cells to re-establish function, growth of organs from single 
stem cells, protein interactions to adhere cells and a newly developed liposome fusion cell 
treatments to produce self-adherent cell lines. Therefore, tissue engineering techniques require 
approaches that are simple, with transient stable cell-cell conjugation techniques that do not alter 
biomolecular pathways, as a general application. Using liposome leaflets as vectors for small 
molecule bio-orthogonal lipids has been shown as a viable method for the surface modification 
of cells for tissue assembly and cell-imaging that addresses many of the above issues. To 
understand the assembly of surface modified cells and control subsequent tissue orientation, we 
used microfluidics as a biophysical analytical tool to study the in situ assembly process directly 
to determine not only assembly kinetics but also cluster architecture using a combination of 
bright-field, fluorescent and confocal microscopy.  
 Microfluidics has been utilized extensively as a method to efficiently mix reagents, sort 
micro and nanoparticles, conduct high-throughput chemical reactions, increase analytical 
sensitivity and has been applied to a multitude of bioanalytical and healthcare applications.   
Microfluidics use micro sized channels to move and mix fluids for analytical and biological 
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assays using small amounts of reagents. These devices have the benefit of low reagent usage, 
multiplexed stepwise processing, small size, efficient mixing and highly controlled reagent 
addition. These properties allow efficient chemical and nanoparticle formation for optical and 
analytical analysis using transparent materials, such as glass, poly (methyl methacrylate) 
(PMMA) and Polydimethylsiloxane (PDMS). By merging microfluidics and liposomal cell 
surface engineering, high throughput manufacturing of tissue generation and research using off 
shelf technologies can be achieved. Microfluidic flow reactors typically have a tube-like design 
with at least one cross-sectional dimension of less than 500 µm in a closed system. By 
incorporating microfluidic technology and liposomal cell surface rewiring control can be exerted 
over assembly kinetics and spheroid compositions, which cannot be performed using traditional 
mixing techniques. This is an advantageous system, where density, flow rate control and small 
reactor size can enhance efficiency, optimize assembly and reagent addition through the tight 
control of reagents, cellular aggregation and spheroid patterning in shorter time frames.   
 Herein, we describe a new platform strategy to rewire cell surfaces with bio-orthogonal 
groups via liposome fusion delivery and use microfluidic technology to control the rapid 
assembly of co-culture micro-tissues via an interfacial ‘click’ chemical reaction in flow. The 
interfacial bio-orthogonal groups delivered to the cell surfaces act as chemoselective molecular 
‘velcro’ to induce a stable click (cell-cell) adhesion process.   
 As a methodology to deliver cargo to cells, liposome formulation and fusion is well-
established for drug therapeutics and imaging technology.12 13 Many fundamental studies of lipid 
membrane fluidity and membrane biology have been advanced by using liposomes as model 
membranes.14 15 To design cells with the capability to associate with any other cell type we chose 
to modify cell surfaces with bio-orthogonal lipids as handles for ligation. Bio-orthogonal 
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chemistry is a powerful suite of chemical conjugation reactions that can ligate molecules in a 
physiological environment rapidly and without side reactions.16 The reactions have led to 
pioneering developments with many applications in cell biology and proteomics.17 18 To control 
the cell assembly process, we used microfluidic technology as a bioanalytical method to control 
spheroid morphology and subsequent tissue orientation. Microfluidic technology has 
revolutionized biomedical research and its programmable features have led to diverse 
innovations in genomics, cell sorting, material science and chemical research.19 20 21 22 However, 
until now microfluidic technology has not been used for assembling cells in flow to generate 
microtissues due to weak or non-existent cell-cell adhesion processes.  
 To rewire cell surfaces with chemical groups that function as bio-orthogonal molecular 
velcro, we first focused on the delivery strategy by generating two different liposome 
populations with complementary ligation groups.  Figure 3.1 describes the cell surface tailoring 
strategy to generate complex co-culture tissue assemblies.  We used the reaction between ketone 
groups and hydroxylamine groups, which form a stable and bio-orthogonal oxime as the ligation 
strategy.  We have previously shown the utility of this strategy for making co-culture spheroids 
and thick tissue multi-layers.23 24 25 26 Each liposome pair was generated with background lipids 
of POPC and DOTAP with the incorporation of either ketone lipid (3) or hydroxylamine lipid (4) 
(Ratio POPC:DOTAP:Bio-orthogonal Lipid  49:49:2).  Once formed, the ketone liposome (5) 
was then added to cells in culture (7) containing serum for 1 hour for rapid fusion and delivery of 
the ketone lipid to the cell surface (9).  Similarly, hydroxylamine liposome (6) was added to a 
second cell type to generate hydroxylamine presenting cells (10). Upon the mixing of ketone (9) 
and hydroxylamine (10) presenting cells, rapid co-culture cell assemblies formed due to the fast 
and polyvalent oxime click chemistry ligation between cells. As a control, no cell assemblies 
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were generated when either the ketone or hydroxylamine groups were not present on the cell 
surface. Fluorescence-activated cell sorting (FACS) analysis was also used to determine the 
amount of bio-orthogonal lipid present on cell surfaces. Previous studies have shown cell 
viability is not affected by the liposome fusion method or the incorporation of bio-orthogonal 
lipids into membranes.27  
 Current tissue engineering methodologies include polymeric scaffolds, decellularized 
scaffolds, organoid formation and layer by layer approaches. Polymeric scaffolds use synthetic 
polymers such as Poly Lactic-co-Glycolic Acid (PLGA), Poly Lactic acid (PLLA), Poly ethylene 
glycol (PEG) or natural materials such as collagen, Matrigel, elastin and agarose to embed or 
encapsulate cells into solid structures to create tissue-like constructs.28 Although these methods 
of collecting individual contact inhibited cell lines into a solid macroscale structure can provide 
mechanical support, engineered growth factors and a adhesive substrate, they also have a number 
of drawbacks such as a lack of fine microscale structure, no initial or low subsequent cell-cell 
contact (signaling), low cell loading and most polymers tend to product toxic metabolic by-
products. Decellularized scaffolds while providing the fine microstructure and large scale 
mechanical support of the original tissue, also provides signaling factors to newly perfused cells.  
Although these scaffolds seem to present a leap forward in tissue engineering, they suffer from 
similar disadvantages as polymer scaffolds such as low cell seeding density and little or no cell-
cell contacts generated due to the limitations of the prepared cells, while also the scaffold can 
contain detrimental factors arising from the death of original organ tissue. Organoid structures 
developed from stem cell culture are excellent for the study of developmental biology are not 
suitable for large scale applications due to growth (time) restraints, manufacturing difficulties 
and unreliable induction of organ growth. 
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 We propose that our CSE methodology for the rewiring of the cellular membrane will 
result in more advanced and stable tissue constructs for use as microtissues for biological 
research as well as macrotissues for the study of organ behaviour and tissue transplantation 
techniques. Our CSE technique for cell-cell assembly has incredible potential as both as a 
standalone methodology and a modular technique to improve existing tissue assembly 
technologies such as polymer scaffolding and cadaverous organ de-cellularization. Two 
important benefits of our CSE technology allow cell-cell contacts to form during contact but also 
enabling the integration of multiple cell types into a single tissue with microstructure such as 
epithelial single cell layer membranes in combination with other cells or mixed layers. This is 
beneficial for the development of physiologically relevant tumor models (containing cancerous 
and non-cancerous cell-types), as well as in vivo tissue mimics for system biology study. Since 
the CSE molecules delivered to the cell membrane are chemoselective for only complimentary 
labeled cells, layers can be easily incorporated into our designed tissues resulting in single layer 
or thick tissue structures commonly observed in in vivo tissues. These physical structures are 
incredibly important to the properties and function of in vivo tissues in many contexts such as the 
Blood Brain Barrier (BBB) or skin, acting as physical barriers to the environment or promoting 
specific cell-cell interactions.
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Figure 3.1: Schematic describing the cell surface tailoring strategy to generate complex co-
culture tissue assemblies.  The combination of bio-orthogonal lipids, liposome formation and 
liposome fusion result in the generation of engineered cell surfaces that can subsequently be 
assembled through an interfacial click reaction. (A) Bio-orthogonal liposomes are formed by 
mixing POPC (1), DOTAP (2) and either a ketone (3) or hydroxylamine (4) terminated presenting 
lipid-like molecule.    (B)  Cell surfaces were engineered to present ketones or hydroxylamines via 
liposome fusion and delivery.  The tailored cells were then mixed and formed rapid assemblies via 
the bio-orthogonal oxime click ligation.  (C) (5) ketone bearing CSE liposome, (6) hydroxylamine 
bearing CSE liposome, (7) or (8) separate native cells lines, (9) ketone CSE cell line, (10) 
hydroxylamine CSE cell line, (11) and (12) adhered or spread out cell line, (13) detached ketone 
CSE cell line, (14) detached hydroxylamine CSE cell line, (15) oxime bond formed upon reaction 
in cell culture conditions between hydroxylamine and ketone moieties. 
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3.2 Materials and Methods 
3.2.1 Materials  
O-dodecylhydroxylamine was synthesized as previously described.23 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) 
were purchased from Avanti Polar Lipids (Alabaster, AL). All other chemicals were obtained 
from Sigma-Aldrich or Fisher Scientific. C3H/10T1/2 mouse embryonic fibroblast cells, RFP 
Expressing Human Neonatal Dermal Fibroblasts (HDNF), GFP expressing NIH3T3 cells were 
obtained from ATCC. Human mesenchymal stem cell (hMSC), hMSC basic,growth, and 
differentiation media were obtained from Lonza. 
3.2.2 Cell Culture   
C3H/10T1/2 were cultured in petri dishes at 37°C and 5% CO2 with DMEM media containing 10 
% fetal bovine serum (FBS) and 1 % penicillin/streptomycin (P/S). HDNF/RFP were maintained 
in DMEM containing 5 % FBS and 1 % P/S. The cell cultures used for experiments were 
between 3 and 8 passages. NIH3T3/GFP cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco), with 10% FBS, 0.1 mM MEM Non-Essential Amino Acids, 2 mM 
L-glutamine, 1 % P/S, and 10 μg/mL Blasticidin. 3T3 Swiss albino mouse fibroblasts were 
cultured in containing 10 % fetal bovine serum (FBS) and 1 % P/S at 37C at 5 % CO2. hMSCs 
were cultured in growth media at 37C in 5 % CO2. Adipogenic differentiation was induced by 
induction and maintenance media as described in the Lonza protocol. 
3.2.3 Microfluidic Device Fabrication and Design  
The microchannel was designed as a simple Y-shape, where cell suspensions are brought 
together in the Y-mixer channel. In order to make a simple, cheap and robust device, PMMA 
blocks were used as the substrate. The experimental devices with micron-sized channels were 
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created using laser ablation etching on PMMA blocks (1/8 in thickness, 1.25 in length and 1.42 
in width). The channels were laser etched on the PMMA surface using Versalaser 2.30 with a 
CO2 laser at 14.25 W power to produce parabolic channels with a measured base width of 170 
µm, a peak height of 200 µm, and a channel length of 1.5 cm. The two fluid inlet connections 
were fabricated using 406 µm (0.016 in) OD stainless steel capillary tubes with an 203 µm 
(0.008 in) ID and a length of 2.0 cm, which were embedded into the PMMA blocks using 
thermal heating to be in line with the channel flow axes. The fluid outlet capillary was cut to 2.0 
cm and embedded by thermal heating and applied pressure similar to the fluid inlets and then 
allowed to cool.  The top block of PMMA is used to cap the channel through thermal bonding 
(with the etched bottom block) in a convection oven for 2 hours at 275°C and allowed to cool 
completely to 23°C for 2 hours under pressure.  Once cooled, the fluid connections were 
completed by slipping poly ethyl ethylene ketone (PEEK) tubing (ID 203 µm/ 0.008 in) over the 
metal capillary and sealed using epoxy resin (3M).  Finally, high pressure HPLC 1 mL Luer lock 
glass syringes (Hamilton) were connected to the PEEK tubing using finger tight female Luer 
connectors (UpChurch Scientific).  
3.2.4 Liposome Formation and Formulation 
To prepare liposomes bearing ketone or hydroxylamine functionalities, 60 µL of 2-dodecanone 
(10 mM in CHCl3) or O-dodecylhydroxylamine (10 mM in CHCl3) was mixed with 430 µL 
POPC (10 mg/mL in CHCl3) and 10 µL of DOTAP (10 mg/mL in CHCl3), and then thoroughly 
dried using N2.  After the CHCl3 was evaporated, the lipid mixture was suspended in 3 mL of 
PBS, followed by tip sonication for 15 min until the suspension became clear.   
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3.2.5 Cell Surface Modification using Liposome Fusion 
Once cells reached 90% confluency, 5% (v/v) liposomes (ketone or hydroxylamine bearing) 
were added to the cell culture media, and incubated with cells at 37°C and 5% CO2 for 1 hour to 
create ketone- or hydroxylamine-tailored cells. 
3.2.6 Microtissue Generation in Microfluidic Device   
GFP and RFP cells were grown to approximately 90% confluency and then treated with 
hydroxylamine and ketone bearing liposomes, respectively using the standard protocol. Once the 
cells were surface engineered, they were washed 3 times with PBS and then detached by 0.25% 
trypsin/EDTA at 37°C and 5 % CO2. Once the cells were detached and neutralized by DMEM 
media (10 % FBS), cell suspensions were transferred to separate 15 mL tubes and spun down at 
800 RPM for 5 minutes.  The supernatant was discarded, the remaining pellet was re-suspended 
in DMEM media to reach a final concentration of 4 x 106/mL. Once the ketone and 
hydroxylamine-tailored cell suspensions were ready, 250 µL of each cell suspension was 
immediately loaded into separate sterilized 1mL gastight Luer lock Hamilton gas 
chromatography syringes. The connection tubing and microfluidic device were sterilized by 
passing 1 mL 70% ethanol solution, followed by 1 mL of PBS buffer. Once sterilized, the loaded 
syringes were finger tightened onto male Luer connections and placed onto a Harvard 11 PLUS 
syringe pump. The flow rate was set to 8 µL/min for 5 minutes to purge air bubbles from the 
system, then lowered to 0.4 µL/min for 5 minutes, where the fluid is discarded and the 
subsequent eluent was collected onto 1 cm2 glass slides. The 1 cm2 glass slides were prepared in 
advance and sterilized by sonication in 70 % ethanol solution for 30 min. The microfluidic 
experiments typically lasted around 45 minutes. Once experiments were complete, the collecting 
slides were transferred to tissue culture plates and incubated at 37°C and 5% CO2 for 25 minutes. 
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The cells on the slides were then fixed using 3.8% formaldehyde solution for 15 minutes, 
followed by gentle washing with PBS. The cell samples were observed and imaged using a 
Nikon Eclipse TE2000-U Fluorescence Microscope.   
3.2.7 Microtissue Generation vs. Flow Kinetics   
Ketone and hydroxylamine engineered C3H/10T1/2 cells were collected to reach a specific cell 
density for cell cluster formation. Once the cell suspension with different cell densities were 
ready, 250 µL of each suspension was immediately loaded into separate sterile 1 mL gas-tight 
Luer lock Hamilton gas chromatography syringes. The connection tubing and microfluidic 
device were sterilized by passing 1 mL 70% ethanol solution, followed by 1 mL of PBS buffer.  
The loaded syringes are attached to the fluid system using Luer connectors and placed onto a 
Harvard 11 PLUS syringe pump. The flow rate was set to 8 µL/min for 5 minutes to purge air 
bubbles from the system, then the flow rate was lower to the experimental flow rate (0.2 µL/min-
0.6 µL/min) for 5 minutes to discard fluid head before collecting cell clusters. Live cell images 
were obtained in situ at 10X using an Olympus CKX41 microscope to record cluster size and 
growth. Images of cell clusters were recorded at 0 mm, 7.5 mm, and 15.0 mm of the microfluidic 
channel (to collect data of cluster size), while flow rate and cell density were changed to study 
the relationship between microtissue generation and microfluidic flow conditions as shown in the 
3D plot (Figure 3.4). 
3.2.8 Confocal Microscopy of RFP/GFP 3D Co-culture Microtissues  
To obtain confocal images of co-culture microtissues, GFP and RFP cells were grown to 
approximately 95% confluency and treated with hydroxylamine and ketone bearing liposomes 
respectively, using our standard protocol. Engineered cells (250 µL, 2 x 106/mL) were 
immediately loaded into separate sterilized 1 mL gas-tight Luer lock Hamilton gas 
71 
 
chromatography syringes, which were finger tightened onto male Luer connections and placed 
onto a Harvard 11 PLUS syringe pump. The flow rate was set to 8 µL/min for 5 minutes to purge 
air bubbles from the system, and then lowered to 0.4 µL/min for 5 minutes. After that, cell 
collection began. Flow experiments were performed for 3 hours, before the collecting slides were 
transferred to tissue culture plates and incubated at 37°C and 5% CO2. After culturing the cell 
clusters for 12 hours, cell samples were fixed with 3.8% formaldehyde, washed with PBS and 
mounted onto thin glass slides with LIGHT DIAGNOSTICS Mounting Fluid (Millipore) for 3D 
confocal microscopy using a Zeiss LSM 700. 
3.2.9 Confocal Microscopy of Three-cell line (red/green/blue) Microtissues 
To generate microtissues composed of three-cell lines to be observed then by confocal 
microscopy, hydroxylamine engineered C3H/10T1/2 cells were treated with 0.3 % v/v of 
CellTracker™ Blue CMAC (Life Technologies) for 45 minutes, and then mixed with ketone 
engineered GFP cells and RFP cells. Blue-stained C3H/10T1/2 cells presenting hydroxylamine 
(4 x 106/mL) were loaded into a 1 mL Hamilton glass syringe, while ketone engineered GFP 
cells (2 x 106/mL) and ketone engineered RFP cells (2 x 106/mL) were loaded into another 1 mL 
Hamilton glass syringe. The two syringes were connected to the microfluidic device and the flow 
rate was set at 0.4 µL/min. Cell clusters were dispensed onto 1 cm2 glass slides for 45 minutes 
and then incubated in tissue culture plates for 12 hours at 37°C with 5 % CO2. Cell samples were 
fixed with 3.8% formaldehyde, washed with PBS and mounted onto thin glass slides with 
LIGHT DIAGNOSTICS Mounting Fluid (Millipore) for 3D confocal microscopy using a Zeiss 
LSM 700. 
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3.2.10 Three-Dimensional Co-culture 3D Multi-Layers of HMSCs and NIH3T3 Fibroblasts 
HMSCs and NIH3T3 fibroblasts were surface engineered with ketone and hydroxylamine 
liposomes respectively. NIH3T3 fibroblasts presenting hydroxylamines were then trypsinized 
and added (105 cells/mL) to the hMSCs. These cells were co-cultured in adipogenic induction 
hMSC Adipogenic BulletKit media (Lonza), hMSC Fibroblast BulletKit media (Lonza) and 
hMSC Osteogenic BulletKit media (Lonza) resulting in the 3D multi-layered, tissue-like 
structures of adipocytes, NIH3T3 fibroblasts and osteoblasts using the standard Lonza protocol. 
The 3D co-cultures were fixed after one day and two weeks using formaldehyde (4 % in PBS, 30 
minutes). Substrates were then immersed in a solution containing water and 60 % isopropyl 
alcohol (3-5 minutes), followed by staining with Oil Red O (5 minutes) and Harris Hemotoxylin 
(1 minute). Substrates were visualized by phase contrast microscopy using a Zeiss inverted 
microscope.  
3.2.11 Collagen Based RFP and GFP Tissue Formation (Fig. 3.7 O,P)   
To make macro-size (2x2 cm2) robust tissue, collagen was introduced. Hydroxylamine tailored 
GFP cells (2 mL, 4x106/mL) and ketone tailored RFP cells (2 mL, 4x106/mL) were loaded into 
the microfluidic device to generate RFP/GFP microtissue. The flow rate was set to 8 µL/min for 
5 minutes to purge air bubbles from the system, and then lowered to 0.4 µL/min for 5 minutes. 
After that, cell collection began. Cell clusters were collected onto a 2x2 cm2 slide loaded with 
liquid collagen solution. Following collection, the collagen/cell hybrid was transferred to a tissue 
culture plate and incubated at 37°C and 5 % CO2 for 30 minutes to allow the collagen solution to 
solidify. Cell culture media was then added and the collagen/cell hybrid tissue was incubated for 
12 hours before being carefully peeled off the glass slide. The collagen supported macrotissue 
was were then fixed with 3.8% formaldehyde, washed with PBS and mounted onto thin glass 
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slides with LIGHT DIAGNOSTICS Mounting Fluid (Millipore) for 3D confocal microscopy 
using a Zeiss LSM 700. 
3.2.12 Three-Dimensional Oriented Co-culture Multi-layers (RFP-GFP-RFP, thin) (Fig. 
7E, F)   
Microscope glass cover slips were cut into small pieces in advance and placed into a 96-well 
microplate. RFP cells were grown on slips in the microplate and grown to 95 % confluency. 
Through standard liposome treatment, the RFP cells were surface engineered to present ketone 
groups. GFP cells presenting hydroxylamine (200 µL, 5 x 105/mL) were then loaded by the 
standard microfluidics procedure onto the ketone tailored RFP cells and cultured for 12 hours. 
After removing most of the media, ketone tailored RFP cells (200 µL, 5 x 105/mL) were loaded 
into the wells by microfluidics and cultured for 6 hours. The slips inside the microplate were 
then gently removed and fixed in 3.8 % formaldehyde, washed with PBS and mounted onto thin 
glass slides with LIGHT DIAGNOSTICS Mounting Fluid (Millipore) for 3D confocal 
microscopy using a Zeiss LSM 700. 
3.2.13 Three-Dimensional Oriented Co-culture Multi-zones (RFP-GFP-RFP, thick) (Fig. 
3.7 G, H)   
Microscope glass cover slips were cut into small pieces in advance and put into a 96-well 
microplate. Ketone tailored RFP cells (150 µL, 1 x 106/mL) and hydroxylamine tailored RFP 
cells (150 µL, 1 x 106/mL) were loaded by standard microfluidics procedure onto the cover slips 
in the microplate, and cultured for 12 hours. After removing most media, ketone tailored GFP 
cells (150 µL, 1 x 106/mL) and hydroxylamine tailored GFP cells (150 µL, 1 x 106/mL) were 
loaded by microfluidics onto the RFP cells, and then cultured for 12 hours. After removing most 
media, ketone tailored RFP cells (150 µL, 1x106/mL) and hydroxylamine tailored RFP cells (150 
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µL, 1 x 106/mL) were loaded by microfluidics again, and cultured for 6 hours. The slides inside 
the microplate were then gently picked up and fixed in 3.8 % formaldehyde, washed with PBS, 
and mounted onto thin glass slides with LIGHT DIAGNOSTICS Mounting Fluid (Millipore) for 
3D confocal microscopy using a Zeiss LSM 700. 
3.2.14 Oxime Bond Formation (Synthesis of 2-(propan-2-ylideneaminooxy)acetic acid) 
To a 10 mL flask containing a magnetic stir bar, 100 mg (1.1 mmol) of o-
(Carboxymethyl)hydroxylamine hemihydrochloride was added and purged with Argon gas.  
Freshly distilled acetone (3 mL) was then added using a syringe and stirred at 23°C for 4 hours. 
Excess acetone was removed using a rotary evaporator to (0.140 g, 99 %) convert to the oxime 
product 2-(propan-2-ylideneaminooxy) acetic acid as a white solid. 1H-NMR (D2O, 300 MHz): δ 
4.45 (s, 2H), 1.85 (s, 3H), 1.79 (s, 3H); 13C-NMR (D2O, 400 MHz): δ 175.45, 160.82, 69.81, 
20.61, 15.31. 
3.2.15 Oxime Hydrolysis Analysis 
Oxime hydrolysis experiments were conducted by adding (1.5 mg,11 µmol) 2-(propan-2-
ylideneaminooxy) acetic acid into five separate scintillation vials,  followed by preparation of 0.1 
M buffered D2O solutions using pyridine (pH 11.0), sodium bicarbonate (pH 8.0), PBS (pH 7.4), 
sodium carbonate (pH 5.0) and sodium formate (pH 3.0), respectively. Once the 5 separate 
samples of 2-(propan-2-ylideneaminooxy) acetic acid were dissolved in 0.5 mL each of the pH 
buffered D2O solutions, their respective NMR spectra were taken (ns=8). Data was gathered 
initially at 3 hour intervals, followed by once a day, then once a week to determine the rate of 
hydrolysis of the starting material.   
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3.2.16 Oxime Formation Kinetics Conditions   
Pseudo-first order rate experiments were conducted using 1H-NMR (300 MHz) spectroscopy.  
These experiments were performed in typical NMR tubes by dissolving methhydroxylamine 
hydrochloride (1.5 mg, 83.52 g/mol, 18 µmol) and freshly distilled acetone (150 µL, distilled 
over drying agents) in 0.25 mL PBS buffered D2O (pH 7.4) at 37.0°C, respectively. The two 
solutions were quickly mixed together in the NMR tube and placed into the spectrometer. The 
first time point was taken immediately, with subsequent data points recorded every 40 seconds.  
This experiment was repeated using 2-(propan-2-ylideneaminooxy) acetic acid (11 mg, 109.30 
g/mol, 11 µmol) dissolved in 0.25 mL PBS buffered D2O (pH 7.4) in a NMR tube at 37.0°C. 
Freshly distilled acetone was added into 0.25 mL PBS buffered D2O (pH 7.4) and warmed to 
37.0°C. The two solutions were then mixed in a NMR tube and placed into the spectrometer. The 
first time point was taken immediately, with subsequent data points recorded every 40 seconds.   
3.2.17 Spheroid Movies in Flow Experimental   
The microfluidic device was mounted on a Nikon Eclipse TE2000-U Fluorescence Microscope. 
Ketone engineered GFP cells (2 x 106/mL) and hydroxylamine engineered GFP cells (2 x 
106/mL) were prepared in PBS and loaded into the Hamilton glass syringes separately. The two 
syringes were connected to the microfluidic device and flow rate was set at 0.4 µL/min. Live 
recording of the two cell populations flowing through the microfluidic channels were taken 
automatically by the microscope over 10-20 second intervals.   
3.2.18 Stem Cell Differentiation in Co-culture 
hMSCs were induced to differentiate for 2 weeks. Total RNA was then extracted using a RNA 
isolation kit (Qiagen). 1 μg of total RNA was converted to cDNA using AMV reverse 
transcriptase and random hexamer primers (Promega). The resulting cDNA was used in PCR 
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with the following primer, LPL (sense 5′-GAG ATT TCT CTG TAT GGC ACC-3′, antisense 5′-
CTG CAA ATG AGA CAC TTT CTC-3′), PPARγ2 (sense 5′-GCT GTT ATG GGT GAA ACT 
CTG-3′, antisense 5′-ATA AGG TGG AGA TGC AGG CTC-3′), Collagen I (sense 5′-TGC 
TGG CCA ACC ATG CCT CT-3′, antisense 5′-TTG CAC AAT GCT CTG ATC-3′), Collagen II 
(sense 5′-ATG ACA ACC TGG CTC CCA AC-3′, antisense 5′-GCC CTA TGT CCA CAC 
CGA-3′), RUNX2 (sense 5′-GAT GAC ACT GCC ACC TCT GAC TT-3′, antisense 5′-CCC 
CCC GGC ACC ATG GGA AAC TG-3′), ALPL (sense 5′-CCA TTC CCA CGT CTT CAC 
ATT-3′, antisense 5′-GAG GGC CAG CGC GAG CAG CAG GG-3′), at annealing temperatures 
of 52°C, 55°C, 53°C, 57°C, 61°C, 66°C, respectively. Amplification reactions were carried out 
for 1 min through 30 cycles and the reaction products were subjected to 1 % agarose gel 
electrophoresis. The reaction products are 276 bp (LPL), 351 bp (PPARγ2), 489 bp (Collagen I), 
359 bp (Collagen II), 362 bp (RUNX2), and 418 bp (ALPL), respectively.  
3.3 Results and Discussion 
 To rapidly generate co-culture assemblies based on bio-orthogonal ligation chemistry in 
microfluidic flow, we determined that the inter-cell surface reaction to be fast and stable.  
Several bio-orthogonal strategies were available, including Diels-Alder and Huisgen 3+2 copper 
catalyzed cyclo-additions but we chose oxime ligation involving the reaction between 
hydroxylamine and ketone groups due to their ease of incorporation into simple lipid-like 
molecules. Figure 3.2 describes the kinetics of formation and stability of the oxime reaction at 
physiological conditions (pH 7.4, 37°C). In solution, a model reaction forms the oxime with a 
half-life of approximately 9 seconds and is stable for many weeks with minimal hydrolysis.   
However, we surmised that on the surface of a cell oxime formation would be several orders of 
magnitude faster, due to the polyvalent nature and fluid mosaic ability of the membrane allowing 
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for the ketone and hydroxylamine lipids within the membrane to rapidly diffuse and thus 
dramatically change their local concentration density.  
 
Figure 3.2: Nuclear Magnetic Resonance (NMR) study of the kinetics and stability of the bio-
orthogonal oxime conjugation reaction at physiological conditions under pseudo first order 
condition. (A) The reaction of a ketone and hydroxylamine at physiological conditions results in 
the rapid formation of the covalent and stable oxime bond. The alpha proton of the hydroxylamine 
(Ai) was compared to the oxime alpha proton (Bi) to obtain a ratio of starting material to product 
to calculate conversion and rate constant. 1H-NMR was used to determine the oxime formation 
kinetics (k=0.98X 10-2 Ms-1, t1/2 = 9 sec). (B) The stability of the oxime bond was studied under 
hydrolytic conditions with 1H NMR using a variety of biological buffers (pH 3.0, 5.6, 7.4, 8.0 and 
11.0). The oxime product was formed with high purity and studied using the alpha oxime proton 
(Ci) and compared to the alpha keto proton of the ketone hydrolysis product (Di). The oxime bond 
was stable with no hydrolysis observed after 3 weeks in pH 3.0 and 5.6. At physiological 
conditions (pH 7.4), there was a 3 % hydrolysis over 3 weeks. 
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 Figure 3.3 describes the overall strategy for the generation of co-culture assemblies in 
microfluidic flow using potential automated systems. First, multiple different cell lines were 
cultured in microwell plates as single monolayers. To these cell cultures, liposomes with either 
ketone or hydroxylamine groups were added, which rapidly fuse and tailor the cell surfaces.   
These cells were then detached and transferred to the standard Y-joint PMMA microfluidic 
device. Each inlet of the microfluidic channel injects a separate cell line tailored with either the 
ketone or hydroxylamine groups. As the cells flow through, they arrive at the mixing channel 
where they come in contact and collide with the complimentary CSE cells, instantly forming 
adhesions due to the inter-cell polyvalent bio-orthogonal oxime reaction. As the spheroid 
assemblies flow through the channel they associate with more cells to generate larger spheroids. 
As the microtissues flow through the channel they were deposited onto microwells to form 3D 
multi-layer tissues. This microfluidic and CSE strategy allows for the rapid assembly of complex 
co-culture tissues for studies of spheroid autocrine and paracrine signalling, tumours and the 
formation of 3D multi-layer tissues for a range of applications. Controls clearly show that no cell 
assemblies form when cell surfaces do not present the oxime pair. Furthermore, only a 
monolayer or single cells in solution are generated when either the ketone or hydroxylamine is 
absent on the cell surfaces. 
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Figure 3.3: Schematic describing the use of microfluidic technology and tailored cell lines to 
generate multi-layer co-culture tissues. (Left) Different cell lines were grown in microwell 
arrays to generate 2D contact inhibited single layers. Liposomes containing either ketone or 
hydroxylamine are added to the microwells. The liposomes quickly fuse to the cells and deliver 
the functional groups to rapidly produce engineered cell surfaces presenting ketone (9) or 
hydroxylamines (10). (Middle) The engineered cells are then transferred via pin arrays to a simple 
microfluidic device. As the cells are flowed through the channels they come into contact and 
assemble into co-culture spheroids through oxime click chemistry. The size of the spheroids are 
determined by flow rate, cell concentration and length of the assembly chamber. (Right) The 
spheroids are then transferred to a microwell plate where they adhere and form co-culture multi-
layered 3D tissues. As controls, cells without the bio-orthogonal functional groups produce no 
spheroids upon mixing in the microfluidic channels and results in no 3D assemblies produced, 
where only standard 2D single cell layer sheets are formed. 
 Figure 3.4 presents various images of spheroid sizes generated along the length of the 
microchannel. Figure 3.4A describes the relationship between the spheroid size generated versus 
flow rate and position within the channel. As the flow rate decreases and the position along the 
channel increases, the size of the spheroid clusters become larger. It is remarkable that the oxime 
ligation chemistry between cells can adhere cells together while subjected to shear forces under 
flow conditions. The generated spheroids and multi-layers are stable, do not fall apart or require 
additional support, such as entrapment within Matrigel® or other polymer based scaffolds. 
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Figure 3.4: Images of cells at various stages of assembly in the microfluidic channel device. 
(A) Illustration of the PMMA microfluidic device showing the flow of cells in the Y-joint followed 
by mixing and assembly at different lengths of the channel. (B) Images of cells flowing through 
the microfluidic device at different flow points. Larger spheroid cell assemblies are produced at 
longer lengths of the channel. (C) Images of representative cell cluster (20X) sizes at different flow 
points along the channel. 
 To generate a range of co-culture spheroids by microfluidic assisted assembly, we used 
several fluorescent cell lines tailored with the bio-orthogonal lipids. Figure 3.5 shows a 
description of the polyvalent nature of the inter-cell co-culture oxime spheroid assembly. GFP 
and RFP cells were used to demonstrate the assembly of co-culture cells in flow. By adjusting 
the initial cell density flowed through the channels, several different co-culture cell ratio 
spheroids could be generated. By adjusting the ratio (stoichiometry) of the two cell types many 
different co-culture assembly combinations could be generated. For example, in Figure 3.5C an 
8:1 ratio of RFP to GFP cells flowed through the channels resulted in spheroids containing a 
single RFP surrounded by GFP cells. Figure 3.5E shows three cell types forming spheroids by 
combining equal numbers of RFP-ketone, GFP-ketone and blue live-dye –hydroxylamine cells. 
Figure 3.5F-G shows GFP and RFP cell spheroid formation based on two sets of cells with 
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complementary ketone and hydroxylamine cell surface chemistry. Figure 3.5H shows fluorescent 
and bright field combined images of a 1:1 RFP to GFP cell spheroids.    
 
Figure 3.5: Schematic illustration and fluorescent images of co-culture spheroid assembly 
via click chemistry ligation. (A, B) Illustration of co-culture assembly based on oxime ligation 
between two different cell types. (C, D) Images depict how changing the ratio of input cells in 
microfluidic flow result in different ratios of co-culture spheroids. A 8:1 ratio (RFP:GFP) of cell 
input results in a single NIH 3T3/GFP cell surrounded by HDNF/RFP cells (C). Reversing the 
ratio to 1:8 (GFP:RFP) results in a single HDNF/RFP cell surrounded by NIH 3T3/GFP cells (D). 
(E) Image of a large 3 cell type spheroid generated by mixing of a 1:1:1 ratio of GFP:RFP:Blue 
C3H10T1/2 cells CMAC (7-Amino-4-Chloromethylcoumarin) in flow. The GFP and RFP cells 
presented ketones and the Blue cells presented hydroxylamine groups. (F) A large spheroid of GFP 
cells obtained by combining two different populations of GFP cells that present ketone and 
hydroxylamine groups. (G) A large spheroid of RFP cells obtained by combining two different 
populations of RFP cells that present ketone and hydroxylamine groups. (H) A large spheroid of 
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RFP and GFP cells obtained by flowing a 1:1 ratio of cells in the microfluidic device. By adjusting 
the flow rate, cell density and ratio of cell density inputs a range of stoichiometric co-culture 
spheroid assemblies and size of spheroids could be generated. 
 Figure 3.6 depicts a 3D plot of spheroid cluster size of complimentary CSE cells in our 
microfluidic device by adjusting the flow rate, reaction time and injected cell density.  The 
assembly of spheroids in microchannels can be accurately controlled through the careful 
selection microfluidic conditions for different cell assembly applications, although in this work 
resulting spheroids were imaged but not used for subsequent experiments. Figure 3.6 
demonstrates an inverse relationship of cluster size to flow rate, where doubling of flow rate 
from 0.2 to 0.4 µL/min results in a 54% reduction in average cluster size from 22.6 to 10.3 cells 
per spheroid cluster. This was not a surprising result, as increasing shear stress as a result of 
laminar flow (Re ~ 1) from increased flow rate would prevent cell-cell assembly from initiating. 
Channel distance or residence time in channel for assembly to occur had a roughly linear positive 
relationship to cluster size, where doubling the channel length resulted in a doubling of cluster 
size. Increasing the injected cell density results in increasing cluster size but is not linear due to 
laminar flow which prevents turbulent mixing of cells in the microchannel (relatively large 10 
µm spheres) and relies on diffusion mixing calculated to be (Tdiff = 13110 min) across the width 
of the microchannel. Therefore high densities are necessary for spheroid assembly to occur while 
lower densities (500K cells/mL) do not result in spheroid assembly (Supplementary Info.). 
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Figure 3.6: 3D plot representing the relationship between flow rate, channel distance, cell 
density, and resulting cell cluster size (spheroid) assembled within a microfluidic channel. 
As the cell density increases and flow rate decreases, spheroids assemble at a faster rate. The 
absence of one (orange) or both (white) surface chemistries results in no spheroid formation. 
Statistical analysis showed cluster size was within 5 % for each condition. Images of cellular 
clusters consist of representative samples of eluted cell clusters. Scale bars (left side) = 50µm. 
 To demonstrate the flexibility of this methodology, several co-culture assemblies were 
generated via microfluidic flow and evaluated. Figure 3.7A-B shows a control monolayer of GFP 
expressing cells that are contact inhibited in culture. Without the bio-orthogonal click chemistry 
on the cell surface, most cells adhere and proliferate until they become contact inhibited and 
form a single monolayer in the x-y plane in culture. These cells do not grow on top of each other 
(in the Z plane, vertical direction) in normal standard cell culture in vitro conditions. However, 
upon delivering bio-orthogonal lipids via liposome fusion the cells will form co-culture multi-
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layers in the Z plane to form multi-layers or 3D tissues. Figure 3.7C-D shows confocal images of 
RFP and GFP cells assembled sequentially in microfluidic flow and then deposited onto cell 
culture dishes to generate oriented co-culture layers. Complex zones of varying thickness of 
multiple cell lines (GFP and RFP) can be generated by simple alteration of the number of cells 
and sequence of cell deposition (Figure 3.7E-H). By depositing many cells onto each other using 
bio-orthogonal chemistry thick layers can be formed and cells proliferate. As described 
previously, the ketone and hydroxylamine lipids dilute over time on the cells via a transient 
transfection model while naturally excreted ECM is produced by the cells taking over as the 
tissue adhesive.29 
 Therefore, the oxime chemistry is slowly diluted and the ECM holds the tissue layers 
together. Figure 3.7K-L, shows a thick multi-layer of hMSC and fibroblast cells that can be 
induced to differentiate distinct lineages based on the orientation of the cells within the multi-
layer (stem cell studies). Figure 3.7M-N shows the formation of 3 cell types in a mixed multi-
layer via bio-orthogonal chemistry. RFP and GFP ketone containing cells were mixed with blue 
(CMAC) stained hydroxylamine cells and assembled spheroids in microfluidics, then deposited 
onto tissue culture plates to generate 3D mixed multi-layers consisting of 3 cell lines. Figure 
3.7O-P shows the combination of the cell assembly click strategy combined with collagen 
scaffolds. Upon cell seeding, the collagen scaffold is filled with cells almost instantly since bio-
orthogonal cells can simultaneously adhere to each other and to the collagen scaffold. This 
strategy allows for a very high cell seeding density, which causes rapid filling of polymer 
scaffolds or de-cellularized materials.  
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Figure 3.7: A range of confocal and bright-field images of various combinations of NIH 
3T3/GFP, HDNF/RFP, Blue live stain C3H/10T1/2 pluripotent embryonic fibroblast stem 
cells, hMSC cells and NIH3T3 cells. (A) Top view of a standard contact inhibited single 
monolayer of NIH 3T3/GFP cells in culture. (B) Angle and side view of monolayer showing a 
thickness of approximately 6 µm. (C) Top view image of RFP-GFP bilayer multi-layer generated 
by first assembly in microfluidic flow of GFP spheroids followed by deposition onto glass slides 
to generate GFP multi-layer. To this GFP multi-layer, RFP spheroids were added as they were 
generated in microfluidic flow.  The sequential spheroid and multi-layer generation resulted in a 
bilayer of multi-layers of GFP and RFP cells (30 µm thick). (E, F, G, H)  Image of serial RFP and 
GFP spheroid assembly in flow followed by sequential deposition resulted in control of co-culture 
orientation multi-layers and thickness (E, F, 30 µm thick) (G, H, 120 µm thick). (I, J) Image of 
Tetramethylrhodamine (TRITC) and 4′,6-diamidino-2-phenylindole (DAPI) stained thick multi-
layers of NIH3T3 fibroblasts (140 µm thick). (K, L) Brightfield image of multi-layers of hMSC 
cells mixed with NIH3T3 fibroblasts. (L) After culturing for 10 days the hMSC cells differentiated 
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to adipocytes in the co-culture. (M, N) Image of 1:1:1 RFP:GFP:Blue C3H/10T1/2 cells mixed 
multi-layers generated by assembly in flow followed by deposition onto glass slides. The RFP and 
GFP cells presented ketones and the Blue cells presented hydroxylamines.  (O)  Photograph of a 2 
cm x 2 cm x 0.5 cm thick collagen tissue containing RFP-ketone and GFP-hydroxylamine cells. 
Spheroids of RFP:GFP cells were generated in flow and then mixed with collagen. (P) Top and 
side views of co-culture cells in collagen. High cell density within collagen was achieved by the 
adhesion of large spheroids. The cells adhere to the collagen and to each other, therefore generating 
high cell density thick tissues instantly. 
 To demonstrate the utility of our CSE methodology, a series of experiments were 
performed using the microfluidic scaffold-free co-culture formation of hMSCs and fibroblasts to 
determine differentiation under CSE assembly (Figure 3.8). Ketone and hydroxylamine 
presenting hMSC and Swiss 3T3 fibroblasts were mixed and induced with differentiation factors 
to form adipocytes, fibroblasts and osteoblasts using typical induction conditions. The cells were 
assembled into multi-layer cultures and assayed after 1 day and 2 weeks to establish a lineage.  
Figure 3.8A-F demonstrates the stability and expression of gene markers over long periods for 
lineage differentiation. This demonstrates the utility of the CSE assembly methodology to study 
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the influence of second cell types in stem cell niche-like conditions that may alter rate and final 
differentiation lineage. 
 
Figure 3.8: Construction of a 3D tissue co-culture system via intercell click ligation and 
application to stem cell differentiation. (A−C) Co-culture system of hMSCs/fibroblasts were 
assembled and then made to differentiate to adipocytes (A), fibroblasts (B) and osteocytes (C) via 
corresponding induction conditions. Adipocytes, fibroblasts and osteoblasts were stained red, 
green and blue, respectively. Images were taken by phase contrast microscopy (20X). 
Corresponding gene markers (LPL for adipocytes, Collagen I for fibroblasts, ALPL for 
osteoblasts) were studied over 2 weeks. (1: day one; 2: 2 weeks) and are represented by the gels 
shown in D, E and F, respectively. 
3.4 Conclusion 
 In summary, we have developed a straightforward strategy to rapidly generate co-culture 
cell assemblies and tissues in flow using bio-orthogonal groups to rewire cells. Liposome fusion 
delivery of the bio-orthogonal lipid like groups to the cell surface is efficient, fast and 
inexpensive. The cell surface oxime ligation strategy is kinetically well behaved, stable and 
allows for rapid complex co-culture and multi-layer tissue construction. It is also simple to 
incorporate existing cargo strategies within the liposomes for simultaneous delivery of payloads 
and lipid molecules to surfaces for multiplex applications, ranging from imaging to theranostics 
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(combined diagnostics and therapy agents). Due to the flexibility of the methodology, many 
other click chemistry reactions may be used and multiple different click chemistries can be 
incorporated on cell surfaces simultaneously. These methods can be used to tailor surfaces with a 
range of molecules, probes, biomolecules and nanoparticles. Since there is no metabolic 
biosynthetic manipulation of the cells, a large scope of novel cell surface capabilities may be 
possible through bio-orthogonal conjugation. Furthermore, autocrine, paracrine, tissue or 
spheroid studies and regenerative medicine applications are now available due to the ease of 
delivery and manipulation of primary cell surfaces. By using more complex microfluidic 
technology it may be possible to incorporate multiple cell lines with in situ liposome fusion in 
flow, followed by cell sorting to engineer cells in various ways. Since the rewired cell acts as the 
scaffold, there is no need to use polymers for tissue construction due to the efficient cell 
economy assembly process. However, the methodology can also be complementary to polymer 
scaffolds, allowing for the rapid filling of molds as cells can adhere to each other and to the 
polymer. The ability to generate spheroids, thick multi-layers and oriented architectures may 
have applications in generating various skin and tissue chips for drug screening or tissue grafting 
and replacement. CSE has the potential to greatly impact clinical and basic science research, 
enabling faster and more in-depth studies using easily generated 3D tissue models and cellular 
manipulation. 
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Chapter 4 
Application of Bio-orthogonal CSE for Directed Nucleic Acid Transfection 
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4.1 Introduction 
The ability to efficiently deliver nucleic acids into cells (transfection) plays a pivotal role 
in the advancement of our understanding of human health.1 Transfection has revolutionized 
fundamental studies in cell biology, biotechnology, agriculture, microbiology, genetics, cancer,  
medicine and biomedical research.2 3 4 5 6 7 Cutting edge research relies on the efficient delivery 
of nucleic acids into a range of cell types for various applications that span gene editing, 
fundamental cell biology studies, therapeutic and vaccine development, human and plant 
biotechnology and scaling protein production.8 9 10 11 Although transfection is of central 
importance and arguably one of the most vital tools in biological research, most cell types are not 
easily transfected with foreign nucleic acids due to variations in nucleic acid stability, delivery 
and host cell defense mechanisms. Furthermore, transfecting cells with nucleic acids in vitro and 
in vivo is not always straightforward due to rapid nucleic acid degradation in serum containing 
media or in vivo conditions. Since, transfection is an initial step in many biological studies, poor 
cell transfection results in tremendous waste of time and effort spent in multiple rounds of 
transfection to improve cell count and money spent in extra labor and reagents. Due to its critical 
importance, reagents that promote transfection have become essential in research in the life 
sciences and commercial market is estimated to be over $1.5 billion/year.12 
The delivery of nucleic acids to mammalian cell lines has been revolutionized over the 
last 20 years through the development of cationic polymer (Viafect, Promega) or cationic lipid 
based (Lipofectamine, Life Technologies) technologies for biological assays. Gene delivery 
technologies insert coding (cDNA) into the cell nucleus, typically in the form of circular DNA or 
plasmids which interact with endogenous transcription factors to produce changes in messenger 
RNA (mRNA) protein expression. Mammalian cell line transfection of plasmid DNA (pDNA), 
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short interfering RNA (siRNA) and other genetic hybrid molecules is a substantial field of study 
encompassing protein production, genetic discovery and manipulation, signal pathway 
elucidation and cellular imaging.   
Genetic engineering transfection generally involves the delivery of oligonucleotides for 
identification or clone isolation of partial genetic content of whole single cells to change cellular 
behaviour, produce desired biological outcomes or elucidate biological signalling pathways. 
Permanent changes to the genome can be achieved through gene editing techniques such as 
molecular scissors, nucleases and most recently Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR)-Cas9 to introduce hereditable changes to reveal gene 
functionality, new therapeutic targets, improve human gene therapy and the commercial 
production of therapeutic agents from standard host cells such as yeast or mammalian cell lines. 
Current methods to introduce permanent changes to the cell involve the use of mega-nucleases 
such as Zinc-Finger (ZF), Transcription activator-like effector nucleases (TALEN) and CRISPR-
Cas9, were first discovered as viral defence mechanisms within bacterial cells.  They empoly 
site-specific DNA cleavage producing DNA double stranded breaks while reducing off target 
gene changes.  
Although mega-nuclease complexes and their mechanism of action have been refined 
through tremendous effort in the biological community, with even further improvements and 
optimization on the horizon, these gene editing techniques do however suffer from a common 
caveat, they all require a vector for delivery to the cytoplasm of the cell. To make any changes to 
the interior of the cell, a mechanism for breaching the robust and protective cell membrane is 
required. The plasma membrane is a significant barrier to polar aqueous soluble molecules, and 
can be highly resistant to DNA and RNA not only through passively blocking physical entry but 
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also employing active mechanisms to repel or inactivate foreign genetic information. To 
circumvent these defense mechanisms, researchers have developed instrumental (physical), 
biological (viral) and reagent (chemical) based methods to transfect cell lines by using vectors to 
insert foreign genetic content.    
Physical based transfection methods employ high strength electromagnetic fields, femto-
lasers, microneedles or gold nanoparticles to introduce physical pores or holes in the membrane 
that allow diffusion of oligonucleotides from the surrounding medium into the cytosol.13 These 
methodologies have aided academic research by enabling transfection of difficult to transfect cell 
lines such as MSCs and primary cell lines. However, these methods are expensive, highly 
cytotoxic and can only be used cultured cell lines.   
After the initial discovery of viral mechanisms for entry into mammalian cells, the 
development of viral vectors for gene editing was quickly established by Paul Berg using 
recombinant DNA to insert bacteriophage genes into the E. coli genome using SV 40 viruses.14  
Viral gene editing has progressed to include lentivirus, adeno-associated and adenovirus vectors 
as replication deficient delivery vehicles for streamlined and efficient transfection. Viral 
techniques utilized whole engineered viral particles to package and deliver DNA payloads for 
genomic integration, where viral protein coat receptors target mammalian membrane receptors to 
hijack endocytic pathways, allowing viral DNA entry into the cytosol. Once inside the nuclear 
envelope the DNA is incorporated into the host genome, while viral replication is disabled to 
inhibit viral propagation and subsequent cell death. However, viral insertion has several 
limitations preventing widespread use in academia, industry and clinical applications including 
limited transgenic length, targeting difficulties and mutagenesis.15 16 
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Chemical based transfection reagents include chemical or molecular substances that when 
combined with plasmids or oligonucleotide sequences produce aggregate complexes termed 
‘lipoplexes,’ which promote the delivery of DNA into cells. Chemical transfection methods 
include calcium phosphate, cationic polymers, cationic lipids and cationic amino acids to 
produce self-assembled lipoplexes with RNA or DNA. The key challenge for efficient and usage 
scope of cell transfection is found at the molecular level: How can negatively charged nucleic 
acids be delivered to negatively charged cells at physiological conditions in serum, with the 
fewest number of steps, while ensuring high viability, efficiency and no post sorting of 
transfected and non-transfected cells? To address this complex question a range of delivery, 
instruments and viral methods have been developed for transfection but each suffer from various 
drawbacks related to cost, viability and efficiency.17 18  
 
Figure 4.1: A general scheme depicting the assembly, association and cell membrane 
adhesion of cationic charge based chemical lipoplexes with mammalian cell lines. 
The overwhelming strategy for nucleic acid delivery has been based on chemical reagents 
binding to nucleic acids, followed by adhesion and cellular uptake. Figure 4.1 outlines three 
main steps in chemical based nucleic acid delivery to cells: 1) The electrostatic reagent forms a 
complex with nucleic acids (Packaging). 2) The complex undergoes adhesion to cell surfaces, 
followed by endocytosis (Delivery). 3) The complex achieves lysosomal escape, where the 
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nucleic acid begins expression within the nucleus (Release). To be useful to the broad research 
community, these processes must be designed with a minimal number of steps, while retaining 
high viability and efficiency. Current strategies and products focus on combining nucleic acids 
via electrostatic complexation of anionic nucleic acids with the excess positive charge of 
polyamine polymers or small molecules.17 The resultant cationic lipid and anionic nucleic acid 
complex or ‘lipoplex,’ is then added to cell media where serum proteins can rapidly absorb or 
degrade a significant fraction of the complex, while the remaining active complex associates 
electrostatically with anionic cell surfaces. The nucleic acid complex undergoes endocytosis and 
a small but functional fraction escapes the lysosome to be expressed or transfect the cell.   
To significantly advance transfection technology and cell biology research, new methods 
that look for alternatives to supplement electrostatic lipoplexes may broaden the scope of cellular 
transfection. Our novel method comprises a combined CSE and bio-orthogonal strategy to 
package and deliver nucleic acids using rapid artificial surface labelling and targeting, while 
reducing the requirement for cytotoxic cationic charge to drive cellular adhesion. This method 
generates a nucleic acid complex with bio-orthogonal groups and CSE to label cell membranes 
with complementary bio-orthogonal chemistry for adhesion and delivery. This method is based 
on selective oxime ‘click’ chemistry which limits non-specific electrostatic interactions between 
the nucleic acid complex and the cell. The methodology we term SnapFect® is: 1) Mild. 2) 
Efficient. 3) High cell viability. 4) Has no post cell sorting steps. 5) Precision targeting of 
specific cells in co-culture. 6) Compatible with complex media. 7) Transient CSE. 8) Does not 
alter cell behaviour using the mild liposomal and bio-orthogonal protocol. 9) Simple two step 
protocol. 
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Liposome fusion has been used as a strategy for the delivery of chemical and biological 
cargo into mammalian cells for a variety of bio-sensing and drug studies as well as therapeutic 
applications.19 20 In this study, we used the liposome strategy to deliver lipid-like functional 
molecules efficiently to the cell surface, where liposome fusion capitalizes on the hydrophobic 
interactions of micelles and lipid bilayers to insert the liposomal bilayer contents with the outer 
plasma membrane structure. In addition, the composition of the liposome background lipids play 
a significant role in inducing particle adhesion and fusion.  
In order to tailor both the cell surface and the nucleic acid complex with complementary 
molecules that can undergo a chemo-selective click reaction in vitro and in vivo without side 
reactions, we used bio-orthogonal chemistry. Bio-orthogonal chemistry refers to a special suite 
of organic chemistry reactions that can be performed at physiological conditions in complex 
mixtures including serum containing media.21 22 Tremendous research has been performed to 
investigate and expand the scope of these special chemical reactions. Several types of click bio-
orthogonal reactions have been used, such as hydrazone, thiol-ene, Diels-Alder, Staudiger, 
Huisgen 3+2 strained alkyne and azides, as well as oxime chemistry for many biological 
applications ranging from in vivo targeting, drug delivery, antibody drug conjugates, to protein 
engineering, proteomics, imaging and bio-sensing.23 24  Figure 4.2 outlines our novel CSE 
approach for cell nucleic acid transfection which integrates liposome fusion, bio-orthogonal 
chemistry and CSE (SnapFect).   
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Figure 4.2: Schematic of combined liposome fusion, bio-orthogonal chemistry and CSE 
strategy for selective nucleic acid transfection of cells (SnapFect). (Top) A liposome containing 
a bio-orthogonal like lipid molecule is delivered to the cell surface via rapid liposome fusion. A 
complementary bio-orthogonal nucleic acid/liposome complex is formed and added to the tailored 
cell. The nucleic acid/liposome complex undergoes a fast click reaction at the cell surface. The 
nucleic acid/lipoplex is then endocytosed where the nucleic acid/lipoplex dissociates and is 
translated. (Bottom) A molecular view of the mild and selective bio-orthogonal mediated 
transfection of cells. A bio-orthogonal liposome containing a ketone group is synthesized and 
added to cell culture. The ketone group is presented on the cell surface through rapid liposome 
fusion. A complementary hydroxylamine liposome is complexed with nucleic acids. The 
hydroxylamine/nucleic acid lipoplex is then added to the ketone presenting cells where rapid 
oxime formation occurs at the cell surface.  The nucleic acid is then endocytosed and released 
within the cell. No transfection occurs if either component of the bio-orthogonal pair is missing.   
We have previously shown that fast and efficient delivery of lipid like bio-orthogonal 
molecules to cell surfaces via liposome fusion provides cells with a new range of capabilities for 
photochemical, redox and biosensing applications.25 26 27 Using CSE we influence the association 
of the lipoplex to the cell membrane during the second step of the transfection process to produce 
a more general approach to lipoplex-cell adhesion with polyvalent oxime reactions rather than 
electrostatic interactions to induce transfection.  This approach will present new capabilities into 
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transfection reagents through the use of selective oxime chemistry to drive the cellular adhesion 
process.  
4.2 Materials and Methods 
4.2.1 Preparation of Cell Cultures 
For our model system we used C3H/10T1/2 mouse embryonic fibroblast cells which were 
cultured and incubated for 3 days at 37°C and 5 % CO2 in 10 cm culture plates (Fisher 
Scientific) with media replaced every other day using DMEM (Sigma Aldrich) with 1% v/v PS 
(Sigma Aldrich) and 10% FBS (Sigma Aldrich) as additives. Cells used for experiments were 
between 2 and 6 passages. RFP expressing human neonatal dermal fibroblasts were cultured 
from liquid nitrogen storage and maintained using DMEM (Sigma Aldrich) with 1 % v/v PS 
(Sigma Aldrich) and 10 % FBS (Sigma Aldrich) as additives and passaged every 3 days. Cells 
used for experiments were between 2 and 6 passages. All cell lines were obtained from ATCC. 
4.2.2 Cellular Engineering Ketone Liposome Formulation and Cell Priming  
To form liposome solutions bearing ketone functionalities, into a 5 mL vial 120 µL of 2-
dodecanone (Sigma Aldrich) (10 mg/mL in CHCl3) was added, followed by 454 µL POPC 
(Avanti Polar Lipids) (10 mg/mL in CHCl3) and 10 µL of DOTAP (Avanti Polar Lipids) (10 
mg/mL in CHCl3), which were then allowed to evaporate over 24 hours. Once the CHCl3 
evaporated, 3 mL fresh PBS (Sigma Aldrich) was added, followed by tip sonication. Sonication 
of the lipid suspensions was performed for 10 minutes in a 23°C water bath and stored at 4°C at 
30W. To apply ketone CSE to cultured cells, they need to be between 75-80 % confluency, the 
cell culture media was then aspirated, followed by the addition of fresh serum containing media 
(2 mL) and 5 % v/v ketone liposome suspension (100 µL) and incubated with the cells under 
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standard growth conditions for 5 minutes followed by three 3 mL washes of PBS and the 
addition of fresh growth media to the cells prior to transfection.   
4.2.3 General SnapFect Transfection of C3H/10T1/2 cells with phMGFP   
C3H/10T1/2 cells were cultured using standard protocols with 10 % FBS and 1 % Penicillin 
Streptomycin High Glucose DMEM in 10 cm culture plates over 2 days to 75% confluency 
before use. The C3H/10T1/2 cells were then for 3 minutes trypsinized using 3 mL of 0.25 % 
trypsin followed by quenching with 6 mL of growth media and centrifugation at 800 RPM for 5 
minutes. The pellet was then isolated and re-suspended in growth media 1 x 104 cells/mL and 
seeded onto 1 cm2 prepared glass slides (180 µL). The following day the cells were treated using 
the general ketone cell surface engineering protocol, followed by the immediate addition of the 
prepared hydroxylamine lipoplex. To form the hydroxylamine lipoplex into a sterile 1.5 mL 
Eppendorf tube, 15 µL of the hydroxylamine liposome suspension containing 210 µL POPC (10 
mg/mL), 60 µL DOTAP (10 mg/mL) and 120 µL dodecyl (tetraethylene glycol) hydroxylamine 
(10 mg/mL) in 3 mL PBS, using tip sonication over 10 minutes in a 23°C water bath and stored 
at 4°C at 30 W, the fluorescent protein of interest was added, typically 2.0 µg of phMGFP (1.4 
µg/µL). This mixture was then incubated at 23°C for 30 minutes, diluted with 200 µL of serum 
free DMEM media and then carefully pipetted onto the slide and incubated at 37°C at 5 % CO2 
for 5 minutes. After the 5 minute incubation period, the samples were given HNDF serum 
containing growth media and incubated for another 24-48 hours. The slides were then fixed by 
washing three times with 3 mL PBS followed by the addition of 5 % formalin solution for 15 
minutes.  The formalin solution was then drained and washed once with PBS followed by 
mounting to glass cover slips for fluorescent microscopy using an inverted Zeiss AX10 
Fluorescence Microscope. 
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4.2.4 Targeted Co-culture Method (HNDF/RFP and C3H/10T1/2) and phMGFP 
Transfection of HNDF cells  
HNDF cells were grown in 10 cm culture plates using the standard growth protocol with 10 % 
FBS and 1 % P/S High Glucose DMEM media to 80 % confluency and then trypsinized using 3 
mL 0.25 % trypsin for 3 minutes followed by quenching with 6 mL of growth media and 
centrifugation at 800 RPM for 5 minutes. The pellet was then isolated and re-suspended in 
growth media for 5 x 103 cells/mL and seeded onto 1 cm2 prepared glass slides (180 µL). The 
cells were then incubated for 4 hours at 37°C at 5 % CO2, followed by the addition of 2 mL fresh 
growth media. The following day (approximately 16 hours) the cell media was replaced with 
fresh media and 5 % v/v ketone liposome suspension (100 µL) was added to the growth media 
and incubated for 5 minutes, followed by three 3 mL washes of PBS. C3H/10T1/2 cells were 
grown in 10 cm culture plates using the standard protocol and once they reached 75 % 
confluency were trypsinized using 3 mL trypsin for 3 minutes followed by the addition of 6 mL 
growth media and centrifuged at 800 RPM for 5 minutes. The pellet was isolated and 
resuspended in growth media to 1 x 104 cells/mL. The tissue plates containing slides with 
adherent HNDF/RFP cells were then drained of media and then 180 µL of C3H/10T1/2 cell 
suspension was added and incubated for 4 hours at 37°C and 5% CO2 followed by the addition of 
2 mL of fresh growth media and incubated for 16 hours. The lipoplex suspension was freshly 
prepared each time. To a sterile 1.5 mL Eppendorf tube, 60 µL of the hydroxylamine liposome 
suspension containing 410 µL POPC (10 mg/mL), 60 µL DOTAP (10 mg/mL) and 120 µL 
dodecyl (tetraethylene glycol) hydroxylamine (10 mg/mL) was added followed by the addition of 
2.0 µg of phMGFP (1.4 µg/µL). This mixture was then incubated at 23°C for 30 minutes and 
then diluted with 700 µL of serum free DMEM media. Then 1 cm2 glass slides were washed 
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twice with 3 mL PBS, with the PBS drained, 200 µL of the lipoplex solution was carefully 
pipetted onto the slide and incubated at 37°C at 5 % CO2 for 5 minutes. After the 5 minute 
incubation period, the samples were given HNDF serum containing growth media and incubated 
for another 24-48 hours. The slides were then fixed by washing 3 times with 3 mL PBS followed 
by the addition of 5% formalin solution for 15 minutes. The formalin solution was then drained 
and washed once with PBS followed by mounting to glass cover slips for fluorescent microscopy 
using an inverted Zeiss AX10 Fluorescence Microscope. 
4.2.5 Firefly Luciferase Stability Assay 
C3H/10T1/2 cells were cultured and incubated for 3 days at 37°C and 5 % CO2 in 10 cm culture 
plates with media replaced every second day using DMEM with 1 % v/v PS and 10 % FBS as 
additives. Cell cultures used for experiments were between 2 and 6 passages. Cells were then 
transferred using 3 mL trypsin into 6 well plates using 7.5 x 103 cells/well. The cells were grown 
overnight and transfected using the general transfection protocol and incubated for 24 hours. The 
cells were surfaced engineered with a liposome solution bearing ketones functionalities, where in 
a clean 5 mL vial 120 µL of 2-dodecanone (10 mg/mL in CHCl3) was added, followed by 454 
µL POPC (10 mg/mL in CHCl3) followed by 10 µL of DOTAP (10 mg/mL in CHCl3), which 
were then allowed to evaporate over 24 hours.  Once the CHCl3 is evaporated 3 mL of fresh PBS 
is added, followed by tip sonication. Sonication of the lipid suspensions was performed for 10 
minutes in a 23°C water bath and stored at 4°C at 30 W.   
Using optimal conditions for transfecting pGFP outlined above, we substituted pGFP for 
Firefly Luciferase (pRL) (Promega) to transfect C3H/10T1/2 cells. pRL lipoplex liposomes were 
synthesized using a sterile 1.5 mL Eppendorf tube 60 µL of the hydroxylamine liposome 
suspension containing 210 µL POPC (10 mg/mL), 60 µL DOTAP (10 mg/mL) and 120 µL 
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dodecyl (tetraethylene glycol) hydroxylamine (10 mg/mL) was added followed by the addition of 
2.0 µg of pRL (1.4 µg/µL). This mixture was then incubated at 23°C for 30 minutes and then 
diluted with 200 µL of serum free DMEM media and carefully pipetted onto the slide and 
incubated at 37°C and 5 % CO2 for 5 minutes. Following the 5 minute incubation period, the 
samples were washed with 3 mL PBS and given HNDF serum containing growth media and 
incubated for another 24 hours.  Control experiments omitted ketone lipids to the pre-treatment 
of the cells before transfection, while retaining the original ratio of background lipids, as well as 
through the absence of hydroxylamine bearing lipids from the formulation of the lipoplex.  
Transfected cell culture plates were then transferred to a 0°C ice bath and washed twice with 2 
mL of PBS treated with 160 µL of lysis buffer and mechanically scrapped from the dishes and 
then transferred into 1.5 mL Eppendorf tubes. The lysate was then heated to 100°C using a 
heating block (Labnet Accublock) for 5 minutes and frozen at -80°C overnight. The following 
day, pRL expression was quantified using an automated Berthold Lumat 3 (LB 9508) with 
luminol. 
4.2.6 Western Blot Assay 
Expression using pRFP was conducted in parallel to pRL luciferase expression analysis.  
C3H/10T1/2 cells were collected using NP-40 lysis buffer (0.5 % [vol/vol] Nonidet P-40, 50 mM 
Tris-HCl [pH 8.0], 150 mM NaCl, 10 mM sodium pyrophosphate, 1 mM EDTA [pH 8.0], and 
0.1 M NaF) containing 10 µg/ml (each) leupeptin and aprotinin, 5 µg/ml pepstatin A, 0.2 mM 
phenylmethylsulfonyl fluoride, and 0.5 mM sodium orthovanadate. Protein extracts were 
denatured in SDS loading buffer at 95°C for 5 minutes and then run on a 10 % SDS-PAGE gel, 
transferred to a polyvinylidene difluoride membrane (Millipore), and blocked in 5 % skim milk 
for 1 hour prior to antibody incubation, using rabbit RFP Antibody (Life Technologies). 
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4.2.7 Comparison Luciferase Assays Using Viafect and Lipofectamine 3000  
Viafect (Promega) and Lipofectamine 3000 (Life Technologies) reagents were optimized for use 
with C3H/10T1/2 with phGFP and optical microscopy to determine the highest transfection 
efficiency using the recommended manufacturer and our general SnapFect protocol. Using the 
standard growth protocol for C3H/10T1/2 cells, the cells were seeded into 6 well plates at 3.5 x 
104 cells/well overnight. The following day 2.0 µg of pRL (0.14 µg/µL) was mixed with 6.0 µL 
of Viafect reagent and incubated at 23°C for 10 minutes, then diluted to 200 µL of total volume 
using non serum containing media. Then the 200 µL of Viafect solution were added to the cells 
containing 2 mL of serum containing media and incubated for 24 hours at 37°C at 5% CO2. For 
Lipofectamine, the following day 9.8 µg of pRL (1.4 µg/µL) was mixed with 4.0 µL of P3000 
reagent for 5 minutes and diluted to 125 µL in serum-free media. Then 4.4µL of Lipofectamine 
3000 reagent was diluted with 125 µL of serum free media, then the two solutions were mixed 
and incubated at 23°C for 10 minutes. Then the 250 µL of complex solution was added to the 
cells containing 2.0 mL of serum containing media and incubated for 24 hours at 37°C at 5 % 
CO2. Then the cells were investigated using our above Luciferase protocol. The control and 
experimental trials were completed in technical triplicate.   
4.2.8 Viability and Efficiency Comparison Assays Using phGFP of Viafect and 
Lipofectamine 
Viability was determined using the above scaled up Luciferase protocol Viafect (Promega) and 
Lipofectamine 3000 (Life Technologies) reagents were used to transfect C3H/10T1/2 cells with 
phGFP and optical microscopy was used to determine viability and efficiency through cell 
counting using the recommended manufacturer protocols. Using the general growth protocol for 
C3H/10T1/2 cells, the cells were seeded onto 6 well plates at 3.5 x 104 cells/well overnight. The 
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following day 2.0 µg of phGFP (1.4 µg/µL) was mixed with 6.0 µL of Viafect reagent and 
incubated at 23°C for 10 minutes, then diluted to 200 µL of total volume using non-serum 
containing media. Then the 200 µL of Viafect solution were added to the cells containing 2 mL 
of serum containing media and incubated for 24 hours at 37°C and 5 % CO2. For Lipofectamine, 
the following day 9.8 µg of phGFP (1.4 µg/µL) was mixed with 4.0 µL of P3000 reagent for 5 
minutes and diluted to 125 µL in serum-free media. Then 4.4 µL of Lipofectamine 3000 reagent 
was diluted with 125 µL of serum-free media, then the two solution were mixed and incubated at 
room temperature for 10 min. Then 250 µL of complex solution was added to the cells 
containing 2.0 mL of serum containing media and incubated for 24 hours at 37°C at 5% CO2. 
The experiments were all performed in parallel. Viability was determined through vital dye 
staining using 0.4% Trypan blue (Sigma Aldrich) using the manufacturer protocol, in addition to 
a (Bright-Line) visual hemocytometer for cell counting. Cell efficiency was determined using the 
above-mentioned transfection protocols for Viafect, Lipofectamine and Snapfect, where 
following a 24 hour incubation period with the relevant reagent the cells were fixed and observed 
using fluorescence microscopy. The visually fluorescent cells were scored as transfected while 
dark cells were counted as non-transfected using ImageJ (National Institute for Health) and 
compared with cell counts of control populations. Nine images from each well were averaged to 
determine efficiency of the reagent.  
4.2.9 Microfluidic Transfection in Flow 
Microfluidic Device Fabrication and Design:  The micro-channel was designed with a simple Y-
shape, where cell suspensions are brought together in the Y-joint mixing zone. In order to make a 
simple, cheap and robust device, poly methyl methacrylate (PMMA) blocks were used as the 
device substrate. The experimental device was created using laser ablation to etch PMMA blocks 
106 
 
(1/8 in thickness, 1.25 in length, and 1.42 in width). The PMMA channels were laser etched 
using Versalaser 2.30 with a CO2 laser at 14.25 W power to produce parabolic channels with a 
measured base width of 170 μm, a peak height of 200 μm and a channel length of 1.5 cm. The 
fluid inlet connections were fabricated using 406 μm (0.016 in) OD stainless steel capillary tubes 
with an 203 μm (0.008 in) inner diameter (ID) and a length of 2.0 cm, which were embedded into 
the PMMA blocks using thermal heating (to be in line with the channel flow axes), while the 
fluid outlet capillary was cut to 2.0 cm and embedded by thermal heating and pressure similarly 
to the fluid inlets and allowed to cool. The top block of PMMA is used to cap the channel 
through thermal bonding with the etched bottom block in a convection oven for 2 hours at 275°C 
and allowed to cool completely to 23°C over 2 hours under pressure. Once cooled, the fluid 
connections were completed by slipping polyether ether ketone (PEEK) tubing (ID 203 μm/0.008 
in) over the metal capillary and sealed using epoxy resin (3M). Finally, high pressure HPLC 1 
mL Luer lock glass syringes (Hamilton) were connected to the PEEK tubing using Luer tubing 
connections (UpChurch Scientific). 
C3H/10T1/2 and HNDF/RFP cells were grown to approximately 80 % confluency in 10 cm 
plastic growth plates and then treated with 5 % v/v ketone bearing liposomes in serum containing 
media, respectively, for 1 minute followed by aspiration of the media. Cells were washed 3 times 
with PBS and then detached using 0.25 % trypsin/EDTA at 37°C and 5 % CO2. Once the cells 
were detached and neutralized by DMEM media (10 % FBS), the cell suspension was transferred 
to 15 mL tubes and spun down at 800 RPM for 5 minutes. The supernatant was discarded and the 
remaining pellet was re-suspended in DMEM media to reach a final concentration of 2 × 105 
cells/mL. The SnapFect reagent was generated using our hydroxylamine liposomes using the 
above general method for SnapFect liposomes. Once the ketone tailored cell suspensions were 
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prepared, 250 μL of the ketone tailored C3H/10T1/2 suspension was loaded into a sterilized 1 
mL gastight Luer lock Hamilton gas chromatography syringe, while 15 µL of the SnapFect 
reagent was diluted in 250 µL of non-serum containing media and loaded into a sterilized 1 mL 
gastight Luer lock Hamilton gas chromatography syringe. The connection tubing and 
microfluidic device were sterilized by passing 1 mL 70 % ethanol solution, followed by 1 mL of 
PBS buffer. Once sterilized, the loaded syringes were attached to Luer connections to complete 
the fluid connection to the device and placed onto a Harvard 11 PLUS syringe pump. The flow 
rate was set to 8 μL/min for 5 minutes to purge air bubbles from the system and then reduced to 
0.4 μL/min for 5 minutes, with a residence time within the device of approximately 1 min, where 
the initial fluid was discarded and subsequent eluent was collected onto 1 cm2 glass slides with 
serum containing media.  The 1 cm2 glass slides were prepared in advance and sterilized by 
sonication in 70 % ethanol solution for 30 minutes. After microfluidic flow was completed, the 
collecting slides were transferred to tissue culture plates and incubated at 37°C and 5 % CO2 for 
25 minutes. Then 3 mL of serum containing media was added and the slides were incubated 
under standard growth conditions for another 24 hours. The transfected cells were then fixed by 
3.8 % formaldehyde solution for 15 minutes, followed with gentle washing using PBS. The cell 
samples were mounted and observed with a Zeiss AX10 Fluorescence Microscope. 
4.3 Results and Discussion 
In this study, the bio-orthogonal liposome fuses rapidly to a range of cell types to present 
the functional group on the cell surface. Our liposome CSE strategy for tailoring cell surfaces 
shown in Figure 4.3A is fast and efficient and does not require complex, slow or laborious 
molecular biology or invasive metabolic biosynthesis techniques. The liposome fusion CSE 
strategy is mild and does not alter cell viability or cell behaviour (Figure 4.3B, C). A 
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complementary bio-orthogonal liposome was then used to complex with nucleic acids and 
generate a hybrid bio-orthogonal tailored lipoplex.  Upon addition of the bio-orthogonal lipoplex 
to the engineered cell, a rapid click ligation occurs at the cell surface.  The nucleic acid/lipoplex 
is then internalized, released and expressed for efficient transfection of the cell.   
We have previously shown the use of liposome fusion to deliver and install ketone and 
hydroxylamine groups on cell surfaces for applications in co-culture spheroid and tissue 
engineering. The current application in transfection changes the engineered partners from a 
complimentary engineered cell to a lipid based engineered nanoparticle. However, lipoplex and 
cell association is based on a bio-orthogonal click oxime ligation method and not through 
electrostatics or physical adsorption processes, followed by the typical process of endocytosis 
and release.  
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Figure 4.3: Schematic of the procedure to transfect cells via bio-orthogonal chemistry and 
cell surface engineering (SnapFect). (A) A keto-liposome is added to cells in culture. The 
liposome rapidly fuses with cells and presents the ketone groups on the surface within seconds. To 
the keto-engineered cells, a DNA/hydroxylamine lipoplex is added. The bio-orthogonal 
DNA/lipoplex quickly clicks onto the cell surface via oxime ligation. The oxime reaction is fast, 
mild and can be performed at physiological conditions in vitro and in vivo. The DNA is then 
endocytosed/released and transfects the cell.  The procedure is straightforward and uses minimal 
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time. Steps can be performed on adhered or suspended cells and in serum containing cell culture. 
(B) Stability of the liposome-ketone reagent for CSE at various temperatures and durations. (C) 
Viability of the cells after liposome-ketone fusion treatment. The liposome fusion method is mild 
and there is no difference in viability or behaviour between treated and normal untreated (native) 
cells. (D) The liposome-ketone fusion to present ketones on the cell surface is transient. After 1 
minute of liposome-ketone fusion treatment, the cells have approximately 2000 ketones 
(determined by flow cytometry), which are rapidly reduced on the cell surface after 24 hours due 
to dilution via growth and division of the cells. (E) The bio-orthogonal mediated nucleic acid 
transfection strategy is fast and can be performed in a microfluidic format. The mixing of the keto-
tailored cells with the nucleic acid lipoplex for transfection occurs in less than 1 minute. The cells 
are then visualized after 24 hours and show high viability and transfection efficiency. (F) RFP 
expressing fibroblasts that are transfected with GFP in the microfluidic format. The cells turn 
yellow and green after GFP transfection via the fast microfluidic method (G). (H) Stained NIH3T3 
fibroblasts are flowed through the microfluidic channel and mixed with GFP nucleic acid lipoplex 
(1 minute). (I) The fibroblasts are visualized after 24 hours are efficiently transfected and show 
green fluorescence with high viability and efficiency.  
Although key parameters for successful cell transfection involve viability, efficiency and 
scope of cell types to be transfected, an equally important consideration for the practical utility of 
transfecting cells are the number of steps, cost of reagents and the duration of the transfection.  
Ideally, the transfection reagents are stable and can be stored without significant degradation or 
loss of transfection ability for long periods, the number of steps are minimal and performed in 
serum containing cell culture media. Figure 4.3A shows the general SnapFect transfection 
procedure based on bio-orthogonal mediated reagents. We found efficient installation of the 
ketone group on the cell surface within seconds to minutes of liposome exposure. The bio-
orthogonal hydroxylamine lipoplex is formed through straightforward addition of the 
hydroxylamine lipoplex to pDNA. To the ketone engineered cells, the bio-orthogonal 
hydroxylamine lipoplex is added for 5 minutes. Interfacial oxime ligation occurs at the cell 
surface and the cells are then evaluated after 24 hours for transfection viability and efficiency. 
The overall SnapFect transfection procedure is two steps and takes less than 10 minutes to 
complete. Figure 4.3B depicts the stability of the liposome ketone reagent compared to viability 
for engineering the cell, where storage in the liposome format for months at low temperatures 
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does not result in loss of transfection ability. Figure 4.3C describes the viability of cells 
undergoing the liposome fusion procedure to install ketones on the cell surface, demonstrating 
that the liposome fusion procedure is mild and fast, while CSE cells are indistinguishable from 
native cells in behaviour and viability. Figure 4.3D displays that ketone groups on the cell 
surface after liposome fusion are transient and decrease over time due to cell growth and 
proliferation. Flow cytometry and viability studies show that the number of bio-orthogonal 
groups on the cell surface are fewer in number and degrade after only a few rounds of cell 
division.  
After 24 hours, the amount of ketone groups on cell surfaces are reduced and treated cells 
are indistinguishable from non-treated (control) native cells. This transient nature of ketone 
group dilution from the cell surface is a key feature of our strategy and is important for various 
pre and post-transfection applications. Figure 4.3E shows that the bio-orthogonal mediated 
transfection method is compatible with various technologies and can also be performed in 
microfluidic flow. We observed that less than 1 minute is required for cells to be efficiently 
decorated with ketone groups and less than 1 minute for lipoplex adhesion in microfluidic flow 
(0.8 L/min) to occur. Cells were evaluated after 24 hours and showed high transfection 
efficiency and viability (>90%). RFP keto-tailored cells were flowed through a microfluidic 
channel, where a bio-orthogonal hydroxylamine lipoplex (containing pGFP) rapidly adhered 
with the cell. After 24 hours, all the RFP cells were expressing GFP and turned either yellow or 
green. The microfluidic integration with transfection demonstrates the flexibility of the SnapFect 
strategy and the ability to combine this method with advanced multiplex technologies.   
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Figure 4.4: Evaluation and comparison of bio-orthogonal mediated transfection (SnapFect). 
(A) Fluorescent image of native C3H/10T1/2 cells with DAPI Nuclei stain. (B) Fluorescent image 
of native C3H/10T1/2 cells treated with hydroxylamine containing DNA-lipoplex. No transfection 
occurred since the cells did not present ketone groups on their cell surface. (C) Fluorescent image 
of native C3H/10T1/2 cells and (D) image of the cells presenting ketone groups exposed to GFP 
hydroxylamine lipoplex after 24 hours. GFP expression resulted due to specific bio-orthogonal 
mediated transfection. (E) Image of RFP transfected fibroblast cells via click chemistry mediated 
transfection. (F) A protein gel demonstrating that the expression of RFP is mediated by the correct 
pairing of the bio-orthogonal chemistry functional groups on the cell surface and on the DNA-
lipoplex. (O+ and K+) represent hydroxylamine containing lipoplexes (O+) and ketone presenting 
cells (K+) were used for RFP transfection. (O- and K-) represent conditions where either 
hydroxylamine or ketone were absent from the cell surface or DNA-lipoplex. Only the correct 
combination resulted in bio-orthogonal mediated transfection. (G, H) Luciferase transfection assay 
for fibroblasts using the bio-orthogonal mediated transfection strategy. (H) Comparison of 
luciferase assay transfection for the bio-orthogonal mediated strategy (SnapFect) and leading 
commercial transfection reagents. (I-K) Comparison of viability, efficiency and amount of cells 
transfected between SnapFect and other commercial transfection reagents. Initially 5 million cells 
were used and the amount of surviving cells that were transfected resulted in the percent efficiency 
of transfection. SnapFect has the highest ratio of viable cells to viable and transfected cells. 
Therefore it does not require further separation of cells and requires less cells for transfection. For 
example Snapfect requires only 5 million cells to generate 3.4 million transfected cells without 
post-sorting, whereas Lipofectamine and Viafect require 18 million and 11.5 million cells 
respectively, to obtain 3.4 million transfected cells with the additional step of separating viable 
transfected versus viable non-transfected cells. 
To demonstrate the bio-orthogonal mediated transfection (SnapFect) of cells, we 
performed and evaluated several standard transfection assays. Figure 4.4A shows a fluorescent 
image of native C3H/10T1/2 cells stained with 4', 6-diamidino-2-phenylindole (DAPI), which 
stains nuclei of cells in culture. Figure 4.4B shows these same cells after treatment with a bio-
orthogonal GFP-hydroxylamine lipoplex. No transfection occurred when C3H/10T1/2 cells did 
not present ketones on their surface. Figure 4.4C, D shows that when C3H/10T1/2 cells present 
ketone groups they are efficiently transfected with GFP delivered via a bio-orthogonal nucleic 
acid/hydroxylamine lipoplex. Figure 4.4E depicts the result of the transfection of pRFP to ketone 
presenting fibroblasts. Western blot analysis Figure 4.41F demonstrates that only when the right 
combination of bio-orthogonal pairs is presented on the cell surface and on the nucleic acid 
lipoplex respectively, does transfection occur. Fibroblasts presenting ketone groups via liposome 
114 
 
fusion and delivery (K+) on their surfaces are efficiently transfected with pRFP 
hydroxylamine/lipoplexes (O+). Any other combination does not result in transfection, clearly 
demonstrating that transfection is mediated by the bio-orthogonal click reaction and not by an 
electrostatic or other non-specific interaction process.   
Figure 4.4G depicts our transfection assay based on luciferase expression in fibroblast 
cells. Both complimentary chemistries on the cell surface and lipoplex are necessary, while the 
lack of either or both chemistries leads to no transfection and no luciferase expression. Figure 
4.4H shows a comparison of luciferase expression in cells of SnapFect compared to two cationic 
based commercial reagents. Figure 4.4I-K shows a comparison of viability and efficiency of 
transfection between SnapFect and other commercial reagents. For these sets of experiments, a 
population of 5 million cells were used and compared for transfection viability and efficiency 
after transfection using commercial reagents. Viability was calculated based on the number of 
cells that survived compared to the initial population (5 million) after treatment with a 
transfection reagent. The efficiency of transfection was then calculated in two ways. The ‘1st 
efficiency’ is the ratio of the number of viable transfected cells to the number of viable surviving 
cells after treatment. The second (overall efficiency) is determined by the number of viable 
transfected cells to the initial number of total cells (5 million). For SnapFect, the viability is 75 
% (3.75 million cell survived over 5 million initial cells) and the efficiency is 90 % (3.4 million 
transfected cells over 3.75 million cells) and overall efficiency is 68 % (3.4 million transfected 
cells over 5 million initial cells). One key consideration is that the number of cells that survive 
compared to the number of cells transfected (1st efficiency) is very high for SnapFect compared 
with other reagent products. With such high 1st efficiency, no additional sorting step is required 
for post processing, since almost all the cells that survive have also been transfected. However, 
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for the other reagents the 1st efficiency is 40 % and 32 %, respectively. This requires a post-
sorting step to separate the surviving non-transfected cells and the surviving transfected cells, 
increased time, cost and effort required to produce a transfected population of cells. As a 
comparison, SnapFect requires only 5 million cells to generate 3.4 million transfected cells 
without post-sorting, whereas Lipofectamine and Viafect require 18 million and 11.5 million 
cells respectively, to obtain the same 3.4 million population of transfected cells, with the added 
step of separating via FACS to obtain viable transfected cells. Due to the mild nature of bio-
orthogonal mediated transfection delivered by SnapFect, fewer cells, reagents, media, time and 
labour are necessary and the additional post-sorting step of other methods is eliminated.  
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Figure 4.5: Precision transfection via bio-orthogonal mediated ligation in co-cultures. (Left) 
RFP expressing HDNF cells (A) are cell surface engineered to present ketone groups (B) via rapid 
liposome fusion (C). Non-fluorescent C3H/10T/1/2 cells (D) and ketone presenting HDNF cells 
(B) are mixed to generate a co-culture (E). To this co-culture, a bio-orthogonal hydroxylamine 
presenting GFP-lipoplex (F) is added. Only the ketone presenting cells (B) are targeted for 
selective transfection via the hydroxylamine presenting lipoplex (E) via oxime ligation. (G) 
Fluorescent image showing only HDNF presenting ketones are transfected with GFP (yellow). 
(Right) Non-fluorescent C3H/10T1/2 cells (D) are cell surface engineered to present ketone groups 
(H) via rapid liposome fusion (C). Red fluorescent HDNF cells (A) and ketone presenting 
C3H/10T1/2 cells (H) are mixed to generate a co-culture (I).  To this co-culture a bio-orthogonal 
hydroxylamine presenting GFP-lipoplex (F) is added. Only the ketone presenting cells (H) are 
targeted for selective transfection via the hydroxylamine presenting lipoplex (F) via oxime 
ligation. (J) Fluorescent image showing only C3H/10T1/2 cells presenting ketones are transfected 
with GFP (green). These co-culture results show transfection is only mediated through targeted 
bio-orthogonal chemistry and not non-specific electrostatic interactions. 
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The ability to selectively target a specific cell or cell type for gene and drug delivery in a 
co-culture in vitro and in vivo is of fundamental interest and a common major hurdle in many 
therapeutic applications for cancer and other chronic diseases. Figure 4.5 demonstrates a novel 
precision transfection capability of SnapFect to selectively transfect a single cell type in co-
cultures. To selectively deliver pDNA two cell populations were chosen, [HDNF/RFPs (A) and 
C3H/10T1/2 (D)] where each cell surface was engineered with ketone liposomes and then mixed 
with a second untreated native cell type. In one scenario this produced a co-culture containing 
keto-RFP HDNF (B) cells and native C3H/10T1/2 cells (D), with another co-culture containing 
native RFP-HDNF (A) cells and keto-C3H/10T1/2 cells (H). Both co-cultures were then treated 
with an identical bio-orthogonal pGFP hydroxylamine-lipoplex (F). Fluorescence microscopy of 
DAPI stained keto-RFP HDNF cells and native C3H/10T1/2 cells (Figure 4.5E) show that upon 
treatment with oxy-lipoplexes of pGFP, only RFP-HDNF cells are transfected and turn yellow 
due to a combination of red and green fluorescence within the cell shown in Figure 4.5G. 
Fluorescence imaging of DAPI stained native RFP-HDNF cells and keto-C3H/10T1/2 cells 
(Figure 4.5I) shows co-culture formation. Upon treatment with bio-orthogonal hydroxylamine-
lipolex pGFP (F) keto-C3H/10T1/2 (H) cells express GFP protein selectively and turn green, 
while the non-labelled RFP-HDNF cells remain unaffected (Figure 4.5J). These results 
demonstrate that the SnapFect method is able to precision target and transfect a specific cell type 
in a co-culture. Since the transfection is only mediated by bio-orthogonal chemistry and not 
electrostatic or other non-specific interactions, this selectivity enables new possibilities for 
targeted delivery in complex cellular environments and transfect cells in vitro and in vivo for 
new applications using our artificial receptors. 
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4.4 Conclusion 
In summary, our SnapFect strategy integrates liposome fusion, CSE and bio-orthogonal 
chemistry for a rapid and efficient nucleic acid cell transfection method with new capabilities 
compared to existing transfection technologies. The approach installs a bio-orthogonal molecule 
on the surface of a cell, while the complementary bio-orthogonal functional group is associated 
with a nucleic acid that subsequently performs an interfacial click reaction at the cell surface for 
efficient nucleic acid delivery. Unlike conventional reagent transfection methods that use various 
molecules composed of positively charged polyamines to complex with nucleic acids which then 
are associated with negatively charged cells via electrostatic association, the SnapFect method 
relies on a precise chemo-selective click chemistry. The method was designed to have broad 
scope and utility, which is mild, efficient, with minimal steps, no additional sorting (of viable 
transfected and viable non-transfected cells), and can be performed on a range of cell types and 
in various cell culture conditions. Furthermore, selective cell transfection and gene silencing can 
be performed in co-cultures due to the specific requirement that only cells presenting bio-
orthogonal groups are targeted for transfection.  
We also show the SnapFect transfection method can occur in microfluidic flow, which 
opens numerous applications using the power of microfluidic technology. The liposome fusion 
method is fast and can be used to simultaneously engineer the cell surface with bio-orthogonal 
groups and to deliver various other small molecules and cargoes into the cell. We have 
demonstrated a bio-orthogonal CSE approach to generate cells with photoactive, redox and 
fluorescent capabilities. Also, we have used this method to generate co-culture spheroids and 
scaffold free 3D tissues for stem cell differentiation studies, liver and cardiac tissue on-a-chip 
applications.28 29 The key feature in this strategy is the rapid placement of an artificial receptor 
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(bio-orthogonal group) on the cell surface without the use of invasive molecular biology or the 
use of modified metabolites. This strategy is a platform technology that can be used to label and 
deliver a range of molecules to cells in vitro and in vivo. Future studies to tailor cell surfaces 
with various bio-orthogonal groups, nanoparticles or fluorescent probes may be pursued for 
various theranostic and systems biology type applications and studies.30 31 The SnapFect method 
provides a new way of thinking about delivery and targeting cells for various applications in 
fundamental biological studies from gene editing to immunotherapy.32 33 The method is 
compatible with other nucleic acid based biotechnologies such as CRISPR-Cas9 and RNA. We 
have previously shown that the CSE approach also functions in a wide range of cell types 
including stem cells and primary cells, while also showing applicability in bacteria.  The ability 
to install a range of molecules on the cell surface will have broad utility in cell biology, tissue 
engineering and act as a molecular handle for a range of bio-analytical sorting and tracking 
technologies.34 
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Chapter 5 
Dialdehyde Reagents for Bioconjugation Applications 
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5.1 Introduction 
 The delivery of bioactive reagents to cells is an important aspect of most biological 
research programs and life science commercial efforts. Chapters 1-4 included the implementation 
of bio-orthogonal lipids or reagents to impart functionality to the cell through liposome fusion 
CSE, which did not react with native biochemistry. Although bio-orthogonal reactions are 
efficient, rapid and non-cytotoxic, they have several drawbacks as a general methodology for 
commercially available small molecules and macromolecules. Bio-orthogonal moieties are 
difficult to synthetically incorporate into biological reagents and biophysical probes, reducing the 
utility of bio-orthogonal strategies where molecules become prohibitively expensive or difficult 
to synthesize. Liposome delivery and bioconjugation strategies have applications for the delivery 
of macromolecules, particularly proteins, peptides and antibodies for drug targeting, peptide 
signalling and functionalization of cell surfaces for research or therapeutic applications, which 
necessitate the use of easily performed and high yield coupling reactions. Simple methodologies 
are necessary to couple these large molecules to delivery agents or liposomes that use naturally 
occurring chemical functional groups to limit difficult engineering on proteins. 
 Primary amines are an important base and nucleophile used in organic synthesis and 
ligation of biological molecules for labelling, purification and stabilization.1 2 3 Biological 
systems utilize primary amine functional groups in every amino acid subgroup and subsequently 
are found in most proteins as lysine amino acids which are critical for hydrogen bonding, 
zwitterion formation, aqueous buffers and nucleophiles in enzymatic reactions.4 5 6 Primary 
amines are also found in antibody drug-conjugates as well as other biologic based drugs making 
primary amines an incredibly abundant and important functional group to chemo-selectively 
target for ligation and labelling applications. 
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 There are several existing bioconjugation strategies for reacting primary amines which 
involve either directly reacting the amine with an electrophilic partner such as halides, or 
activating moieties such as carboxylic acids to form amide bonds. Figure 5.1 shows several 
primary amine reaction strategies including NHS-esters, isocyanates, isothiocyanates and 
reductive amination of imines that are widely available as commercial reagents or kits.7 8 9 10 11 A 
classic amine reaction technique relies upon carboxylic acid activation using N-hydroxy 
succinimide-dicyclocarbodiimide (NHS-DCC) to form stable amide bonds, which has provided a 
powerful strategy for conjugation but suffers several limitations. First, the production of toxic 
by-products can be produced in significant quantities, depending upon the strategy. Second, the 
reagents are generally expensive. Third, activated acids are sensitive to air and moisture due to 
rapid hydrolysis. Fourth, poor atom economy, requiring multiple reagents and producing 
significant by-products which are not incorporated into the desired molecule. These issues have 
limited the field, where expensive proteins or macromolecules are wasted through purification 
steps and incomplete reactions.   
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Figure 5.1: Selection of primary amine conjugation reactions used in research and 
commercially available kits for reacting amines with small molecules or biomolecules. (A) 
NHS-esters, (B) Isocyanates, (C) reductive amination of imines and (D) Amine cyclization. 
 To design bioconjugation reactions for applications with broad scope a few basic criteria 
must be met: 1) the reaction between the native biomolecule functional group and the 
conjugation partner must display fast kinetics under aqueous conditions; 2) the reaction must be 
chemo-selective for the desired functional group; 3) there should be minimal or no by-products; 
4) the conjugation reagent must be relatively easy and efficient to synthesize using convergent 
synthesis techniques; 5) the reaction should use an existing chemical moiety commonly found on 
biomolecules or reagents such as amines, to reduce the number of functionalization steps. 
Therefore, reactions which accommodate these criteria can be successful methods to attach a 
variety of probes, small molecules or macromolecules to primary amine bearing molecules under 
mild, aqueous conditions, selectively with high yields.      
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 As inspiration for a new type of bioconjugation reaction we used glutaraldehyde as our 
base methodology, which has been used as a fixation agent in cellculture. Glutaraldehyde acts as 
a cross-linking agent for proteins both inside and outside the cell, since the small molecule can 
pass through the cell membrane to easily reach the cytosol, fixing the dynamic structures of the 
cell using primary amines for examination using microscopy.12 To achieve primary amine 
conjugation a retro synthetically designed glutaraldehyde functional group was synthesized to 
conjugate amine containing molecules such as PEG, alkyl groups, biotin and 2,4-nitrophenol 
(DNP) for surface labelling, protein cross-linking and tissue engineering applications. Figure 5.2 
demonstrates the model dialdehyde molecule for the general conjugate of primary amine 
containing amino acid side chains eg. Lysine.13 The rationale using glutaraldehyde as our base 
conjugation scheme was first informed by modifying the 3-position of the glutaraldehyde 
backbone for placement of functional groups (R1 and R2) to form a stable molecule which 
hinders aldol-type self-condensations. Second, the 1,5-pentanedial group has the correct carbon 
length (5 carbons) to act as an intramolecular trap to quickly perform a six-membered ring 
closing reaction. The ring closing reaction occurs through initial intermolecular condensation to 
form an imine via the primary amine attack with a single C1 aldehyde, then rapidly condenses 
again through an intramolecular reaction with the C5 aldehyde to form the final six-membered 
dihydropyridine ring (Figure 5.2).  
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Figure 5.2: Scheme of the dialdehyde click reaction of primary amines under aqueous 
conditions to form a ligated conjugate molecule. The reaction occurs at 23°C to generate a 
dihydro pyridine moiety with a quaternary carbon which can consist of different groups (R1 and 
R2). The reaction has efficient atom economy, while requiring no purification and produces water 
as the byproduct with high yields. 
 Instability of aldehydes to oxidation in air has been a known issue as well as aldol-type 
condensations, resulting in polymerized products which could deactivate the 1, 5-pentanedial 
moiety. To mitigate these issues, we formed a quaternary carbon at the 3-carbon position, where 
steric hindrance would limit self-reaction but would also result in a protected and stable 
intramolecular hydrate (hemiacetal cyclic pyran). Not only does this quaternary carbon prevent 
self-condensation, it also provides an installation handle for a range of molecules to the 
dialdehyde, such as fluorescent molecules, biophysical probes or hydrophobic lipid tails. 
 To demonstrate the utility and benefits of our modified dialdehyde moiety to conjugate 
primary amines, we reacted the moiety with a variety of molecules spanning small molecules, 
peptides, amino acids, proteins, beads and live cells for our strategy. Characterization was 
performed using NMR, microscopy, flow cytometry and confocal microscopy to visualize and 
elucidate the both capabilities and limitations of using this novel backbone modified 
glutaraldehyde strategy. 
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5.2 Materials and Methods 
5.2.1 Synthesis of Lipid Dialdehyde (9) and Conjugate (10) 
 
diethyl cyclopent-3-ene-1,1-dicarboxylate (5). To a solution of diethyl malonate 
4 (2.00g, 12.48 mmol) in 50 mL t-butanol and metallic Na (s) (0.287 g, 12.48 
mmol) was added cis-1,4-dichlorobut-2-ene was added. The mixture was stirred until a yellow 
solution was obtained, only then another portion of (0.287 g, 12.48 mmol) of metallic sodium was 
added and stirred for 12 hours. t-butanol was distilled off under vacuum and the mixture was 
diluted with dichloromethane (DCM). The organic solution was filtered and washed with H2O (6 
x 50 mL), saturated NH4Cl (3 x 50 mL), and H2O (2 x 50 mL), dried over MgSO4, and purified 
with silica Hex:EtOAc (2:8) to afford a clear oil solid (11.23 mmol, 90%) 1H-NMR (400 MHz; 
CDCl3): δ 5.62 (s, 2H), 4.21 (d, J = 7.1 Hz, 2H), 3.03 (s, 4H), 1.27 (d, J = 7.2 Hz, 3H). 13C-NMR 
(700 MHz; CDCl3): δ 172.2, 127.8, 61.5, 58.8, 40.8, 14.0. 
cyclopent-3-ene-1,1-diyldimethanol (6). To a suspension of lithium aluminum hydride 
(1.706 g, 44.92 mmol) in dry 100 mL tetrahydrofuran (THF) at -78°C, diethyl cyclopent-3-ene-
1,1-dicarboxylate (5) (2.38 g, 11.23 mmol) was added dropwise over 1 hour. The mixture was 
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stirred for 5 hours, and then quenched with 15 mL 1M NaOH. The mixture was stirred for an 
additional 2 hours, then concentrated and up taken in diethyl ether and dried over MgSO4 to afford 
white solid (9.54 mmol, 85%).1H-NMR (700 MHz; CDCl3): δ 5.65 (s, 2H), 3.73 (s, 4H), 2.24 (s, 
4H).  
4,4-bis(dodecyloxymethyl)cyclopent-1-ene (7). To a suspension of excess NaH in 
dry 100 mL dry THF at -78°C was added cyclopent-3-ene-1,1-diyldimethanol (6) 
(1.222 g, 9.54 mmol) and stirred for 1 hour. Temperature was gradually increased to -40°C and 
bromododecane (7.104 g, 28.62 mmol) was added drop wise over 30 minutes. The mixture was 
mildly refluxed overnight. THF was distilled off under vacuum and the mixture was diluted with 
DCM. The organic solution was filtered and washed with H2O (6 x 50 mL), saturated NH4Cl (3 x 
50 mL), and H2O (2 x 50 mL), dried over MgSO4, and purified with silica Hex:EtOAc (2:8) to 
afford a clear oil solid (7.60 mmol, 80%) 1H-NMR (700 MHz; CDCl3): δ  5.60 (s, 2H), 3.43 (t, J 
= 6.7 Hz, 4H), 3.33 (s, 4H), 2.21 (s, 4H), 1.57 (dd, J = 9.4, 5.2 Hz, 4H), 1.28 (s, 20H), 0.90 (t, J = 
7.1 Hz, 6H). 
4,4-bis(dodecyloxymethyl)cyclopent-1-ene-1,2-diol (8). To a solution of 4,4-
bis(dodecyloxymethyl)cyclopent-1-ene (7) (3.541 g, 7.60 mmol) in acetone: 
acetonitrile (1:1) was added catalytic amount of OsO4 and excess N-methylmorpholine N-oxide 
50% in H2O. Reaction was monitored with thin layer chromatography (TLC) for complete 
disappearance of starting material. Solvent was distilled off under vacuum and the product was 
taken into diethyl ether and dried over MgSO4, further purified with silica Hex:EtOAc (3:7) to 
afford a white solid (6.84 mmol, 90%) 1H-NMR (700 MHz; CDCl3): δ  3.93 (d, J = 7.2 Hz, 2H), 
3.53 (t, J = 6.7 Hz, 2H), 3.38 (t, J = 6.6 Hz, 2H), 3.29 (s, 2H), 3.16 (s, 2H), 1.85 (dd, J = 14.1, 6.2 
Hz, 2H), 1.69 (dd, J = 14.2, 5.0 Hz, 2H), 1.63 (t, J = 7.3 Hz, 2H), 1.55 (t, J = 7.0 Hz, 2H), 1.31 (d, 
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J = 6.8 Hz, 40H), 0.90 (t, J = 7.1 Hz, 6H). 13C-NMR (700 MHz; CDCl3): δ 77.19, 77.01, 76.94, 
76.83, 76.1, 74.4, 71.86, 71.68, 45.0, 37.6, 31.9, 29.68, 29.64, 29.62, 29.55, 29.49, 29.46, 29.40, 
29.36, 26.17, 26.12, 22.7, 14.1 
3,3-bis(dodecyloxymethyl)pentanedial (9). To a solution of (8) (3.4063 g, 6.84 
mmol) in H2O: methanol (1:9) was added NaIO4. Mixture was stirred for 1 hour 
until a flaky white, solid iodate salt, was obtained. Solvent was distilled off under vacuum and the 
product was taken into diethyl ether and dried over MgSO4 and used for subsequent reactions.  
4,4-bis((dodecyloxy)methyl)-1-propyl-1,4-dihydropyridine (10). To a 
solution of (9) (20 mg, 0.4032 mmol) in DCM was added excess 
propylamine and stirred for 15 min at 23°C. Solvent and excess propylamine were distilled off 
under vacuum and the final product was taken into diethyl ether and dried over MgSO4 to afford 
pure clear oil. 1H-NMR (700 MHz; CDCl3): δ  5.91 (d, J = 7.7 Hz, 2H), 4.27 (d, J = 7.8 Hz, 2H), 
3.43 (t, J = 6.7 Hz, 4H), 3.28 (s, 4H), 2.99 (t, J = 7.0 Hz, 2H), 1.55 (dq, J = 23.0, 7.3 Hz, 6H), 1.32 
(t, J = 6.9 Hz, 36H), 0.90 (t, J = 7.1 Hz, 9H). 13C-NMR (700 MHz; CDCl3): δ 130.8, 99.9, 71.7, 
55.0, 40.6, 31.9, 29.71, 29.69, 29.67, 29.61, 29.55, 29.54, 29.52, 29.50, 29.44, 29.38, 26.22, 26.18, 
23.4, 22.7, 14.1, 11.1 
5.2.2 Synthesis of Acetonide Precursor (24) 
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 1-methylcyclopent-3-enecarboxylic acid (20). To a solution of cyclopent-3-
enecarboxylic acid (19) (0.5000, 4.459 mmol) in 50 mL dry THF at -78°C under inert atmosphere 
(Ar) was added t-butyl lithium 1.7M (9 mL, 13.37 mmol, 3 eq) over 1 hour. The mixture was 
stirred at the same temperature for an additional 30 minutes until dianion is successfully generated, 
then excess iodomethane was added gently. A white precipitate forms to produce a suspension, 
which dissolves at 45°C overnight. The mixture is quenched by 1 mL of H2O and stirred for 15 
minutes, then solvent THF is stripped off under vacuum and the remaining crude is diluted with 
DCM. The organic solution was filtered and washed with H2O (6 x 50 mL), saturated NH4Cl (3 x 
50 mL), and H2O (2 x 50 mL), dried over MgSO4, and purified with silica Hex:EtOAc (2:8) to 
afford a clear oil solid (3.121 mmol, 80%), repeating the experiment on the crude will yield 100% 
product. 1H-NMR (700 MHz; CDCl3): δ 5.64 (s, 2H), 2.98 (d, J = 14.7 Hz, 2H), 2.28 (d, J = 14.8 
Hz, 2H), 1.36 (s, 3H). 13C-NMR (700 MHz; CDCl3): δ 184.1, 128.2, 47.6, 44.6, 25.7. 
 (1-methylcyclopent-3-enyl)methanol (21). To a suspension of lithium aluminum 
hydride (0.3358 g, 8.837 mmol, 3 eq) in dry 100 mL THF at -78°C, cyclopent-3-enecarboxylic 
acid (20) (0.3704 g, 2.945 mmol) was added drop wise over 1 hour. The mixture was stirred for 6 
hours, and then quenched with 15 mL 1M NaOH. The mixture was stirred for an additional 2 
hours, then concentrated and up taken in diethyl ether and dried over MgSO4 to afford clear liquid 
(1.885 mmol, 63%). 1H-NMR (700 MHz; CDCl3): δ  5.64-5.63 (m, 2H), 3.47 (s, 3H), 2.35-2.32 
(m, 2H), 2.12-2.07 (m, 2H), 1.13 (s, 3H). 13C-NMR (700 MHz; CDCl3): δ 129.2, 71.4, 43.0, 24.9 
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2-((1-methylcyclopent-3-enyl)methoxy)acetic acid (22) To a suspension of 
excess NaH in 100 mL of dry THF at 0°C  was added (1-methylcyclopent-3-enyl)methanol (21)  
(0.4494 g, 4.008 mmol) and stirred for 15 minutes. Then 2-chloroacetic acid (0.3767 g, 4.008 
mmol) pre-dissolved in dry cool THF was added to the suspension via syringe. The mixture was 
mildly refluxed overnight. THF was distilled off under vacuum and the mixture was diluted with 
DCM. Content was treated with 1N NaOH to remove the organic impurities, then treated with 1N 
HCl and uptaken in DCM and dried over MgSO4 to afford white solid (3.206 mmol, 80%) 
1H-
NMR (700 MHz; CDCl3): δ 5.63 (s, 2H), 4.15 (s, 2H), 3.43 (s, 2H), 2.38 (d, J = 14.3 Hz, 2H), 2.11 
(d, J = 14.2 Hz, 2H), 1.16 (s, 3H). 13C-NMR (700 MHz; CDCl3): δ 172.3, 129.0, 80.4, 68.4, 42.1, 
25.4 
2-((3,4-dihydroxy-1-methylcyclopentyl)methoxy)acetic acid (23) To a 
solution of crude product in previous step (22) (0.5456 g, 3.206 mmol) in acetone: acetonitrile 
(1:1) was added catalytic amount of OsO4 and excess N-methylmorpholine N-oxide 50% in H2O 
at pH 8. Reaction was monitored with TLC for complete disappearance of the starting material. 
Solvent was distilled off under vacuum and the product was taken into ethyl acetate and dried over 
MgSO4, further purified with silica Hex:EtOAc (5:5) to afford a white solid as a mixture of isomers 
(2.308 mmol, combined 72%) 1H-NMR (700 MHz; CDCl3): δ 4.16 (t, J = 4.4 Hz, 2H), 4.14 (s, 
2H), 3.27 (s, 2H), 1.99 (dd, J = 13.7, 6.2 Hz, 2H), 1.61 (dd, J = 13.7, 4.9 Hz, 2H), 1.22 (s, 3H). 
13C-NMR (700 MHz; CDCl3): δ 171.1, 81.0, 76.6, 74.4, 68.1, 41.8, 39.8, 27.4 
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2-((2,2,5-trimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-
yl)methoxy)acetic acid (24) To a solution of (23) mixture of isomers, (0.4713, 2.308 mmol) in dry 
THF and catalytic amount of p-TsOH was added a large excess of 2,2-dimethoxypropane. Reaction 
was monitored with TLC for complete disappearance of starting material. THF was distilled off 
under vacuum and the mixture was diluted with DCM. The organic solution was filtered and 
washed with H2O (2 x 50 mL), dried over MgSO4, and purified with silica Hex:EtOAc (7:3) to 
afford a mixture of diasteriomers as white solid (2.193 mmol, combined 95%) 1H-NMR (700 MHz; 
CDCl3) Isomer I: δ  4.73-4.72 (m, 2H), 4.13 (s, 2H), 3.29 (s, 2H), 1.87 (dt, J = 14.5, 2.2 Hz, 2H), 
1.74 (d, J = 14.2 Hz, 2H), 1.54 (s, 3H), 1.32 (s, 3H), 1.26 (s, 3H). 1H-NMR (700 MHz; CDCl3): δ  
4.72 (dd, J = 3.4, 2.2 Hz, 3H), 4.16 (s, 2H), 4.13 (s, 2H), 3.61 (s, 2H), 3.28 (s, 2H), 2.01 (d, J = 
14.8 Hz, 2H), 1.90 (ddd, J = 14.7, 4.9, 1.5 Hz, 2H), 1.72 (d, J = 14.1 Hz, 2H), 1.54 (s, 4H), 1.51 
(s, 3H), 1.31 (d, J = 6.8 Hz, 6H), 1.25 (s, 3H), 1.10 (s, 3H). 13C-NMR (700 MHz; CDCl3): δ 173.5, 
172.6, 110.18, 110.06, 81.7, 81.4, 80.5, 78.6, 68.5, 68.2, 44.49, 44.46, 41.81, 41.71, 26.41, 26.23, 
25.9, 24.5, 23.7, 23.4 
5.2.3 Synthesis of Dialdehyde Amide (29) and Conjugate (30) 
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N-propyl-2-((2,2,5-trimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-
5-yl)methoxy)acetamide (46) To a solution of (24) mixed isomers (0.2000 g, 0.8196 mmol) in 
DCM/Acetonitrile (ACN) and excess of sodium bicarbonate was added along with 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) (0.3426 g, 0.9016 
mmol, 1.1 eq). Reaction was monitored with TLC for complete disappearance of starting material. 
Once the activated carboxylic acid is generated, confirmed by disappearance of carboxylic acid 
intermediate, excess of propylamine was dispended. Mixture was stirred for 30 minutes, then 
concentrated and flushed through a pad of silica Hex:EtOAc (4:1) to afford clear oil (0.7786 mmol, 
95%) Mixture of Isomers: 1H-NMR (400 MHz; CDCl3): δ 4.72 (t, J = 2.1 Hz, 2H), 3.95 (s, 2H), 
3.29 (q, J = 6.7 Hz, 2H), 3.22 (s, 2H), 1.77 (d, J = 3.0 Hz, 4H), 1.57 (dd, J = 13.3, 8.0 Hz, 9H), 
1.32 (s, 3H), 1.28 (s, 3H), 0.96 (t, J = 7.4 Hz, 3H).  
2-((3,4-dihydroxy-1-methylcyclopentyl)methoxy)-N-propylacetamide 
(49) To a solution of (46) (0.1900 g, 0.7786 mmol) in methanol:H2O (1:1), 3 drops of 1N HCl was 
added. Reaction was monitored with TLC for complete disappearance of starting material. Solvent 
was distilled off under vacuum and the product was taken into ethyl acetate and dried over MgSO4, 
further purified with silica MeOH:EtOAc (0.5:9.5) to afford a white solid (0.7786 mmol, 100%) 
1H-NMR (700 MHz; CDCl3): δ 4.12 (t, J = 4.3 Hz, 2H), 3.94 (s, 2H), 3.27 (q, J = 6.8 Hz, 2H), 
3.18 (s, 2H), 1.92-1.90 (m, 2H), 1.61-1.53 (m, 2H), 1.20 (s, 3H), 0.94 (t, J = 7.4 Hz, 3H). 13C-
NMR (700 MHz; CDCl3): δ 169.5, 80.8, 74.4, 70.9, 41.9, 40.5, 39.9, 27.5, 22.9, 11.3 
2-(2-methyl-4-oxo-2-(2-oxoethyl)butoxy)-N-propylacetamide (29) To a 
solution of (47) (190.7 mg, 0.7786 mmol)  in H2O:methanol (1:9) was 
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added NaIO4 and stirred for 1 hour until a flakey white, solid iodate salt appeared. Solvent was 
distilled off under vacuum and the product was taken into diethyl ether and dried over MgSO4 and 
used for subsequent reactions.  
2-((4-methyl-1-propyl-1,4-dihydropyridin-4-yl)methoxy)-N-
propylacetamide (30) To a solution of (29) (20 mg, 0.4000 mmol) in DCM was added excess 
propylamine and stirred for 30 minutes at 23°C. Solvent and excess propylamine were distilled off 
under vacuum and the final product was taken into diethyl ether and dried over MgSO4 to afford 
clear oil.  
5.2.4 Synthesis of Phenyl Dialdehyde (33) and Conjugate (51) 
 
N-phenethyl-2-((2,2,5-trimethyltetrahydro-3aH-
cyclopenta[d][1,3]dioxol-5-yl)methoxy)acetamide (48) To a solution of (24) mixed isomers 
(0.2000 g, 0.8196 mmol) in DCM/ACN and excess of sodium bicarbonate was added HBTU 
(0.3426 g, 0.9016 mmol, 1.1 eq). Reaction was monitored with TLC for complete disappearance 
of the starting material. Once the activated carboxylic acid was generated, confirmed by TLC, 
phenethylamine (0.0991 g, 0.8196 mmol) is added to the reaction vessel. Mixture was stirred for 
30 minutes, then concentrated and flushed through a pad of silica Hex:EtOAc (4:1) to afford clear 
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oil (0.7377 mmol, 90 %) 1H-NMR (700 MHz; CDCl3): δ  7.33-7.31 (m, 1H), 7.25-7.23 (m, 1H), 
7.21-7.20 (m, 1H), 4.62-4.61 (m, 2H), 3.89 (s, 2H), 3.59 (q, J = 6.5 Hz, 2H), 3.09 (s, 2H), 2.84 (t, 
J = 6.8 Hz, 2H), 1.62 (d, J = 7.8 Hz, 2H), 1.58 (s, 3H), 1.52 (s, 3H), 1.30 (s, 3H), 1.14 (s, 3H). 13C-
NMR (700 MHz; CDCl3): δ 169.5, 138.6, 128.7, 126.7, 110.1, 81.5, 80.4, 70.8, 44.2, 41.7, 39.6, 
35.5, 26.3, 24.4, 23.6. 
2-((3,4-dihydroxy-1-methylcyclopentyl)methoxy)-N-
phenethylacetamide (49): To a solution of (48) (0.2560 g, 7.377 mmol) in methanol:H2O (1:1), 3 
drops of 1N HCl was added. The reaction was monitored with TLC for complete disappearance of 
the starting material. Solvent was distilled off under vacuum and the product was taken into ethyl 
acetate and dried over MgSO4, further purified with silica MeOH:EtOAc (0.5:9.5) to afford a clear 
oil (7.377 mmol , 100 %) 1H-NMR (700 MHz; CDCl3): δ  7.33 (t, J = 7.5 Hz, 1H), 7.24 (d, J = 7.3 
Hz, 1H), 7.21 (d, J = 7.4 Hz, 1H), 3.96 (d, J = 3.5 Hz, 2H), 3.90 (s, 2H), 3.61 (d, J = 19.4 Hz, 2H), 
3.07 (s, 2H), 2.85 (d, J = 13.4 Hz, 2H), 1.76 (dd, J = 13.8, 6.4 Hz, 2H), 1.49 (dd, J = 13.8, 5.2 Hz, 
2H), 1.08 (s, 3H). 13C-NMR (700 MHz; CDCl3): δ 169.5, 138.6, 128.89, 128.76, 126.6, 80.7, 74.3, 
70.8, 41.7, 39.73, 39.55, 35.5, 27.4. 
2-(2-methyl-4-oxo-2-(2-oxoethyl)butoxy)-N-phenethylacetamide 
(33) To a solution of (49) (2.2647 g, 7.377 mmol)  in H2O:methanol (1:9) was added NaIO4 and 
stirred for 1 hour until a flakey white, solid iodate salt appeared. Solvent was distilled off under 
vacuum and the product was taken into diethyl ether and dried over MgSO4 and used for 
subsequent reactions.  
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2-((4-methyl-1-propyl-1,4-dihydropyridin-4-yl)methoxy)-N-
phenethylacetamide (51) To a solution of (33) (20 mg, 0.4000 mmol) in DCM was added excess 
propylamine and stirred for 30 minutes at 23°C. Solvent and excess propylamine were distilled off 
under vacuum and the final product was taken into diethyl ether and dried over MgSO4 to afford 
clear oil.  
5.2.5 Synthesis of Biotin Dialdehyde (37) and Conjugate (38) 
 
5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)-N-(3-(2-((2,2,5-trimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-
yl)methoxy)acetamido)propyl)pentanamide (52) To a solution of (24) mixed isomers (0.0589 g, 
0.2415 mmol) in MeOH/ACN and excess of sodium bicarbonate was added HBTU (0.0917 g, 
0.2656 mmol, 1.1 eq). The reaction was monitored with TLC for complete disappearance of 
starting material. Once the activated carboxylic acid was generated, confirmed by TLC, biotin 
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cadaverine trifluoroacetate (0.1000 g, 0.2415 mmol, 1 eq) was added to the reaction vessel. 
Mixture was stirred for 30 minutes, then concentrated and flushed through a pad of silica 
MeOH:EtOAc (1:4) to white crystal. 1H-NMR (700 MHz; MeOD): δ 4.74-4.73 (m, 2H), 4.51 (dd, 
J = 7.8, 5.0 Hz, 1H), 4.32 (dd, J = 7.8, 4.5 Hz, 1H), 3.95 (s, 2H), 3.37 (s, 2H), 3.33 (q, 1H), 3.25 
(s, 2H), 3.23 (d, J = 6.9 Hz, 2H), 2.95 (dd, J = 12.7, 5.0 Hz, 2H), 2.72 (d, J = 12.7 Hz, 2H), 2.24 
(t, J = 7.3 Hz, 2H), 1.94 (dd, J = 14.2, 5.1 Hz, 2H), 1.71-1.66 (m, 4H), 1.49 (d, J = 4.9 Hz, 2H), 
1.46 (d, J = 6.9 Hz, 2H), 1.46 (s, 3H),  1.30 (s, 3H), 1.24 (s, 3H). 
2-(2-methyl-4-oxo-2-(2-oxoethyl)butoxy)-N-
phenethylacetamide (37) To a solution of (52) (87.74 mg, 0.1800 mmol) in H2O:methanol (1:9) 
was added 3 drops of dilute acid and stirred for 30 minutes, then NaIO4 was added and stirred for 
1 hour until a flakey white, solid iodate salt appeared. Solvent was distilled off under vacuum and 
the product was taken into diethyl ether and dried over MgSO4 and used for subsequent reactions. 
N-(3-(2-((4-methyl-1-propyl-1,4-dihydropyridin-
4-yl)methoxy)acetamido)propyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)pentanamide (38) To a solution of (37) (20 mg, 0.4000 mmol) in MeOH was added excess 
propylamine and stirred for 30 minutes at 23°C. Solvent and excess propylamine were distilled off 
under vacuum and the final product was taken into diethyl ether and dried over MgSO4 to afford 
white solid.  
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5.2.6 Synthesis of DNP Dialdehyde (35) and Conjugate (36) 
 
N1-(2,4-dinitrophenyl)hexane-1,6-diamine trifluoroacetate (16) : To 
a solution of N-Boc-1,6-hexanediamine hydrochloride  (0.2000 g, 0.793 mmol) in dimethyl 
formamide (DMF)/H2O in (9:1) and excess of sodium bicarbonate was added 24 (0.1771 g, 0.9523 
mmol, 1.2 eq) and stirred overnight. The solvents were stripped off under high vacuum and the 
content was dissolved in MeOH and treated with 80 % trifluoroacetic acid (TFA) and stirred for 1 
hour at 23°C. After complete evaporation of solvent, fresh MeOH was added and filtered. Final 
product was isolated as yellow crystals of trifluoroacetate quaternary salt. 1H-NMR (700 MHz; 
MeOD): δ 9.05 (dd, J = 5.5, 2.9 Hz, 1H), 8.30 (ddd, J = 9.5, 2.4, 1.9 Hz, 1H), 7.19-7.18 (m, 1H), 
3.53 (d, J = 7.1 Hz, 2H), 2.97-2.94 (m, 2H), 1.80 (t, J = 7.3 Hz, 2H), 1.72-1.70 (m, 2H), 1.55-1.49 
(m, 4H). 13C-NMR (700 MHz; MeOD): δ 161.74, 161.55, 148.3, 135.5, 130.1, 129.7, 123.38, 
123.37, 119.3, 117.7, 116.0, 114.3, 42.7, 39.2, 28.1, 27.1, 26.0, 25.7 
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N-(6-(2,4-dinitrophenylamino)hexyl)-2-((2,2,5-
trimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-yl)methoxy)acetamide  (55): To a solution 
of (16) mixed isomers (0.2000 g, 0.8196 mmol) in MeOH/ACN and excess of sodium bicarbonate 
was added HBTU (0.3426 g, 0.901 mmol, 1.1 eq) and stirred for 1 hour at 23°C. Reaction was 
monitored with TLC for complete disappearance of the starting material carboxylic acid. Once the 
activated carboxylic acid was generated, confirmed by TLC, (59) (0.4643 g, 0.901 mmol, 1.1 eq) 
was added to the reaction vessel. Mixture was stirred for 30 minutes, then concentrated and flushed 
through a pad of silica Hex:EtOAc (4:1) to afford yellow crystal (0.737 mmol, 90 %). 1H-NMR 
(700 MHz; CDCl3): δ  9.17 (d, J = 2.5 Hz, 1H), 8.57 (s, 1H), 8.31-8.30 (m, 1H), 6.94 (d, J = 9.5 
Hz, 1H), 6.63 (d, J = 5.9 Hz, 1H), 4.72 (d, J = 4.7 Hz, 2H), 3.99 (s, 2H), 3.54 (s, 2H), 3.43 (q, J = 
6.4 Hz, 3H), 3.33 (q, J = 6.7 Hz, 3H), 1.99 (d, J = 14.7 Hz, 2H), 1.82 (t, J = 7.3 Hz, 3H), 1.62-1.59 
(m, 3H), 1.57 (s, 2H), 1.54 (td, J = 9.8, 4.0 Hz, 6H), 1.49-1.48 (m, 4H), 1.46 (q, J = 7.5 Hz, 3H), 
1.30 (s, 3H), 1.09 (s, 3H). 13C-NMR (700 MHz; CDCl3): δ 170.1, 148.3, 136.0, 130.4, 124.4, 113.8, 
110.0, 81.3, 70.7, 44.5, 43.5, 41.8, 38.5, 29.5, 28.6, 26.56, 26.43, 26.2, 26.0, 23.4 
2-((3,4-dihydroxy-1-methylcyclopentyl)methoxy)-N-
(6-(2,4-dinitrophenylamino)hexyl)acetamide (56) To a solution of (55) (0.3747 g, 0.737 mmol) 
in methanol:H2O (1:1), 3 drops of 1N HCl was added. The reaction was monitored with TLC for 
complete disappearance of the starting material. Solvent was distilled off under vacuum and the 
product was taken into ethyl acetate and dried over MgSO4, further purified with silica 
MeOH:EtOAc (0.5:9.5) to afford yellow crystals (0.700 mmol, 95 %). 1H-NMR (700 MHz; 
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CDCl3): δ 9.16 (d, J = 2.6 Hz, 1H), 8.57 (s, 1H), 8.30 (dd, J = 9.5, 2.5 Hz, 1H), 6.94-6.93 (m, 1H), 
6.46 (s, 1H), 4.13 (q, J = 4.3 Hz, 2H), 4.03 (s, ), 3.96 (s, 2H), 3.43 (q, J = 6.2 Hz, 3H), 3.34 (q, J 
= 6.8 Hz, 3H), 3.32 (d, J = 10.3 Hz, 1H), 3.20 (d, J = 6.7 Hz, 2H). 13C-NMR (700 MHz, CDCl3): 
δ 169.6, 148.3, 136.0, 130.4, 124.4, 113.9, 80.8, 74.4, 70.9, 43.5, 41.9, 39.8, 38.6, 29.5, 28.6, 27.5, 
26.56, 26.45 
N-(6-(2,4-dinitrophenylamino)hexyl)-2-(2-methyl-4-
oxo-2-(2-oxoethyl)butoxy)acetamide (35) To a solution of (56) (32.7 mg, 0.700 mmol) in 
H2O:methanol (1:9) was added NaIO4 and  stirred for 1 hour until a flakey white, solid iodate salt 
appeared. Solvent was distilled off under vacuum and the product was taken into diethyl ether and 
dried over MgSO4 and used for subsequent reactions. 
N-(3-(2-((4-methyl-1-propyl-1,4-dihydropyridin-4-
yl)methoxy)acetamido)propyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamide (36) To a solution of (35) (20 mg, 0.4291 mmol) in MeOH/DCM was added 
excess propylamine and stirred for 30 minutes at 23°C. Solvent and excess propylamine were 
distilled off under vacuum and the final product was taken into diethyl ether and dried over MgSO4 
to afford yellow solid.  
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5.2.7 Synthesis of Lysine O-methyl Dialdehyde Conjugate (36) 
Methyl-2-amino-6-(4-methyl-4-((2-oxo-2-
(phenethylamino)ethoxy)methyl)pyridin-1(4H)-
yl)hexanoate (36) To a solution of L-Lysine methyl ester dihydrochloride (20 mg, 0.8583 mmol) 
in H2O and excess bicarbonate was added (26 mg, 0.8583 mmol)  (49) and stirred for 30 minutes 
at 23°C. Solvent was distilled off under vacuum and the final product was taken into MeOH and 
filtered through a layer of MgSO4 to afford white solid. 
5.2.8 Synthesis of Dialdehyde Glass Surfaces 
Acetonide Surface: A (1 x 1 cm) glass SuperAmine substrate (Arrayit) was carefully cut and 
submerged in a solution of excess bicarbonate and water. The glass substrate was stirred at 23°C 
for 30 minutes to generate a free-base amine surface. In another vial, excess 
dicyclohexylcarbodiimide (DCC)/N-hydroxysuccinimide and bicarbonate was mixed in THF and 
stirred for 15 minutes to which, 0.001 moles of substrate 24 was added. Once the activated ester 
was generated, the glass substrate was submerged into the vial to allow for formation of the amide 
bond between substrate 24 and the amine surface over 3 hours at 23°C. The glass substrate was 
removed and rinsed 3X with MeOH/H2O to remove all by-products and impurities. The generated 
protected diol surface is stable and could be stored at 4-8°C indefinitely.  
Dialdehyde Surface (44): The acetonide glass surface is submerged in a mixture of MeOH/H2O 
(1:9) to which 1 drop of dilute HCl acid is added and stirred for 4 hours to ensure the acetonide 
protecting group was completely removed. The substrate was then removed from the solution and 
rinsed with MeOH/H2O five times. The resulting surface displays a 1,2 vicinal diol and was 
submerged into a vial containing excess NaIO4 in MeOH/H2O and stirred for 4 hours at 23°C. The 
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glass substrate presenting dialdehyde was then rinsed thoroughly with MeOH/H2O and used for 
immobilization applications.  
5.2.9 Immobilization of Fluorescent Beads onto Dialdehyde Glass Surfaces 
Immobilization of fluorescent amine beads to dialdehyde surface.  Synthesized surface displaying 
dialdehyde headgroup was submerged into a 12 mL vial charged with 10 µL of L1030 (Sigma 
Aldrich) amine presenting latex beads in an aqueous solution for 4 hours. The substrate was 
removed and rinsed with aqueous solution to remove any non-specific and non-covalent 
interaction from the surface. The resulting solid surface was rinsed and images were obtained using 
fluorescent microscopy.   
Control Dialdehyde surface quenched with propylamine displays no fluorescent amine bead 
immobilization. Synthesized surface displaying dialdehyde headgroup was submerged into a 12 
mL vial charged with MeOH and treated with excess propylamine for 4 hours. The substrate was 
then removed and washed with MeOH/H2O thoroughly. The glass substrate was submerged into a 
12 mL vial containing 10 µL of L1030 (Sigma Aldrich) amine presenting latex beads in an aqueous 
solution for 4 hours. The resulting surface was rinsed and images were obtained showing no 
fluorescent bead immobilized.  
5.2.10 Cell Surface Engineering via Liposome Fusion using Dialdehyde Liposomes (15) 
Dialdehyde Liposome (Pathway A) 
General Dialdehyde Liposomes  
The dialdehyde lipid molecule 9 (0.6451 mmol, 3.2 mg) in chloroform was aliquoted into a 5 mL 
autoclaved glass vial, followed by the addition of 295 µL of POPC (10 mg/mL) in chloroform 
(Avanti Polar) and 25.6 µL of DOTAP (10 mg/mL) in chloroform (Avanti Polar). The lipid 
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solution was then evaporated under a stream of air for 1 hour until dry. Then 1.92 mL of culture 
grade PBS (Sigma Aldrich) was added to the dry lipids and immediately tip sonicated (Fisher 
Scientific) for 10 minutes at 30 W in a 23°C water bath. The resulting lipid suspension was used 
within 24 hours or stored at 4°C until use. 
General Blank Liposomes: 
Into an autoclaved 5 mL glass vial, 295 µL of POPC (10 mg/mL) in chloroform and 25.6 µL of 
DOTAP (10 mg/mL) in chloroform were added, followed by evaporation using a stream of air for 
1 hour. Then 1.92 mL of culture grade PBS was added to the dry lipids and immediately sonicated 
for 10 minutes at 30 W in a 23°C water bath. The resulting lipid suspension was used within 24 
hours or stored at 4°C until use. 
General Control Liposomes [Liposome with no dialdehyde lipid molecule (9)]:  
Into an autoclaved 5 mL glass vial, reporter-amine (0.9677 mmol) was added followed by 295 µL 
of POPC (10 mg/mL) in chloroform and 25.6 µL of DOTAP (10 mg/mL) in chloroform were 
added, followed by evaporation using a stream of air for 1 hour. Then 1.92 mL of culture grade 
PBS was added to the dry lipids and immediately tip sonicated for 10 minutes at 30 W in a 23°C 
water bath. The resulting lipid suspension was used within 24 hours or stored at 4°C until use. 
General Quenched Dialdehyde Liposomes: 
The dialdehyde lipid molecule 9 (0.6451 mmol, 3.2 mg) in chloroform was treated with excess 
propylamine and stirred for 4 hours. The excess reagents and all other volatiles were evaporated. 
The content was aliquoted into a 5 mL autoclaved glass vial, followed by the addition of 295 µL 
of POPC (10 mg/mL) in chloroform and 25.6 µL of DOTAP (10 mg/mL) in chloroform. The lipid 
solution was then evaporated under a stream of air for 1 hour until dry. Then 1.92 mL of culture 
grade PBS was added to the dry lipids and immediately tip sonicated for 10 minutes at 30 W in a 
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23°C water bath. The resulting lipid suspension was used within 24 hours or stored at 4 °C until 
use. 
5.2.11 Synthesis of Cell Surface Engineering Liposome Probes 
DNPC-Dialdehyde Conjugation Liposome Preparation  
Dialdehyde liposome 14 was transferred into a 5 mL autoclaved glass vial and treated with DNP-
amine (0.9677 mmol, 4.8 mg). The mixture was incubated for 2 hours at 23°C with moderate 
agitation. 
Biotin-Dialdehyde Conjugation Liposome Preparation  
Dialdehyde liposome 14 was transferred into a 5 mL autoclaved glass vial and treated with biotin 
cadaverine 17 (0.9677 mmol, 4.6 mg). The mixture was incubated at 23°C for 2 hours with 
moderate agitation. 
FLAG-Dialdehyde Conjugation Liposome Preparation  
Dialdehyde liposome 14 was transferred into a 5 mL autoclaved glass vial and treated with 
FLAG peptide 18 (4.0 mg). The mixture was incubated at 23°C overnight with moderate 
agitation. 
5.2.12 Cell Surface Engineering via Liposome Fusion using Dialdehyde Liposomes (15) 
Dialdehyde Liposome (Pathway B) 
DNPC-Dialdehyde Conjugation Liposome Preparation 
The dialdehyde lipid molecule 9 (0.6451 mmol, 3.2 mg) was transferred into a 5 mL autoclaved 
glass vial and dissolved through the addition of 1.5 mL of a mixed solvent system (1:3) of THF 
and methanol respectively. To this solution, molecule 16 DNP cadaverine (0.9677 mmol, 4.8 
mg) was added, along with a magnetic stir bar and reacted for 2 hours at 23°C. The product was 
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then obtained by evaporating the solvent under a stream of air. The conjugate product was then 
immediately used to form conjugate liposomes 15. 
To the 5mL glass vial of synthesized DNP-dialdehyde conjugate, 295 µL of POPC (10 mg/mL) in 
chloroform and 25.6 µL of DOTAP (10 mg/mL) in chloroform were added, followed by 
evaporation using a stream of air for 1 hour.  Then 1.92 mL of culture grade PBS was added to the 
dry lipids and immediately tip sonicated for 10 minutes at 30 W in a 23°C water bath.  The resulting 
lipid suspension was used within 24 hours or stored at 4°C until use. 
Biotin-Dialdehyde Conjugation Liposome Preparation  
The dialdehyde lipid molecule 9 (0.6451 mmol, 3.2 mg) was transferred into a 5 mL autoclaved 
glass vial and dissolved through the addition of 1.5 mL of a mixed solvent system (1:3) of THF 
and methanol respectively. To this solution, molecule 17 biotin-amine (0.9677 mmol, 4.6 mg) was 
added, along with a magnetic stir bar and reacted for 2 hours at 23°C. The product was then 
obtained by evaporating the solvent under a stream of air. The product was then immediately used 
to form a single batch of liposomes. 
To the 5 mL glass vial of synthesized biotin-Dialdehyde conjugate 295 µL of POPC (10 mg/mL) 
in chloroform and 25.6 µL of DOTAP (10 mg/mL) in chloroform were added, followed by 
evaporation using a stream of air for 1 hour.  Then 1.92 mL of culture grade PBS was added to the 
dry lipids and immediately tip sonicated for 10 minutes at 30 W in a 23°C water bath.  The resulting 
lipid suspension was used within 24 hours or stored at 4°C until use. 
FLAG-Dialdehyde Conjugation Liposome Preparation  
The dialdehyde lipid molecule 9 (0.6451 mmol, 3.2 mg) was transferred into a 5 mL autoclaved 
glass vial and dissolved through the addition of 1.5 mL of a mixed solvent system (1:1) of H2O 
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and methanol, respectively. To this solution, molecule 18 FLAG peptide (4.0 mg) was added, along 
with a magnetic stir bar and reacted overnight (16 hours) at 23°C. The product was then obtained 
by evaporating the solvent under a stream of air. The product was then immediately used to form 
a single batch of liposomes. 
To the 5 mL glass vial of synthesized FLAG-Dialdehyde conjugate 295 µL of POPC (10mg/mL) 
in chloroform and 25.6 µL of DOTAP (10 mg/mL) in chloroform were added, followed by 
evaporation using a stream of air for 1 hour. Then 1.92 mL of culture grade PBS was added to the 
dry lipids and immediately tip sonicated for 10 minutes at 30 W in a 23°C water bath.  The resulting 
lipid suspension was used within 24 hours or stored at 4°C until use. 
5.2.13 Mammalian Cell Surface Engineering via Dialdehyde Conjugate Liposome (15) 
DNPC-dialdehyde (A) or Biotin-dialdehyde (B) Conjugate Liposome Delivery  
C3H/10T1/2 cells (ATCC) were cultured using DMEM media supplemented with 10% FBS and 
1% P/S under standard growth conditions. For experiments, the cells were treated with 3 mL 
trypsin for three minutes to place cells in suspension and then quenched using 6 mL of growth 
media. The suspension was then centrifuged at 800 RPM for 5 minutes, the media decanted and 
the cells re-suspended in 500 µL of PBS. To the prepared cell suspension, 500 µL of the liposomal 
solution of pathway A or B DNP-dialdehyde was added and incubated at 23°C for 10 minutes 
followed by the addition of 9 mL of PBS and centrifuged at 800 RPM for 5 minutes and decanting 
of the supernatant. The resulting pellet was then re-suspended in 500 µL of PBS and 40 µL of 2 
mg/mL anti-dinitrophenyl-KLH, Alexa Fluor 488 conjugate (Life Technologies) and was 
incubated at 23°C for 1 hour. After incubation, the samples were diluted with 9 mL of PBS, 
centrifuged and the resulting pellet was washed again using 9 mL of PBS and centrifuged. The 
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pellet was then re-suspended in 500 µL of PBS. Flow cytometry and fluorescence microscopy was 
used to characterize the resulting cell suspension. 
Biotin-Dialdehyde Conjugate Liposome Delivery  
C3H/10T1/2 cells were cultured using DMEM media supplemented with 10 % FBS and 1 % P/S 
under standard growth conditions. For experiments, the cells were treated with 3 mL trypsin for 3 
minutes to place cells in suspension and then quenched using 6 mL of growth media. The 
suspension of cells was then centrifuged at 800 RPM for 5 minutes, the media decanted and the 
cells re-suspended in 500µL of PBS. To the prepared cell suspension, 500 µL of the liposomal 
solution A or B biotin-dialdehyde was added and incubated at 23°C for 10 minutes followed by 
the addition of 9 mL of PBS and centrifuged at 800 RPM for 5 minutes, and decanting of the 
supernatant. The resulting pellet was then re-suspended in 500 µL of PBS and 40 µL of 
Streptavidin-(FITC) 1 mg/mL and was incubated at 23°C for 1 hour. After incubation, the samples 
were diluted with 9 mL of PBS, centrifuged and the resulting pellet was washed again using 9 mL 
of PBS and centrifuged. The pellet was then re-suspended in 500 µL of PBS.  Flow cytometry and 
fluorescence microscopy was used to characterize the resulting cell suspension. 
FLAG-Dialdehyde Conjugate Liposome Delivery  
C3H/10T1/2 cells were cultured in 10 cm plates for 2 days until 90% confluent using High Glucose 
DMEM supplemented with 10% FBS and 1% P/S at 37°C and 5% CO2. The cells were removed 
using 3 mL trypsin for 4 minutes followed by addition of 6 mL media. The cells were collected 
and centrifuged at 800 RPM for 5 minutes followed by decanting of the media. The cells were re-
suspended in 500 µL PBS and treated with 500 µL of the pathway A or B FLAG-dialdehyde 
prepared liposome suspension. The contents were incubated for 10 minutes followed by dilution 
with 9 mL of PBS and centrifuged followed by decantation. The pellet was re-suspended in 500 
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µL of PBS. The resulting pellet was then re-suspended in 500 µL of PBS, the C3H/10T1/2 cells 
were treated with 5 µL of 2 mg/mL anti-FLAG peptide (Life Technologies) and incubated at 23°C 
for 1 hour followed by dilution with 9 mL of PBS. Content was centrifuged and re-suspended in 
500 µL of PBS and then further characterized by flow cytometry and fluorescence microscopy. 
5.2.14 Bacteria Cell Surface Engineering via Dialdehyde Conjugate Liposome (15) 
Biotin-Dialdehyde Conjugate Liposome Delivery  
Bacteria E. coli BL21, were grown to OD650= 0.6, corresponding to approximately 4 x l08 
CFU/mL. The cells were harvested by centrifugation at 6000 RPM for 10 minutes, washed with 
100 mM CaCl2 and re-suspended in 6 mL of 100 mM CaCl2 for 2 hours at 4°C. Aliquoted cells 
were suspended in 10 mL of 0.5 mM HEPES buffer pH 4.3. Cells were then treated with 6 µL 
EDTA (50 mM pH 8.4) and incubated at 37°C for 1 hour. 550 µL of liposomal solution obtained 
from pathway A or B was added to the cell culture and incubated at 23°C for 30 minutes. Cells 
were then spun down and the resulting pellet was re-suspended in 500 µL of PBS and 40 µL of 
STREPT-(FITC) 1 mg/mL. Content was incubated at 25°C for 1 hour or 15 minutes at 37°C. After 
incubation, cells were centrifuged and the resulting pellet was washed three times using 2 mL of 
fresh PBS. The pellet was then re-suspended in 500 µL of PBS.  Flow cytometry and fluorescence 
microscopy was then used to characterize the resulting cell suspension. 
5.2.15 Cell Surface Engineering via Liposome Fusion using Amine Liposomes (42) 
Amine Liposome (Pathway A) 
General Dodecylamine Liposomes  
The dodecylamine molecule 39 (0.02702 mmol, 5.0 mg) in chloroform was aliquoted into a 5 mL 
autoclaved glass vial, followed by the addition of 295 µL of POPC (10 mg/mL) in chloroform and 
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25.6 µL of DOTAP (10 mg/mL) in chloroform. The lipid solution was then evaporated under a 
stream of air for 1 hour until dry. Then 1.92 mL of culture grade PBS was added to the dry lipids 
and immediately tip sonicated for 10 minutes at 30 W in a 37°C water bath. The resulting lipid 
suspension was used within 24 hours or stored at 4°C until use. 
General Blank Liposomes: 
Into an autoclaved 5 mL glass vial 295 µL of POPC (10 mg/mL) in chloroform and 25.6 µL of 
DOTAP (10 mg/mL) in chloroform were added, followed by evaporation using a stream of air for 
1 hour.  Then 1.92 mL of culture grade PBS was added to the dry lipids and immediately tip 
sonicated for 10 minutes at 30 Watts in a 37°C water bath.  The resulting lipid suspension was 
used within 24 hours or stored at 4°C until use. 
General Control Liposomes (No Dodecylamine):  
Into an autoclaved 5 mL glass vial reporter-dialdehyde (0.4054 mmol) was added followed by 295 
µL of POPC (10 mg/mL) in chloroform and 25.6 µL of DOTAP (10 mg/mL) in chloroform were 
added, followed by evaporation using a stream of air for 1 hour. Then 1.92 mL of culture grade 
PBS was added to the dry lipids and immediately tip sonicated for 10 minutes at 30 W in a 37°C 
water bath. The resulting lipid suspension was used within 24 hours or stored at 4°C until use. 
General Quenched Dodecylamine Liposomes: 
The dodecylamine molecule 39 (0.1081 mmol, 20.0 mg) in DCM was treated with excess HCl and 
stirred for 1 hour. The excess reagents and all other volatiles were evaporated. The content was 
aliquoted into a 5 mL autoclaved glass vial, followed by the addition of 295 µL of POPC (10 
mg/mL) in chloroform and 25.6 µL of DOTAP (10 mg/mL) in chloroform. The lipid solution was 
then evaporated under a stream of air for 1 hour until dry. Then 1.92 mL of culture grade PBS was 
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added to the dry lipids and immediately tip sonicated for 10 minutes at 30 W in a 37°C water bath.  
The resulting lipid suspension was used within 24 hours or stored at 4°C until use. 
DNPC-Dialdehyde-Dodecylamine Conjugation Liposome Preparation  
Amine liposome 41 was transferred into a 5 mL autoclaved glass vial and treated with molecule 
35 DNP-dialdehyde (0.04054 mmol, 2.0 mg). The batch was then incubated at 23°C for 2 hour 
with moderate agitation. 
Biotin-Dialdehyde-Dodecylamine Conjugation Liposome Preparation  
Amine liposome 41 was transferred into a 5 mL autoclaved glass vial and treated with molecules 
37 biotin-dialdehyde (0.04054 mmol, 1.9 mg). The batch was then incubated at 25°C for 2 hours 
with moderate agitation. 
5.2.16 Cell Surface Engineering via Liposome Fusion using Amine Liposomes (42) 
Amine Liposome (Pathway B) 
DNPC-Dialdehyde Conjugation Liposome Preparation 
Dodecylamine molecule 39 (0.02688 mmol, 5.0 mg) was transferred into a 5 mL autoclaved glass 
vial and dissolved with the addition of 1.5 mL of a mixed solvent system (1:3) of THF and 
methanol, respectively. To this solution, molecule 35 DNP-dialdehyde (0.04032 mmol, 18 mg) 
was added, along with a magnetic stir bar and reacted for 2 hours at 23°C. The product was then 
obtained by evaporating the solvent under a stream of air. The product was then immediately used 
to form a single batch of liposomes. 
To the 5 mL glass vial of synthesized DNP-dialdehyde-dodecylamine conjugate, 295 µL of POPC 
(10 mg/mL) in chloroform and 25.6 µL of DOTAP (10 mg/mL) in chloroform were added, 
followed by evaporation using a stream of air for 1 hour. Then 1.92 mL of culture grade PBS was 
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added to the dry lipids and immediately tip sonicated for 10 minutes at 30 W in a 23°C water bath.  
The resulting lipid suspension was used within 24 hours or stored at 4°C until use. 
Biotin-Dialdehyde-Dodecylamine Conjugation Liposome Preparation  
Dodecylamine molecule 39 (0.02688 mmol, 5.0 mg) was transferred into a 5 mL autoclaved glass 
vial and dissolved with the addition of 1.5 mL of a mixed solvent system (1:3) of THF and 
methanol respectively. To this solution, molecule 37 biotin-dialdehyde (0.04032 mmol, 20 mg) 
was added, along with a magnetic stir bar and reacted for 2 hours at 23°C. The product was then 
obtained by evaporating the solvent under a stream of air. The product was then immediately used 
to form a single batch of liposomes. 
To the 5mL glass vial of synthesized biotin-dialdehyde-dodecylamine conjugate 295 µL of POPC 
(10 mg/mL) in chloroform and 25.6 µL of DOTAP (10 mg/mL) in chloroform were added, 
followed by evaporation using a stream of air for 1 hour. Then 1.92 mL of culture grade PBS was 
added to the dry lipids and immediately tip sonicated for 10 minutes at 30 W in a 23°C water bath.  
The resulting lipid suspension was used within 24 hours or stored at 4°C until use. 
5.2.17 Mammalian Cell Surface Engineering via Amine Conjugate Liposome (42) 
DNPC-Dialdehyde-Dodecylamine Conjugate Liposome Delivery  
C3H/10T1/2 cells were cultured in 10 cm plates for 2 days until 90% confluent using High Glucose 
DMEM supplemented with 10% FBS and 1% P/S at 37°C and 5% CO2. For experiments, the cells 
were treated with 3 mL trypsin for 3 minutes to place cells in suspension and then quenched using 
6 mL of growth media. The suspension of cells was then centrifuged at 800 RPM for 5 minutes, 
the media was decanted and the cells re-suspended in 500 µL of PBS. To the prepared cell 
suspension, 500 µL of the liposomal solution of pathway A or B DNP-dialdehyde-dodecylamine 
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was added and incubated at 23°C for 10 minutes followed by the addition of 9 mL of PBS and 
centrifuged at 800 RPM for 5 minutes, followed by decanting of the supernatant. The resulting 
pellet was then re-suspended in 500 µL of PBS and 40 µL of 2 mg/mL anti-dinitrophenyl-KLH, 
Alexa Fluor 488 conjugate (Life Technologies) and was incubated at 23°C for 1 hour. After 
incubation, the samples were diluted with 9 mL of PBS, centrifuged and the resulting pellet was 
washed again using 9 mL of PBS and centrifuged. The pellet was then re-suspended in 500 µL of 
PBS. Flow cytometry and fluorescence microscopy was used to characterize the resulting cell 
suspension. 
Biotin-Dialdehyde-Dodecylamine Conjugate Liposome Delivery  
C3H/10T1/2 cells were cultured in 10 cm plates for 2 days until 90% confluent using High Glucose 
DMEM supplemented with 10% FBS and 1% P/S at 37°C and 5% CO2. For experiments, the cells 
were treated with 3 mL trypsin for 3 minutes to place cells in suspension and then quenched using 
6 mL of growth media. The suspension of cells was then centrifuged at 800 RPM for 5 minutes, 
the media was decanted and the cells re-suspended in 500 µL of PBS. To the prepared cell 
suspension, 500 µL of the liposomal solution A or B biotin-dialdehyde-dodecylamine was added 
and incubated at 23°C for 10 minutes followed by the addition of 9 mL of PBS, centrifuged at 800 
RPM for 5 minutes, followed by decanting of the supernatant. The resulting pellet was then 
suspended in 500 µL of PBS and 40 µL of STREPT-FITC (1 mg/mL) and then incubated at 25°C 
for 1 hour. After incubation, the samples were diluted with 9 mL of PBS, centrifuged and the 
resulting pellet was washed again using 9 mL of PBS and centrifuged again. The pellet was then 
re-suspended in 500 µL of PBS. Flow cytometry and fluorescence microscopy was used to 
characterize the resulting cell suspension. 
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5.2.18 Bacteria Cell Surface Engineering via Amine Conjugate Liposome (42) 
DNP-Dialdehyde-dodecylamine Conjugate Liposome Delivery  
E. coli BL21, were grown to OD650= 0.6, corresponding to approximately 4 x l08 CFU/mL. The 
cells were harvested by centrifugation at 6000 RPM for 10 minutes, washed with 100 mM CaCl2 
and re-suspended in 6 mL of 100 mM CaCl2 for 2 hours at 4°C. Aliquoted cells were suspended 
in 10 mL of 0.5 mM HEPES buffer (pH 4.3). Cells were then treated with 6 µl EDTA (50 mM pH 
8.4) and incubated at 37°C for 1 hour. 550 µL of liposomal solution obtained from pathway A or 
B was added to the cell culture and incubated at 23°C for 30 minutes. Cells were then spun down 
and the resulting pellet was re-suspended in 500 µL of PBS and 40 µL of 2 mg/mL anti-
dinitrophenyl-KLH, Alexa Fluor 488 conjugate (Life Technologies) and then incubated at 23°C 
for 1 hour. Content was incubated at 25°C for 1 hour or 15 minutes at 37 oC.  After incubation, 
cells were centrifuged and the resulting pellet was washed three times using 2 mL of fresh PBS.  
The pellet was then re-suspended in 500 µL of PBS.  Flow cytometry and fluorescence microscopy 
was used to characterize the resulting cell suspension. 
Biotin-Dialdehyde-dodecylamine Conjugate Liposome Delivery  
E. coli BL21, were grown to OD650= 0.6, corresponding to approximately 4 x l08 CFU/mL. The 
cells were harvested by centrifugation at 6000 RPM for 10 minutes, washed with 100 mM CaCl2 
and re-suspended in 6 mL of 100 mM CaCl2 for 2 hours at 4°C. Aliquot cells were suspended in 
10 mL of 0.5 mM HEPES buffer (pH 4.3). Cells were then treated with 6 µl EDTA (50 mM pH 
8.4) and incubated at 37°C for 1 hour. 550 µL of liposomal solution obtained from pathway A or 
B was added to the cell culture and incubated at 23°C for 30 minutes. Cells were then spun down 
and the resulting pellet was re-suspended in 500 µL of PBS and 40 µL of STREPT-FITC (1 
mg/mL). Content was incubated at 25°C for 1 hour or 15 minutes at 37°C.  After incubation, cells 
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were centrifuged and the resulting pellet was washed three times using 2 mL of fresh PBS. The 
pellet was then re-suspended in 500 µL of PBS.  Flow cytometry and fluorescence microscopy 
was used to characterize the resulting cell suspension. 
5.2.19 Cross-linking of Protein LAR D1D2 and CS2 Domain 
20 µL of Protein LAR D1D1 18.5 µM was mixed with 20 µL of CS2 domain 20 µM and incubated 
for 30 minutes for complete interactive binding, to which, 20 µL of homobifunctional cross-linker 
dialdehyde (70) 20 mg/mL was added. The mixture was further diluted to a total of 50 µL volume 
using PBS pH 8.4 buffer and incubated at 25°C and 37°C for 15 minutes.   
Control protein (Cross-linker Deficient): A native control experiment was also conducted by 
mixing 20 µL of Protein LAR D1D2 18.5 µM and 20 µL of CS2 20 µM, incubated for 30 minutes 
for complete interactive binding for complex formation. 
Control Cross-linker reagent (Quenched Head Groups): A native control experiment was also 
conducted using quenched linker with propylamine, presenting a terminated head group 
dialdehyde functional group. 20 µL of homobifunctional cross-linker dialdehyde (70) 20 mg/mL 
was mixed with excess propylamine in a 1 mL vial and incubated at 23°C for 5 hours to ensure 
both head groups were terminated. The solvent and excess volatile reagents were evaporated using 
a stream of air overnight. The content was resolved in 20 µL of fresh PBS (pH 8.4) and added to 
20 µL of protein complex which was further diluted to a total of 50 µL volume using PBS pH 8.4 
buffer and incubated at 25°C and 37°C for 15 minutes.  
Positive Control Cross-linker Reagent (Glutaraldehyde): To investigate the extent of cross-
linking, a positive control experiment was also performed with conventional 50% glutaraldehyde 
consistent with the total concentration of the protein-protein complex. 20 µL of Protein LAR D1D2 
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was mixed with 20 µL of CS2 20 µM and incubated for 30 minutes for complete interactive 
binding, to which, 5 µL of homobifunctional cross-linker glutaraldehyde was added, further 
diluted to a total of 50 µL volume using PBS buffer (pH 8.4) and incubated at 25°C and 37°C for 
15 minutes.   
5.2.20 Cross-linking of Protein EA22 
3 µL of Protein EA22 Lambdaphage 1 mg/ml was mixed with 15 µL of homobifunctional cross-
linker dialdehyde (72) 20 mg/ml, further diluted to a total of 50 µL volume using PBS buffer (pH 
8.4) and incubated at 25°C for 15 minutes.   
Control Cross-linker Reagent (Quenched Head Groups): A native control experiment was also 
conducted using quenched linker with propylamine, presenting a terminated head group 
dialdehyde functional group. 3 µL of homobifunctional cross-linker dialdehyde (70) 20 mg/ml was 
mixed with excess propylamine in a 1 mL vial and incubated at 23°C for 5 hours to ensure both 
head groups were terminated. The solvent and excess volatile reagents were evaporated using a 
stream of air overnight. The content was resolved in 10 µL of PBS (pH 7.8) and added to 3 µL of 
protein EA22 further diluted to a total of 50 µL volume using PBS buffer (pH 8.4) and incubated 
at 25°C for 15 minutes. 
5.2.21 Cross-linking of Protein PP16 
3 µL of Protein PP16 Lambdaphage (1 mg/mL) was mixed with 15 µL of homobifunctional cross-
linker dialdehyde (70) 20 mg/mL, further diluted to a total of 50 µL volume using PBS buffer (pH 
8.4) and incubated at 25°C for 15 minutes.   
Control Cross-linker reagent (Quenched Head Groups): A native control experiment was also 
conducted using quenched linker with propylamine, presenting a terminated head group 
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dialdehyde functional group. 15 µL of homobifunctional cross-linker dialdehyde (70) 20 mg/ml 
was mixed with excess propylamine in a 1 ml vial and incubated at 23°C for 5 hours to ensure both 
head groups were terminated. The solvent and excess volatile reagents were evaporated using a 
stream of air overnight. The content was resolved in 10 µL of PBS (pH 7.8) and added to 3 µL of 
protein PP16 further diluted to a total of 50 µL volume using PBS buffer (pH 8.4) and incubated 
at 25°C for 15 minutes.  
SDS Gel Electrophoresis Analysis:   A 20 µL aliquot of each complex above was mixed with equal 
volume of 2X SDS dye and resolved on a 12% SDS-PAGE gel. The gel was stained with 
Coomassie Brilliant Blue staining solution and imaged.  
5.2.22 Dialdehyde Cross-linking and Acid Release of Commercial Latex-Amine Beads in 
Aqueous Solution   
In a 5 mL test tube, 10 µL of L1030 (Sigma Aldrich) amine presenting latex beads in aqueous 
solution were aliquoted and diluted with 500 µL of ddH2O and then gently agitated. An aqueous 
solution of cross-linking tetraethylene glycol (TEG)-dialdehyde (70) in 250 µL (0.011 mM) using 
ddH2O or methanolic solution of cross-linker dialdehyde (66) in methanol was made. 250 µL of 
either solutions of cross-linker dialdehyde was aliquoted into the latex-amine bead suspension, 
gently agitated and reacted overnight at 23°C. Examination of the overnight reaction yielded 
precipitated beads. 
Blank Control Liposomes (dialdehyde deficient): In a 5 mL test tube, 10 µL of L1030 amine 
presenting latex beads in aqueous solution were aliquoted and diluted with 500 µL of ddH2O and 
then gently agitated. Next, 100 µL of ddH2O was aliquoted into the latex-amine bead suspension 
and reacted overnight at 25°C. No change in opaque suspension of beads was observed. 
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N-propylamine Quenched Aldehyde Control: An aqueous solution of cross-linking TEG 
containing dialdehyde (70) in 250 µL (0.011 mM) was made using ddH2O and solution of cross-
linker (66) in 250 µL of methanol (0.011 mM). N-propylamine was added and reacted at 25°C for 
1 hour to both solutions separately. Then 250 µL of the quenched cross-linking dialdehyde was 
added to a suspension of latex amine presenting beads formed through the dilution of 15 µL of 
L1030 beads diluted using 500 µL of ddH2O. No change in opaque suspension of beads was 
observed. 
Cross-linked Dialdehyde Acid Release: First a precipitated cross-linked bead sample was produced 
using a 5 mL test tube 10 µL of L1030 (Sigma Aldrich) amine presenting latex beads in aqueous 
solution were aliquoted, diluted with 500µL of ddH2O and then gently agitated. An aqueous 
solution of (70) in 250 µL (0.011 mM) was made using ddH2O. Similar methanolic solution was 
made using (66). 250 µL of cross-linker solution was aliquoted into the latex-amine bead 
suspension, gently agitated and reacted overnight at 25°C. Examination upon overnight reaction 
yielded precipitated beads. The remaining liquid was decanted using a micropipette, leaving 
behind only the precipitated beads. To the beads 450 µL of ddH2O treated with 1M HCl to pH 2.0 
was added and agitated. The suspension was then allowed to react and then visualized to determine 
if the beads continued to precipitate or remained in suspension.  Then, after a 12 hour reaction of 
the cross-linked beads with water (pH 2.0), the bead suspensions were centrifuged at 8000 RPM 
for 10 minutes, followed by decanting of the supernatant and the addition of fresh 500 µL of ddH2O 
(pH 2.0) and re-suspended. The beads were allowed to react for a further 30 minutes and then 
centrifuged at 8000 RPM for 10 minutes, followed by decanting of the supernatant and the addition 
of fresh 500 µL of ddH2O and re-suspended. The beads were allowed to sit for 16 hours and images 
were obtained of the final suspension along with controls using fluorescent microscopy.   
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Fluorescent Microscopy of Dialdehyde Cross-linking of Amine Beading in Solution: In a 5 mL test 
tube, 10 µL of L1030 amine presenting latex beads in aqueous solution were transferred and 
diluted with 500 µL of ddH2O and gently agitated. An aqueous solution of cross-linker TEG 
containing dialdehyde (70) in 250 µL (0.011 mM 1.5 mg) was made using ddH2O and solution of 
cross-linker (66) in 250 µL of methanol (0.011 mM, 1.5 mg). 250 µL of the cross-linker solution 
was aliquoted into the latex-amine bead suspension, gently agitated and reacted overnight at 25°C. 
Examination of the overnight reaction yielded precipitated beads. The beads were transferred onto 
glass slides and imaged using phase contrast and fluorescent microscopy to visualize aggregation. 
5.2.23 Cross-linker Dialdehyde Generation of Tissue Constructs 
General Tissue Formation through Dialdehyde Cross-linking: C3H/10T1/2 cells were cultured in 
10 cm tissue for 2 days until 90% confluent using optimal growth conditions. For experiments, 
cell cultures were suspended using 3 mL trypsin for 4 minutes followed by addition of 6 mL 
DMEM media. The cells were collected and centrifuged at 800 RPM for 5 minutes followed by 
decanting. The pellet was re-suspended in approximately 650 µL of serum free media to obtain a 
concentration of 4 x 106 cells/mL using a hemocytometer. The suspension was then treated with 2 
µL of a 20 mg/mL dialdehyde cross-linker aqueous solution. Then 200 µL of the treated suspension 
was carefully added on top of a sterile 1 cm2 glass slide and incubated for 1 hour at 37°C and 5% 
CO2. The glass slides were then washed once with PBS, fresh serum containing media and the 
plates were further incubated for 16 hours (overnight), then washed twice with PBS and fixed with 
4% formalin solution. For confocal microscopy, the cells were stained with DAPI and TRITC for 
3D visualization using the manufacturers protocol. The images were obtained by mounting onto 
thin glass slides with LIGHT DIAGNOSTICS Mounting Fluid (Millipore) for 3D confocal 
microscopy using a Zeiss LSM 700. 
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Tissues were also formed using RFP and GFP expressing cell lines by using the above protocol. 
The cells were combined in suspension with 1:1 ratio with an overall concentration of 4 million 
cells/mL. These tissues were visualized without staining by mounting onto thin glass slides with 
LIGHT DIAGNOSTICS Mounting Fluid (Millipore) for 3D confocal microscopy using a Zeiss 
LSM 700. 
Cell Viability Assay of C3H/10T1/2 cells with Cross-linker Dialdehyde: The cell viability assay 
was performed using C3H/10T1/2 cells using the general tissue engineering protocol. After cells 
were treated with the cross-linker dialdehyde molecule (70), washed and replaced with fresh serum 
media, following 16 hours of incubation (overnight) the cells were re-suspended and the cell 
viability assay was performed using Trypan Blue (Sigma Aldrich) staining, following the 
manufacturer’s protocol. 
5.2.24 Synthesis of Dialdehyde Cross-linker (49) 
 
 
N,N'-(2,2'-(2,2'-oxybis(ethane-2,1-
diyl)bis(oxy))bis(ethane-2,1-diyl))bis(2-((2,2,5-trimethyltetrahydro-3aH-
cyclopenta[d][1,3]dioxol-5-yl)methoxy)acetamide) (47) To a solution of (46) mixed isomers 
(0.0635 g, 0.2604 mmol) in MeOH/ACN and excess of sodium bicarbonate was added HBTU 
(0.2078 g, 0.546 mmol, 2.1 eq). Reaction was monitored with TLC for complete disappearance of 
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starting material. Once the activated carboxylic acid is generated, confirmed by TLC, 1,11-
diamino-3,6,9-trioxaundecane (0.0250 g, 0.1302 mmol) was added to the reaction vessel. Mixture 
was stirred for 0.5 hours, then concentrated and flushed through a pad of silica MeOH:EtOAc (1:4) 
to afford clear oil (0.1236 mmol, 95%). The product was not purified as an isolated compound as 
it was used in subsequent steps.  
N,N'-(2,2'-(2,2'-oxybis(ethane-2,1-
diyl)bis(oxy))bis(ethane-2,1-diyl))bis(2-
((3,4-dihydroxy-1-methylcyclopentyl)methoxy)acetamide) (48) To a solution of (47) (0.8000 g 
,0.1236 mmol) in methanol:H2O (1:1), 3 drops of 1N HCl was added. The reaction was monitored 
with TLC for complete disappearance of the starting material. Solvent was distilled off under 
vacuum and the product was taken into ethyl acetate and dried over MgSO4, further purified with 
silica MeOH:EtOAc (1:4) to afford a clear oil (0.1236 mmol, 100%). 1H-NMR (700 MHz, CDCl3): 
1.28-1.39 (4s, 12H), 1.518 (s, 3H), 1.540 (s, 3H), 1.92- 1.95 (d, 2H, J= 14.59Hz), 2.28-2.30 (d, 
2H), 2.68-2.70 (d, 2H, J= 14.51Hz), 4.682-4.689 (d, 1H, J= 4.38Hz), 4.760-4.769 (d, 1H).  
N,N'-(2,2'-(2,2'-oxybis(ethane-2,1-
diyl)bis(oxy))bis(ethane-2,1-diyl))bis(2-(2-
methyl-4-oxo-2-(2-oxoethyl)butoxy)acetamide)(49) To a solution of (48) (0.8000 g ,0.1236 
mmol) in H2O:methanol (1:9) was added NaIO4 and stirred for 1 hour until a flakey white, solid 
iodate salt appeared. Solvent was distilled off under vacuum and the product was taken into diethyl 
ether and dried over MgSO4 and used for subsequent reactions.  
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5.3 Results and Discussion 
To show the utility of the modified glutaraldehyde moiety for primary amine conjugation 
we synthesized a number of dialdehyde containing molecules for a wide range of applications.  
Figure 5.3 depicts the synthetic scheme used to produce the lipidated dialdehyde molecule (9), 
which was used as a ‘liposome loading’ or ‘lipidation strategy’ for delivery of amine containing 
molecules to cells. These molecules can be useful for conjugating a variety of probes for 
biophysical, cell membrane and biology studies. The synthetic strategy for the lipid dialdehyde 
(9) only requires 5 synthetic steps, which also proceed with high yields as a straightforward and 
robust methodology. 
 
Figure 5.3: Lipidated dialdehyde reagent synthetic route. (A) cis-1,4-Dichloro-2-butene (1.0 
equiv), Na (2.2 equiv), anhydrous t-butanol, 12 hours, 95%. (B) LiAlH4 (3.0 equiv), −78°C, dry 
THF, 2 hours, CH3COOH/H2O 1 M, 3 hours, 95%. (C) NaH (excess), dry THF, Argon, 1-
bromododecane (2.2 equiv) 24 hours, 80%. (D) OsO4, N-methylmorpholine N-oxide (excess), 
CH3CN/acetone/H2O, 12 h, 90%. (E) NaIO4, Acetone/H2O, 2 hours, 75%. 
 Using 1H-NMR, we studied the conjugation of dialdhyde (9) containing a quaternary 
carbon as our model by reacting (9) with propyl amine, (Figure 5.4). To probe the reactivity of 
the quaternary dialdehyde (9) we performed the reaction under aqueous conditions at 23°C to 
produce conjugate (10).  We found dialdehyde (9) to be stable under aqueous 23°C conditions 
and neat conditions. Under aqueous conditions for proton NMR analysis, the unreacted 
dialdehyde molecule (9) did not polymerize or undergo intermolecular reactions but rather 
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existed as a cyclic hydrate pyran diol. After exposure of dialdehyde (9) to a primary amine such 
as propylamine shown in Figure 5.4, one aldehyde quickly reacts with the amine to form an 
imine, but due to the close proximity of the second aldehyde group a fast intramolecular reaction 
occurs trapping the amine to form a six-membered diol piperidine-type moiety, which then 
undergoes dehydration to form the 1,4-dihydropyridine conjugate (10). Proton NMR analysis of 
dialdehyde (9) and conjugate (10) shown in Figure 5.5 was used to follow the reaction by 
focusing on the appearance of the vinylic and alpha proton peaks of propylamine. The reaction 
kinetics were quantified using NMR by following the formation of vinylic peaks to obtain t1/2 of 
less than 5 seconds (kobs = 0.14 s
-1 ± 0.02), with a subsequently slow hydration step to form the 
1,4-dihydropyridine group. Without the proximity of the intramolecular second aldehyde group 
to trap the amine, the initial imine formation was not favorable under aqueous conditions and 
became quickly hydrolyzed due to the equilibrium heavily favoring the reactants (dialdehyde and 
amine).14 15 Yet, at low pH (< 3.0) conditions the conjugate (10) undergoes cleavage, which may 
permit the release of the dialdehyde and amine molecule. The release of these molecules may 
have utility for incorporation into fluorescence resonance energy transfer (FRET) probes or pH 
biosensors for aggregate nanoparticles, which would enable switchable conjugation using high 
pH reactions and low pH release of the parent reactants. The dialdehyde-amine conjugation 
reaction is a true click reaction which does not require an activating agent, while also releasing 
no other by-products other than water, proceeds rapidly, is traceless and reacts with high atom 
economy.  
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Figure 5.4: Reaction of lipidated dialdehyde (9) with propyl amine to produce the lipid conjugate 
(10). The reaction occurs in aqueous media at 23°C with propylamine to produce the desired 
conjugate (10) in high yield with no byproducts in under 30 minutes. 
 
Figure 5.5: 1H-NMR spectra comparison of the modified glutaraldehyde molecule (9) and the 
conjugated molecule (10). The reaction of the dialdehyde with primary propylamine rapidly 
generated the conjugate. Comparison of the final conjugate with the starting material dialdehyde 
NMR spectra show key proton peaks which were used for kinetic studies. The key proton peaks 
include the 9.6 ppm Hd aldehyde proton and peaks in the 4.7-5.3 ppm region (dialdehyde cyclic 
pyran hydrate). The key peaks for the conjugate (10) include Hc at 6.0 ppm and Hb at 4.3 ppm 
vinylic protons and Hd at 3.1 ppm α nitrogen protons.  
 The utility of our lipid dialdehyde conjugation strategy was demonstrated using a 
liposome nanoparticle delivery and CSE to perform various applications.  Liposomes have been 
an effective component of biological research, understanding molecular signalling and the 
synthesis, adaptation and delivery of these lipid nanoparticles as a fundamental instrument for 
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biophysical research as probe and drug delivery mechanism and model membrane system.16 17 18 
19 20   
 
Figure 5.6: Reaction rate of primary amine (propylamine) and dialdehyde (9) to generate the 
dihydro pyridine conjugate (10). With a short half-life (25°C, pH 7.0) of t1/2 of less than 5 seconds 
(kobs = 0.14 s
-1 ± 0.02) it also subsequently undergoes a slow dehydration step. 
 Current research performed by the Yousaf group focused on the use of liposomes as lipid 
delivery vehicles via liposome fusion with cell membranes to insert bio-orthogonal-like lipids 
into membranes for a range of applications.21 22 23 24 25 This method was used to engineer plasma 
membranes which present lipid molecules that impart new capabilities to the cell including 
redox, photoswitchable and fluorescent properties.24 25 26 This system was also used to 
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incorporate complementary bio-othrogonal moieties into multiple cell types to form scaffold free 
spheroids and functional 3D cardiac and liver tissues.23 27 26 
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Figure 5.7: Scheme depicting the flexible liposome functionalization strategy using 
incorporated dialdehyde lipids. (A) Pathway A describes incorporating dialdehyde lipids (9) into 
a fully formed liposome suspension using background lipids (12 and 13), to produce dialdehyde 
liposomes (14). These dialdehyde liposomes can then be reacted with primary amine containing 
ligands, small molecules or probes to form useful conjugate liposomes (15). (B) Pathway B 
describes reacting the dialdehyde lipid (9) with probes, peptides or other amine small molecules 
first to form the conjugate lipid (11), followed by mixing with background lipids (12 and 13) to 
form the conjugate presenting liposome (15). (Bottom) The formed conjugate presenting liposome 
(15) can then be delivered to both bacterial or mammalian cell membranes via liposome fusion. 
 Figure 5.7 demonstrates two competing methods to generate conjugate liposomes (15) 
using our lipid dialdehyde (9) with a variety of primary amine containing molecules for delivery 
to the plasma membrane. Due to the flexibility of our dialdehyde bioconjugation strategy, two 
different pathways for the formation of conjugated liposomes (15) may be used to tailor 
membranes. Pathway A illustrates the synthesis of liposomes containing background lipids and 
dialdehyde molecule (ratio of lipids 12:13:9 at 86%/ 7%/ 7%). After self-assembly of the 
nanoparticle (14), a number of amine containing reporter molecules can then be reacted with the 
dialdehyde to form a stable conjugate with the liposome leaflet (15). It is possible to couple 
multiple different ligands to a single liposome using the primary amine and dialdehyde click 
reaction to form multiplexed liposomes. 
 Pathway B demonstrates an alternative method to synthesize conjugate liposomes. The 
active dialdehyde (9) is initially reacted with an amine ligand to form the conjugate molecule 
(11), which is then mixed with the background lipids (12 and 13) to then form the conjugate 
liposome (15). This strategy requires no activating groups or catalysts and generates no by-
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products, while also being straightforward and enables the formation of complex multimodal 
liposomes without the need of subsequent dialysis or purification.   
 
Figure 5.8: Flow cytometry scheme of cells rapidly treated with amine containing bio-
molecular probes conjugated to lipid dialdehyde liposomes using CSE via liposome fusion. 
(A) Amine-DNP cadaverine conjugated liposomes treated to mammalian fibroblast cells via 
dialdehyde click chemistry and characterized using FITC antibody coupled with flow cytometry 
and fluorescent microscopy (+). Cells do not fluoresce when treated with liposomes devoid of the 
dialdehyde or when the dialdehyde was first reacted with propylamine (quenched) under identical 
conditions (-). (B,C) Fibroblasts cells were treated with biotin cadaverine and FLAG peptide 
conjugated to dialdehyde liposomes and exposed to STREPT-FITC and anti-FLAG respectively 
(+). (D) E. coli BL21 were engineered with biotin cadaverine via dialdehyde liposome fusion and 
characterized with STREPT-FITC in flow cytometry. Scale bar: 20 µm. 
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 Figure 5.8 illustrates an assortment of liposome conjugates expressing a variety of 
surface coupled ligands for delivery to the cell surface. The liposomes were functionalized using 
Pathway A, where the dialdehyde liposomes were treated with primary amine ligands and 
delivered to mammalian fibroblasts and bacteria (E. coli) cells, that underwent rapid liposome 
fusion to deliver the ligands onto the cell surface. For bacterial cells, liposome background lipids 
included POPC and 1,2-dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) 
(DMPG) lipids, while POPC and DOTAP (12 and 13) were used due to physiological differences 
in cell membrane properties.19 21 
 Characterization of liposome conjugate ligand delivery to the cell surface was performed 
using the ligand tailored cells through exposure to their specific fluorescent antibodies, followed 
by flow cytometry analysis and fluorescent microscopy.  Figure 5.8 demonstrates that our ligand 
conjugated fusion liposomes were successful incorporating ligands on the cell surface. 
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Figure 5.9: 3D plots of various ligands delivered to the cell membrane by dialdehyde amine 
click chemistry using liposome fusion describing the relationship concerning the amount of 
ligand characterized using flow cytometry. (A) Mammalian membrane fusion using dialdehyde 
liposome fusion quantifies lipid incorporation using liposome fusion and flow cytometry. (B) 
Prokaryotic membrane fusion using dialdehyde liposome fusion quantified lipid incorporation 
using liposome fusion and flow cytometry. Control cells do not display ligands nor do quenched 
dialdehyde show any fluorescence signal. Only positive liposomes bearing dialdehyde groups 
which were reacted with primary amine ligands showed cell surface ligand display through 
fluorescence. 
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 To quantify the number of conjugated ligands to the cell surface via dialdehyde-amine 
click chemistry and liposomes, we utilized flow cytometry. Figure 5.9 is a 3D plot displaying the 
relationship between liposome composition and amount of ligand delivered onto mammalian and 
bacterial cell surfaces. The relationship between the identity of the ligand, concentration of the 
liposome conjugates and the duration of exposure influenced the delivered number of conjugate 
ligand molecules.20 21 These elucidated parameters are important to engineer cells with known 
ligand density for a variety of applications. Previous work has shown that application of CSE 
liposomes to cells does not result in changes to viability or cell behavior for a range of cell types 
and bacteria.23 24 25 26 For our control experiments, when blank liposomes and quenched 
dialdehyde liposomes were used, no ligands were found on the cell surface. 
 Figure 5.10 demonstrates the broad utility of our bioconjugation strategy by synthesizing 
a small set of dialdehyde coupling reagents and by developing a synthesis strategy for dialdehyde 
moieties. These dialdehyde reagents were made using minimal steps and high yields to generate 
a key intermediate (24) to allow the convergent synthesis of a variety of ligands, probes and 
monomers. Figure 5.11 describes our synthesized list of dialdehyde containing molecules and 
their conjugate forms. To illustrate the bioconjugation strategy, dialdehyde molecules were 
tethered to lysine (34) and other known recognition small molecules such as biotin (37) and DNP 
(35).28 29 
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Figure 5.10:  A general synthetic methodology to generate dialdehyde reagents. (i) t-Butyl 
lithium (3.0 equiv), −78 °C, dry THF, 6 hours, MeI (excess), 12 hours, 100%. (ii) LiAlH4 (3.0 
equiv), −78°C, dry THF, 2 hours, CH3COOH/H2O 1 M, 3 hours, 85%. (iii) NaH (excess), dry THF, 
Argon, chloroacetic acid (1.2 equiv) 24 hours, 95%. (iv) OsO4, N-methylmorpholine N-oxide 
(excess), CH3CN/acetone/H2O, 12 hours, 60%. (v), 1,2 Dimethoxypropane, dry THF, pTsOH 
(cat), 2 hours, 95%. (vi) Dry THF, sodium bicarbonate, DCC, N-hydroxysuccinimide, 1 hours, 
general amine, 30 minutes. (vii) MeOH/H2O (1:9) dilute HCl, 2 hours. (viii) H2O/methanol (1:9), 
NaIO4, 1 hour. 
 Figure 5.11 depicts our general strategy for engineering cell surfaces with ligands 
through the initial coupling of dialdehyde containing ligands with amine-terminated lipids or 
liposomes for delivery to the plasma membrane via fusion. 
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Figure 5.11: List of synthesized dialdehyde molecules and dialdehyde conjugates used in this 
study. 
Pathway A in Figure 5.12 depicts the formation of an amine engineered liposome (41) 
through mixing terminal amine lipids (39) with background lipids (12 and 13).  The amine 
liposome can then be loaded or reacted with dialdehyde presenting ligands (27), which undergo 
fast reaction to ligate with the liposome via dialdehyde and amine click chemistry (42).  Pathway 
B describes the reaction of amine lipids (39) with dialdehyde ligands (27) first to form a lipid 
conjugate (40), followed by the mixing and assembly with background lipids to synthesize the 
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ligand engineered liposome (42).  The generated ligand presenting liposomes are then added to 
mammalian or bacterial cells (E. coli), which undergo rapid fusion followed by ligand display.                                  
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Figure 5.12: Scheme depicting the flexible liposome functionalization strategy using 
incorporated dialdehyde lipids. Pathway A describes incorporating amine lipids (39) into a full 
formed liposome suspension using background lipids (12 and 13), to produce amine presenting 
liposomes (41). These liposomes can then be reacted with dialdehyde containing ligands, small 
molecules or probes to form useful conjugate liposomes (42). Pathway B describes reacting the 
amine lipid (39) with probes, peptides or other dialdehyde containing small molecules first to form 
the conjugate lipid (40), followed by mixing with background lipids (12 and 13) to form the 
conjugate presenting liposome (42). The formed conjugate presenting liposome can then be 
delivered to both bacterial and mammalian cell membranes via liposome fusion. 
 Figure 5.13 presents flow cytometry and fluorescence data gathered from the conjugation 
of dialdehyde terminated DNP and biotin (37 and 35) to amine lipids (39), and amine liposomes 
(41) delivered using liposome fusion. The generation of ligand presenting liposomes (42), DNP-
dialdehyde and biotin-dialdehyde are mixed with amine liposomes for 2 hours with a mole ratio 
(amine/dialdehyde) of 1.5:1. The final dialdehyde conjugate DNP or biotin liposome was then 
treated to cultured fibroblasts for 2 hours with a mole ratio (amine/dialdehyde) of 1.5:1. 
Fluorescent DNP or streptavidin antibodies for were added and followed by flow cytometry and 
fluorescent microscopy to characterize our CSE strategy. Results indicate a clear successful 
conjugation and delivery of our designed ligands to cells. Control experiments where performed 
through quenching the dialdehyde with propylamine or the amine liposomes were not exposed to 
the relevant ligand resulting in no cell fluorescence. Results for biotin and DNP dialdehyde 
conjugation and delivery for E. coli cells was similar. These experiments demonstrate the 
efficient conjugation of our dialdehyde modified ligands to liposomes for delivery via liposome 
fusion. 
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Figure 5.13: Depiction of dialdehyde terminated ligand delivery to cells using rapid CSE via 
liposome fusion using click chemistry and characterized using flow cytometry and 
fluorescence microscopy. (A,B) The depiction and characterization of the delivery of biotin (37) 
and DNP (35) to cells using liposome fusion. The dialdehyde terminated reagents are conjugated 
to amine bearing liposomes (41) to form ligand bearing liposomes using click chemistry (42). Cells 
are then exposed to the appropriate antibody or protein, then characterized using flow cytometry 
and fluorescent microscopy (+). Control experiments in which either the dialdehyde, amine-
terminated liposome, or quenched dialdehyde ligand with propylamine are delivered to cells do 
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not fluoresce (−). (C,D) Delivery of biotin and DNP (37 and 35) via liposome fusion to bacterial 
cells (E. coli). The reagents were conjugated to amine bearing liposomes using dialdehyde ligands 
to form ligand presenting liposomes (42). The cells were then treated with fluorescent antibodies 
or adhesion proteins for flow cytometry and fluorescent microscopy for analysis (+). Control 
experiments were performed where either the dialdehyde, amine terminated liposome, or quenched 
dialdehyde ligand with propylamine were delivered to cells do not fluoresce (−). Scale bar: 20 μm. 
 This general click chemistry conjugation strategy can be applied to many different 
applications including the immobilization of ligands to inorganic substrate materials or a cross-
linking strategy to combine proteins, peptides or small molecule containing amines.30 31 32  
Figure 5.14 depicts the general applicability of the dialdehyde-amine reaction method for 
tailoring material surface modification and reaction.  To demonstrate the method, we converted 
an amine presenting glass slide (43) into a dialdehyde modified glass slide (44) using precursor 
molecule (24) followed by oxidation.  To the modified dialdehyde surface, we added fluorescent 
polystyrene beads with amine presenting groups.  The amine beads became efficiently bound to 
the dialdehyde surface via click chemistry. However, in the control no beads attached to 
dialdehyde surfaces when deactivated using propylamine or when the amine beads were first 
reacted with a dialdehyde capping reagent. 
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Figure 5.14: Diagram and images depicting the production of a dialdehyde modified glass 
substrate for primary amine terminated immobilization. An amine presenting substrate (43) 
was converted to a dialdehyde terminated surface (44) through the reaction of intermediate (24) 
with the surface amines followed by oxidation. To show conjugation, fluorescent latex beads (45) 
which have surface presenting amine groups are treated to the dialdehyde engineered substrate. 
When dialdehyde groups are present upon the solid substrate, the fluorescent beads become 
immobilized to the surface via click chemistry. While control experiments comprised of the 
dialdehyde surface deactivated using propylamine did not result in bead adhesion to the substrate. 
Scale bar: 5 mm. 
These results demonstrate that our dialdehyde presents an adaptable conjugation method 
and can be used on different materials including nanoparticles, inorganic and organic materials, 
and as a method for synthesizing smart materials and coatings.33 34 35 36 37 An additional potential 
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feature of our conjugation strategy involves the reaction of two moles of oxyamine or hydrazine 
containing ligands with one mole of dialdehyde reagent to form oxime or hydrazone through 
classical aldehyde chemistry. Using our organic and inorganic work as a foundation for 
expanding the scope of the dialdehyde methodology, we furthered our work to include biological 
manipulation, cellular manipulation for protein cross-linking, stapling of enzymes, 
biomacromolecules and tissue generation.   
The study of associated protein complexes is vital in the discovery of transitory signalling 
complexes. These complexes form transitory structures with short half-lives that are difficult to 
study due to their short lifespans and weak binding interactions, which readily dissociate in 
laboratory conditions. Protein stapling or cross-linking provides a methodology to permanently 
associate and stabilize these complexes in their native form for study. 
 
Figure 5.15: Scheme depicting the synthesis of cross-linking dialdehyde molecule (49).  Starting 
from the general dialdehyde building block (46), the cross-linker (49) was achieved in 3 steps 
using a similar methodology to other dialdehyde molecules. 
Figure 5.15 outlines the synthetic methodology for synthesizing a water soluble molecule 
containing two dialdehyde moieties that has significant chain length to act as a cross-linking 
molecule (49) to covalently bridge two intramolecular or intermolecular primary amines.  Our 
cross-linking strategy using our dialdehyde cross-linker reacts with N-terminus amines and the 
primary amine side chains of lysine, which are readily abundant in most proteins.  By cross 
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reacting primary amines, both through inter- and intramolecular stapling, the proteins can be 
characterized and studied in their native form.   
Figure 5.16 shows the ability of (49) to cross-link lysine containing macromolecules. We 
treated a solution containing LAR D1D21 and Caskin SAM2 (48), proteins that form a complex 
during embryonic motor axon development in Drosophila as a method to irreversibility bind the 
protein complex (50). Under electrophoretic separation (SDS-PAGE) proteins are denatured and 
separated based on their size and charge, while addition of the dialdehyde cross-linker (49) 
results in the covalent binding of the two proteins into a single protein band of 250 kDa (Lane 2) 
(Figure 5.16). The control (Lane 1) shows the untreated complex (48) readily dissociates under 
electrophoretic conditions. 
 
Figure 5.16: Depiction and data of protein stapling of LAR D1D21 (A) and Caskin 2 SAM2 
(B) (47) using the dialdehyde cross-linker (49). LAR D1D21 and Caskin 2 SAM2 undergo natural 
association (A/B) when incubated in solution (48). Once treated with the dialdehyde cross-linker 
(49) the lysine amino acids become cross-linked into a covalently bound (A/B) complex, which 
does not dissociate following gel electrophoresis (50). The control (Lane 1) shows the 
electrophoretic separation of the native bound (A/B) complex (48), while Lane 2 demonstrates the 
covalently crosslinked (A/B) complex, which remains as a single complex under separation 
conditions. 
Although the study of associated complexes such as those comprised of enzymes, are 
important there are also numerous applications for single protein aggregation studies such as 
amyloid plaques and tangles associated with Alzheimer’s disease. In Figure 5.17, we 
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demonstrate the dialdehyde cross-linker capability to form dimers and stapled complexes from 
single protein solutions of PP16 and EA22, RNA binding and DNA translation proteins, 
respectively. The addition of our cross-linker (49) to individual protein solutions resulted in the 
formation of dimerized proteins and stapled proteins under SDS gel conditions (Figure 5.17). 
The crosslinked PP16 (53) and EA22 (56) SDS gel demonstrates the irreversible doubling of the 
mass (kDa) of the respective protein solutions. Control experiments, where the propylamine 
quenched cross-linker (51) was treated to PP16 (54) and EA22 (57) did not produce a dimerized 
product. Therefore, this methodology has applications for producing aggregates of amine 
presenting macromolecules for studies in vitro. The assembly of advanced macroscopic materials 
is also of considerable interest, for colorimetric probes, sensors and drug delivery vehicles. 
 
Figure 5.17: Depiction of proteins PP16 and EA22, RNA binding and DNA translation 
proteins respectively, treated with dialdehyde cross-linker (49) conditions to form dimers and 
stapled protein complexes. Treatment of individual proteins with (49) cross-linker resulted in the 
formation of dimers and stapled protein aggregates (53 and 56) with doubled masses (kDa). Two 
identical proteins treated with (49) results in intramolecular crosslinks to produce covalently bound 
dimers and stapled proteins which have intermolecular binding of the dialdehyde molecule to 
amine groups within the same protein.  Control experiments used the cross-linker quenched with 
propylamine (51) and did not result in dimerized proteins (54 and 57), respectively. 
The aggregation of solid nanoparticles is a broad field of study that encompasses 
colorimetric assays, pH tests and biophysical analyses for both academic and commercial 
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applications. The utility of surface chemical groups of materials are essential, since they confer 
stability and functionality, while imbuing the material with covalent and non-covalent properties 
with further characteristics based upon the type of chemistry used. Adsorption or covalent 
interactions between the solid particle and ligand or cross-linker of interest produce a measurable 
response upon reaction and incorporate switchable mechanisms for purification, drug release, 
assembly and spectroscopic output. Figure 5.18 outlines our demonstration of the dialdehyde 
cross-linker (49) as a method to aggregate fluorescent beads into spheroid like structures, and 
release as individual beads upon addition of acid (pH < 3.0). Initially, the amine presenting beads 
were treated with molecule (49) to allow cross-linking of the solid particles in aqueous solution, 
which resulted in the aggregate cross-linked spheroids under fluorescent microscopy. While the 
addition of HCl (aq) to reduce the pH of the solution resulted in the quick release of the beads 
into their native form (Figure 5.18). Controls using quenched dialdehyde cross-linker (51) did 
not result in bead aggregation. Further incorporation of additional subunits into the cross-linker 
ethoxy chain could possibly produce further functionality for a variety of solid materials 
applications such as smart plastics, bioimplants and tissue engineering. 
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Figure 5.18: Scheme depicting the assembly and release of primary amine presenting 
fluorescent beads using dialdehyde cross-linker (49). (A) Chemical scheme depicting the 
lowering of pH (pH < 3.0) results in the release of the primary amines from the dihydropyridine 
ring. (B) Amine presenting beads treated with cross-linker (49) in aqueous solution assemble 
clusters, where upon lowering of pH with HCl (aq) to approximately pH 3.0 results in the release 
of the beads from the clusters to individual beads. (C) Fluorescent microscopy and macroscopic 
images of the resulting bead solutions shows efficient assembly of the beads using the cross-linker 
dialdehyde molecule, while lower pH solutions result in bead release. Control experiments with 
quenched dialdehyde (51) demonstrates no assembly occurs if (49) is first reacted with 
propylamine.  
Spheroids and tissue products are important substrates for regenerative medicine, drug 
testing and engineered bioproducts, such as biologics. In vitro formation of tissues is important 
for the discovery and elucidation of molecular signaling pathways, which is hindered by in vitro 
cellular contact inhibition, preventing the growth of 3D tissues in the Z plane. To demonstrate 
the use of dialdehyde cross-linker (49) as a method to grow 3D co-cultures, suspended cells were 
mixed with aqueous soluble molecule (49) (Figure 5.19). The reaction between the amine 
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containing cell membrane surface proteins and cross-linker (49) resulted in adhesion and 
formation of tissues through the deposition of cells upon glass substrates. We studied the 
formation of our co-culture tissues in Figure 5.19B using confocal microscopy to show that the 
dialdehyde cross-linker generated tissues were similar to previous tissue work using bio-
orthogonal insertion of complimentary groups delivered via liposome fusion. Our control 
experiments did not produce multilayers, but rather single layers of contact inhibited cells. 
Although the cross-linker molecule has a similar moiety as glutaraldehyde (fixing agent), Trypan 
Blue staining assays (Figure 5.19C) demonstrate that the cells retained high viability following 
24 hours of treatment, possibly due to the inability of the molecule to cross the plasma 
membrane.   
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Figure 5.19: Cell assembly of large scale cell aggregates into 3D co-culture tissues using 
dialdehyde cross-linker (49). (A) Co-culture suspensions of one or more cell types treated with 
aqueous soluble cross-linker (49) assembles cells through intercellular amine surface reactions.  
(B) Confocal microscopy of C3H/10T1/2 and NIH3T3 cells treated with cross-linker in suspension 
and deposited on glass slides in high concentration to form viable tissues of 3-4 cell layers thick 
using contact inhibited cell types. (C) Trypan Blue cell viability assay performed using the 
propylamine treated (51) quenched and active dialdehyde cross-linker (49) to determine cell 
viability after cell assembly conditions. 
5.4 Conclusion  
In conclusion, we have developed a novel general click chemistry strategy which can 
conjugate dialdehyde substituents and primary amine containing molecules. The resulting 
dihydropyridine moiety is stable and the reaction does not require activation or a catalyst.  
Moreover, the reaction displays fast kinetics and high yield under aqueous conditions and 25°C 
conditions. The dialdehyde and amine reaction proceeds with high atom efficiency, with only 
water as a byproduct. Therefore, purification is not necessary to remove toxic byproducts. This is 
an advantageous system, where amines are an abundant moiety in biological and chemical 
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systems, is a major group in bioconjugation chemistry and a key chemical handle for material 
and nanoparticle tailoring. We designed and synthesized a range of dialdehyde containing 
molecules, while demonstrating their applicability in a diverse range of applications in CSE, 
materials and tissue engineering. This novel general amine conjugation system has great 
potential in future applications in green chemistry, molecular tagging, antibody drug conjugates, 
nanoparticle modification, biosensors and polymers.  
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Chapter 6 
Conclusions and Future Directions 
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6.1 Conclusions 
In this work, several cell surface engineering techniques and technologies were 
developed for the control and study of cellular behavior for in vitro research applications.  In 
Chapters 2 and 3 NMR spectroscopy, oxime reaction kinetics and oxime cell surface engineered 
cell adhesion was correlated and probed under microfluidic conditions, while the robustness of 
adhesion and flexibility of cluster and tissue formation was established using live cell techniques 
microfluidics.  The rapidity and general applicability of bioorthogonal CSE was also probed 
under a variety of conditions, while tissues formed using this technology were studied for 
biological activity.1 2 3  Using this as a base strategy, we developed a general method for the 
microfluidic manipulation and cell surface engineering of cells for dual labelling and flexible 
delivery of nucleic acids and small molecule ligands (unpublished work).    
In Chapter 4 the bioorthogonal liposomal strategy originally utilized for cell adhesion and 
cell membrane ligand integration was modified and extended to transfect mammalian cell lines 
with nucleic acids limiting the use of cationic charge as a mild and general method to tag and 
target cells in monocultures and cocultures.4  This methodology using complimentary oxime 
chemistry on the cell membrane and the lipoplex allowed for the reduction of cationic charge for 
cell-lipoplex interaction and internalization to occur, while the method was characterized using 
microscopy, protein production quantification and targeting in complex cocultures for selective 
internalization. 
Finally, in Chapter 5 a new chemical moiety termed a dialdehyde was designed and 
synthesized for the easy and mild conjugation of primary amine containing molecules.5  This 
conjugation strategy was used to deliver small molecule ligands and macromolecules to bacterial 
and mammalian cell membranes using a generalized liposomal formation method.  The 
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dialdehyde moiety was characterized and modified to contain two dialdehyde moieties with a 
PEG linker for crosslinking proteins, inorganic surface functionalization, organic bead 
aggregation and cell aggregation for tissue formation.6 
6.2 Future Directions 
 Regarding the studies conducted in Chapter 2, future directions include the precision 
delivery of two or more bioorthogonal ligands to achieve simultaneous multiplexed delivery of 
biomolecular ligands for cellular studies of complex cell membrane biophysics, clinical tissue 
engineering, membrane biophysics, and immobilization. Surface labelling of cells for complex 
applications can benefit from the extension of this methodology by giving access to wider arrays 
of molecular probes for live cell staining and lipid trafficking studies. Ongoing work includes 
assembly and transfection of co-culture tissues containing stem cells for stem cell niche studies 
and cancer metastasis, tumor penetration studies.   
 Future research for work conducted in Chapter 3 include the generation of complex 3D 
tissues containing 3 or more cell types for paracrine or autocrine signaling, stem cell 
differentiation, stem cell growth and maintenance or development of blood-brain barrier models 
for drug screening studies. This methodology can also be extended to the study of macroscopic 
in vivo cell migration of implanted cellular patches through a pulse-chase model of 
bioorthogonal delivery, implantation and selective labelling of cells. This could enable the 
monitoring of spatio-temporal events including teratoma formation, tumor metastasis and 
developmental biology milestones.   
 With the introduction of cell surface engineering driven transfection in Chapter 4, the 
development of the future technology requires the further optimization of the liposomes and CSE 
for higher transfection rates, efficiencies and cell viability. This methodology can also be 
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extended to polymer based transfection methods using the installation of complimentary 
methodology into transfection polymers to drive transfection. Other future work should include 
transfection of primary cells, stem cells and other difficult to transfect cell lines to determine the 
overall applicability and general cellular mechanisms of the endocytic process of internalizing a 
neutral lipoplex using chemical reactions at the membrane interface. 
 Lastly, Chapter 5 was developed as an extension or add-on to the original liposome 
methodology, where a dialdehyde moiety could be used to conjugate amine containing 
biomolecules and small molecule to liposomes or other molecules for delivery to the plasma 
membrane of T-cells, stem cells or other cell types for biological study or therapeutic 
applications. Future studies based could include the development of magnetic or polymeric solid 
particles with surface presenting dialdehydes for solid based enzymatic reactions and 
purifications for biological applications and research. The conjugation and release of dialdehydes 
and primary amines through the lowering of pH should be pursued as a methodology for 
lysosomal antibody-drug conjugate release, surface modification using macromolecules for 
functional studies and cell delivery applications. The crosslinking dialdehyde has applications for 
functional studies of short-lived protein complexes, protein aggregate studies, colorimetric 
sensors and further studies into tissue formation using soluble cross-linkers for drug testing 
assays. 
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7.0 Appendix 
 
Theoretical Microsphere Calculations of Diffusion Time  
Sample calculation of diffusion coefficient for spheres (rounded cells) 
We estimated the (Rh) Hydrodynamic radii or Stokes radius as 10 micrometers, where larger proteins are 
~6-8 Angstroms. The Stokes radius estimates a hard sphere that diffuses at the same rate as a molecule of 
roughly the same size. 
(hydrodynamic radii) Rh = 1E-5m  
(temperature) T = 37oC (310.15K) 
(Boltzmanns constant) kb = (1.3806E-23kg m2 s-2 K-1) 
(kinematic viscosity of water) η = 0.000426kg m-1s-1 
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Therefore the estimated diffusion coefficient for rounded 10µm is 5.34E-14m2s-1. While at 75nm sphere 
has a D = 3.02E-12 
Calculation of diffusion time of spheres through water across a 200μm channel width 
 (smallest channel dimension) w = 0.0002m 
(diffusion coefficient) D = 5.34E-14m2 s-1 
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A 75nm has a Tdiff = 98min 
Renoylds number calculation for the microfluidic flow in the PMMA device  
(channel area) A = hb/2 = (1.70E-4 m)(2E-4 m)/2 = 1.70E-8 m2 
(channel length) L = 0.015m 
(total flow rate) Q = 1.2μL/min = 2.00E-11m3/s 
(kinetic viscosity of water) η = 0.001004 m2s-1 
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Supplemental Linear Plots depicting the Effective Relationship of Cell Density, Flow Rate and Channel 
Distance upon number of cells per cluster (Spheroids) using our general microfluidic Y-channel device 
Using data for Figure 3.6. 
 
Table 1: Experimental results depicting changing conditions of liposome delivery to cells in flow to 
achieve cell surface engineering to form tissues.  Thick tissue formation was observed (YES) when 
varying liposome concentration and changing the % composition of background lipids (DOTAP and 
POPC) in relation to concentration in our dual Y-joint microfluidic device (Fig 3) as a result of sufficient 
CSE.  When liposomal CSE was not in sufficient concentrations or the biorthogonal chemistry was in low 
mol% there was only monolayers of cells observed (NO). 
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